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ABSTRACT 
INTERACTIONS OF VIRAL AND CELLULAR HELICASES 
by  
Megan Josephine Corby 
The University of Wisconsin-Milwaukee, 2018 
Under the Supervision of Professor David Frick 
 
The innate immune system is a part of the first line of defense against virus infection. An 
important subset of the innate immune system consists of a group of intracellular pattern 
recognition receptors (PRRs) which recognize conserved features of bacteria and viruses and 
initiate an interferon response. The RIG-I like receptors (RLRs) are PRRs that bind to RNA viruses 
(such as hepatitis c virus) and signal through the adaptor mitochondrial anti-viral signaling 
protein (MAVS).  
Hepatitis C virus (HCV) is a small enveloped RNA virus that belongs to the flaviviridae 
family of viruses. HCV infects hepatocytes and can cause a persistent infection. If a chronic 
infection is established, progressive liver damage along with cirrhosis and sometimes 
hepatocellular carcinoma may occur. The multi-functional HCV non-structural-3 (NS3) protein is 
essential for HCV replication and contains covalently linked protease and helicase/ATPase 
domains. A covalently linked protease and helicase is unique to the flaviviridae family of viruses 
and it is unclear why the two functions are linked. There are multiple effective direct acting 
anti-virals which target the protease, but none currently approved which inhibit the helicase. In 
addition to aiding in viral replication, the NS3 protease assists HCV in establishing a persistent 
infection through cleaving the innate immune RIG-I adaptor protein, MAVS. The purpose of the 
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studies contained in this thesis is to gain a greater understanding of the function and purpose 
of the covalently linked HCV NS3 protease and helicase. Förster resonance energy transfer 
(FRET) is used to explore the interaction of NS3 with RIG-I like receptor proteins and to use 
FRET to look at the interaction of the RLRs with themselves.  
The interaction of the NS3 protease and helicase domain was probed through the 
exploration of the mechanism of action of a NS3 inhibitor (HPI) which is able to inhibit both the 
protease and helicase functions of NS3, while not disrupting the ATPase activity. The activity of 
HPI was determined in vitro using a fluorescent protease cleavage assay and a fluorescent 
helicase unwinding assay. HPI can inhibit both functions with low micro-molar EC50.  Next, 
analysis of HPI to inhibit peptide hydrolysis by wild-type NS3 and a set of NS3 mutants with 
mutations in the protease domain, helicase domain, and the allosteric groove between the 
protease and helicase domain suggested that HPI forms a bridge between the NS3 helicase 
RNA-binding site and the allosteric groove between the protease and helicase domains. The 
activity of HPI was measured in cells using an HCV sub-genomic replicon tagged with a 
luciferase reporter. The inhibition of HPI alone and in the presence of other protease inhibitors 
was tested. HPI can inhibit the HCV genotype 1b sub-genomic replicon and when applied in 
conjunction with first generation protease inhibitors, telaprevir and boceprevir, the inhibition 
was additive, as defined by the Bliss Independence Model of additive inhibition. However, 
when HPI was used in conjunction with macro-cyclic protease inhibitors, danoprevir and 
grazoprevir, modest synergy was observed. 
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To look at the protein:protein interactions of the NS3 helicase and the RIG-I like 
receptor helicases in live cells, a series of quantitative FRET spectrometry studies were 
employed. Quantitative micro-spectroscopic imaging (Q-MSI) is a technique which uses a 
fluorescent dye or fluorescent protein to identify sub-cellular regions and then calculates 
Förster Resonance Energy Transfer (FRET) efficiency and the concentrations of the donor and 
acceptor proteins. The technique was first applied in vitro with a fluorescently tagged NS3 
helicase and fluorescently tagged DNA molecules. Next, the technique was applied to 
combinations of recombinant fluorescently tagged helicases expressed in HEK293T cells. The 
NS3 helicase, RIG-I like receptor helicases, DDX1, DDX3, and DDX5 helicases, and MAVS were all 
designed to express off plasmids which also encode and attach a fluorescent protein. The 
fluorescent proteins used were either cyan fluorescent protein (CFP), enhanced green 
fluorescent protein-2 (GFP2), yellow fluorescent protein (YFP) or Venus fluorescent protein and 
each combination included a donor (CFP or GFP2) and an acceptor (YFP or Venus) fluorescent 
protein. The combinations were tested in presence or absence of polyinosinic-polyctyidlic acid 
(poly I:C) which is a synthetic RNA analog capable of eliciting an RLR response. To localize the 
interaction to the mitochondria, the mitochondrial stain, Mito-Tracker-Red, was used in some 
experiments. 
The experiments revealed a previously unknown interaction between NS3 and the RLR 
protein, laboratory of genetics and physiology protein-2 (LGP2) which may be biologically 
relevant. In addition, the relocation of LGP2 cytoplasmic foci in cells over-expressing DDX3 was 
observed. Q-MSI was used to visualize previously known interactions of RLRs at the 
mitochondria and in conjunction with MAVS.  
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Chapter 1 Introduction 
Hepatitis C virus (HCV) is a member of the flaviviridae family of RNA viruses. It can 
replicate without producing symptoms causing a persistent infection which results in 
progressive liver damage and sometimes liver cirrhosis or hepatocellular carcinoma. Currently, 
there are up to 103 million people chronically infected world-wide (Ansaldi et al., 2014). The 
blood supply was first tested for HCV in the early 1990s and therefore risk factors for HCV 
include a blood transfusion prior to 1992 along with intravenous drug usage and unsterile 
medical practices. There are six HCV genotypes and more sub-types. HCV genotype 1 is the 
most common in the United States and one of the harder genotypes to treat. Therefore, in 
addition to a serum antibody test and HCV RNA measurement, diagnosis also includes 
determination of viral genotype, sub-type, and resistance-associated mutations. By determining 
the specific genotype and subtype and the presence of any resistance associated mutations, it 
is possible to choose the best course of treatment (Ansaldi et al., 2014).   
Hepatitis C virus RNA encodes both structural and non-structural proteins (Figure 2-3). 
Structural proteins are those which make up the HCV virion structure and packaging. The 
structural proteins include core, envelope 1 (E1), and envelope 2 (E2). The non-structural 
proteins are involved in HCV replication and establishing an infection. The non-structural 
proteins include the accessory protein p7, the cysteine protease NS2, the covalently linked 
protease/helicase NS3, the protease co-factor NS4A, the inter-membrane accessory proteins 
NS4B and NS5A, and the RNA polymerase NS5B. The current standard of care for HCV infection 
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involves a combination of direct acting antivirals which target non-structural proteins involved 
in crucial steps in the HCV lifecycle. Presently, FDA approved direct acting antivirals target the 
NS3:NS4A protease, the NS5A protein and the RNA-dependent RNA polymerase, NS5B. By 
combining 2-3 of these anti-viral drugs, over 90% of patients (regardless of genotype) are cured 
(Ansaldi et al., 2014). 
Despite the resounding success of current direct acting anti-virals, it is still not possible 
to cure 100% of those infected with HCV and an error prone NS5B polymerase means that drug 
resistant strains are constantly evolving. Additionally, the cost of HCV treatment is high and 
may be cost prohibitive for some individuals because insurance companies are not always 
willing to cover direct-acting anti-viral treatments despite proof of long term cost effectiveness. 
Therefore, many HCV treatments still include the use of interferon which results in un-wanted 
side-effects and reduces treatment adherence treatment strategies (Elana S Rosenthal and 
Camilla S Graham, 2016). Furthermore, HCV is closely related to other viruses such as Zika or 
Dengue fever and therefore understanding more about the HCV life-cycle can impact not only 
HCV treatment, but also the treatment of like-viruses. One area of viral research, and HCV 
research specifically, which leaves much to be discovered is the ability of viruses to manipulate 
and control host immune responses. Gaining a better understanding of the interplay between 
virus and host could lead to better host-directed therapies and more effective treatments. 
Viral research dates back to the late 19th century where Dmitry Ivanovsky demonstrated 
that a crushed sample of tobacco leaves infected with tobacco mosaic virus retained its ability 
to infect other tobacco plants even after being filtered with a Chamberlain filter to remove 
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bacteria (Lechevalier, 1972). An understanding of immunity dates back even farther to the 5th 
century B.C.E. where Thucydides observed and wrote about individuals who recovered from the 
plague being able to care for those currently infected with the disease without becoming re-
infected (Ranger, 1995). Today, the fields of immunology and virology have progressed, 
however, the burden of viral illness is ever present. Viruses find ways to mutate and evade the 
best developed therapies and yet most people recover from viral infections without the aid of 
drugs or therapies. The immune system itself is incredibly effective at targeting and eradicating 
viruses. Understanding the immune response to viruses is an important component to viral 
research and one which has yielded new therapeutic directions such as treatments for 
Influenza-A which seek to limit the immune system derived inflammation that causes lung 
damage (Ramos and Fernandez-Sesma, 2015) or host-directed therapies which improve 
treatment to HIV by delivering recombinant interferons to stimulate a beneficial host response 
(Kaufmann et al., 2017). The host’s own immune system is the best tool for fighting viral 
replication and a greater understanding of the immune system and its interplay with disease 
could lead to the development of new therapeutics for treating pathogens (Kaufmann et al., 
2017; Ramos and Fernandez-Sesma, 2015; Wodarz and Lloyd, 2004). 
The human immune system is complex. Aspects of the immune system from physical 
and mucosal barriers to specialized pathogen targeting proteins are present in every part of the 
human body and are indispensable to human survival. The immune system recognizes and 
neutralizes known targets and those which it has never encountered, all with the goal of 
preserving health and homeostasis. One way to subdivide the components of the immune 
system is to separate them into the innate immune system and the adaptive immune system.  
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The innate immune system is a non-specific system present in all classes of plant and 
animal life and important to human survival. It responds to pathogens in a generic way through 
physical barriers or through identifying generic features of pathogens not present in the host. 
But unlike the adaptive immune system, the innate immune system does not provide any 
immunological memory. Despite its lack of specificity, the innate immune system is essential to 
survival and includes major functions such as producing cytokines to recruit other immune cells 
to the area of an infection, activation of the complement cascade to identify and clear foreign 
or damaged material in the body, white blood cells to engulf and remove pathogens, physical 
and mucosal barriers to infectious agents such as the skin and lining of the gut, specialized 
intra-cellular proteins which recognize when a cell has been infected with a pathogen, and a 
critical connection to the adaptive immune response through antigen presentation (Alberts et 
al., 2002). 
A sub-set of innate immune system intra-cellular proteins are called the RIG-I like 
receptors (RLRs) (John S.Errett Michael Gale Jr, 2015; Y. M. Loo and Gale, 2011). Members of 
this family include, RIG-I, MDA5, and LGP2 (Y. M. Loo and Gale, 2011). The RLRs are part of a 
larger group of innate immune system proteins known as pattern recognition receptors (PRRs) 
(Yoneyama et al., 2015). PRRs recognize conserved features of pathogens and initiate a 
signaling response which results in the production of cytokines (Bruns and Horvath, 2012; 
Marques et al., 2006; Pichlmair et al., 2015). RIG-I like receptors specifically recognize viral RNA 
in the cytoplasm of cells. One key component to proper RLR function is their ability to recognize 
only those RNAs associated with a viral infection and not ones which may be a part of normal 
cellular function (such as mRNAs, tRNAs, or siRNAs). To separate the host RNAs from the viral 
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RNAs, RLRs only respond to those RNAs which have patterns absent in host RNAs. Some 
examples include long double-stranded RNAs and RNAs lacking the 5’ 7-methyl-guanylate cap. 
Once the RLRs have recognized their particular ligand, they oligomerize and interact with the 
adaptor protein, mitochondrial anti-viral signaling protein (MAVS). MAVS transmits the signal to 
downstream kinases which leads to the translocation of interferon regulatory factor 3 (IRF-3) to 
the nucleus to up-regulate the production of interferon. Interferon then aids in localizing other 
immune cells to the area, including those involved in antigen presentation and the adaptive 
immune system’s immunological memory.  
The adaptive immune system is a specific system which is highly specialized to identify 
and kill known pathogens. Whereas the innate immune system can function and/or respond 
almost immediately to a perceived threat, the adaptive immune system often requires time, 
sometimes days, to operate at full capacity. This is due to the highly specific nature of the 
adaptive immune system which responds with a tailored response to a specific pathogen based 
off of its immunological memory (Owen et al., 2013). The adaptive immune system is constantly 
changing as the host encounters and survives pathogenic diseases. With each immune 
challenge, a new set of antibodies are acquired and the adaptive immune system changes to 
prepare to meet future challenges. Some of the major roles of the adaptive immune system 
involve recognizing “self” from “non-self” antigens during antigen presentation, developing 
immunological memory (antibodies) to retain specific information related to the identification 
of pathogens through memory B and T cells, and mounting specific attacks on pathogens or 
pathogen-infected cells (Alberts et al., 2002; Owen et al., 2013). 
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The immune system is effective at combatting pathogenic infection and many 
pathogens have developed ways to manipulate or alter the immune response in order to 
facilitate their infection. One example of pathogenic evasion is achieved through antigenic drift 
whereby a virus mutates in response to immune system antibodies, so that it is now 
undetectable by currently circulating antibodies. An example of antigenic drift is the flu. Each 
year new strains of flu emerge which have slightly different surface antigens than those 
previously seen and every year people are infected or die from the flu, even though they most 
likely have contracted the flu in the past and have an immunological memory (antibodies) of 
some influenza virus antigen (Anderson et al., 2017). In addition to evading the adaptive 
immune response, several pathogens have established ways to evade the innate immune 
response. Innate immune response evasion is particularly important for establishing an 
infection since the innate immune system may be the first system encountered by an infectious 
pathogen.  
One of the initial innate immune system barriers encountered by a pathogen are the 
epithelial cells of the skin and gut (Owen et al., 2013). The epithelial cells secrete antimicrobial 
peptides such as defensins, gramicidins, and cathelicidins which disrupt bacterial membrane 
integrity. One way that bacteria are able to avoid these antimicrobial peptides is through a 
simple avoidance mechanism characterized by electrostatic repulsion. For example, 
Staphylococcus aureus evades cationic defensin molecules by adding a lysine residue to its 
outer membrane (Peschel et al., 2001). In addition, some bacteria, such as Bacillus anthracis 
secrete proteases which cleave defensins and/or other anti-microbial peptides. If a bacterium 
successfully breaches the physical barrier, the bacterium must still overcome pattern 
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recognition receptors in order to survive. In response to these challenges, some bacteria have 
developed ways to alter their molecular structure such that it is not recognizable to the PRRs. 
For example, lipopolysaccharide (LPS) is a core component of many bacterial cell walls and it is 
recognized by the PRR, toll like receptor 4 (TLR4). But some bacteria have chemically modified 
the LPS in their cell wall, such that it is no longer recognizable by TLR4 (Reddick and Alto, 2014).  
Many viruses also employ techniques to evade or disrupt detection by PRRs. For 
example, by localizing replication to sub-cellular compartments inaccessible to cytosolic PRRs, 
dengue fever and influenza A are able to replicate undetected (Onomoto et al., 2012; Ramos 
and Fernandez-Sesma, 2015). In addition, many viruses disrupt PRR signaling through cleaving 
adaptor proteins. For example, hepatitis C virus (HCV) cleaves the adaptor proteins 
mitochondrial anti-viral signaling protein (MAVS) and TIR-domain containing adaptor inducing 
interferon-β (TRIF), thus cutting off the pattern recognition signaling and allowing the virus to 
establish a persistent infection (Doehle and Michael Gale, 2013; Hoving et al., 2014; Y. Loo and 
Gale, 2007). To gain a greater understanding of the function of the RLRs, a study of RLR 
protein:protein interactions is beneficial. 
Several techniques can be used to look at protein:protein interactions. Analyzing 
proteins which co-purify with proteins expressing an epitope tag, such as a glutathione s-
transferase (GST) tag, is a commonly used technique (Scopes, 2010). The proteins pulled down 
with an epitope tag can be identified using activity assays, antibodies, or through protein mass 
spectrometry. Co-immunoprecipitation is another example of a technique used to identify 
interacting partners. It involves isolating the protein of interest with a specific antibody and 
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then identifying the interacting partners via Western blotting or protein mass spectrometry 
(Ehle and Horn, 1990). Some drawbacks to the technique are that an antibody specific to the 
protein is needed, weak interactions may disintegrate once the protein is separated from the 
cell and it gives no information as to the architecture of the protein:protein complex. Another 
technique used to identify protein:protein interactions is bimolecular fluorescence 
complementation which involves tagging two proteins of interest with one half of a 
complementary fluorescent protein. If the two halves of the fluorescent protein come close 
enough to each other, they interact and spontaneously fold to form a complete and functional 
fluorescent protein. If the two halves are not near each other, no complementation can occur 
and the halves remain non-fluorescent. Therefore if there is no interaction between tagged 
proteins, there is no fluorescence. If there is interaction, a fluorescent signal can sometimes be 
observed (Miller et al., 2015). This technique can provide information not only on whether or 
not an interaction occurs but also demonstrate under what conditions the interaction may not 
take place (i.e. in presence of an inhibitor). It can be performed in live cells but it only gives a 
yes/no answer. It does not provide any information as to the subtleties of the dynamics or 
arrangements of protein:protein interactions and it may miss temporary or weak interactions.  
Förster resonance energy transfer (FRET) (Lakowicz, 2010) is another technique for 
exploring protein:protein interaction. FRET involves the non-radiative transfer of energy 
between a donor fluorescent tag and an acceptor fluorescent tag. The FRET quantity 
determined from experiments is the FRET efficiency of the number of occurences of non-
radiative energy transfer from donor to acceptor. If molecular complexes being measured are 
made up of several donors or acceptors (i.e. a mixture of monomers, dimers, trimers, etc) then 
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an apparent FRET efficiency (Eapp) is measured (Raicu and Schmidt, 2017). Eapp includes all the 
contributions from donors and acceptors within a given system.  
The energy transferred between donor and acceptor is dependent on distance. 
Therefore, the extent to which there is a transfer of energy between the donor and acceptor 
molecules can give an indication as to the distance between donor and acceptor.  By tagging 
two proteins of interest with a fluorescent FRET pair designed so that the emission of the donor 
excites the acceptor, it is possible to not only judge whether the fluorescently tagged proteins 
are interacting but also to get an idea of the distance between the fluorescent molecules 
(Lakowicz, 2010). There are many different experimental procedures and methods of analysis 
which can be used in the calculation of FRET and a few of the options will be discussed in more 
detail in Chapter 2. However, many of them are fraught with the same issues. Specifically, FRET 
analysis can often be confounded by direct excitation of the acceptor at the peak donor 
excitation wavelength, giving the appearance of FRET when there is actually none. If the 
spectrum of the donor is broad, there may also be a contribution of donor to the acceptor 
emission wavelength. In addition, some FRET methods (such as acceptor-photo bleaching) 
cause destruction to the acceptor molecule after just one measurement which significantly 
limits the amount of data which can be collected from any given sample. Other FRET techniques 
(such as three-filter sensitized emission) involve the use of multiple excitation scans to 
determine FRET. The time that passes in between excitation scans allows molecular diffusion to 
occur within the cell. The molecular diffusion which occurs between excitation scans means 
that the molecules imaged in the first excitation scan are not the same as the molecules 
measured in the second excitation scan and therefore FRET can only be calculated as an 
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average over a larger area as opposed to over smaller pixel level areas. (Clegg, 1995; Lakowicz, 
2010; Piston and Kremers, 2007; Selvin, 2000).  
A FRET method which seeks to address some of the issues with the calculation of FRET is 
optical microspectroscopy and FRET spectrometry (Raicu et al., 2009; Raicu and Singh, 2013). 
Optical microspectroscopy uses a single, two-photon excitation, and spectral imaging to collect 
the full fluorescent emission spectrum of donor and acceptor molecules.  FRET spectrometry 
incorporates fully quantitative analysis to calculate FRET (Eapp) and look at the interactions of 
proteins in living cells. Each component of optical microspectroscopy was specifically chosen to 
maximize the advantages and minimize the disadvantages of FRET measurement and analysis. 
Optical microspectroscopy uses carefully chosen donor and acceptor fluorophores and a 
single excitation scan to collect all the information necessary to calculate FRET. The use of a 
single excitation scan is important because if multiple images must be acquired to calculate 
FRET then the molecules have time to diffuse from one image to another. Specifically, the 
molecules measured in the first image are not the same molecules measured in the second 
image. The molecular diffusion that occurs between multiple excitation scans means that FRET 
cannot be calculated at the pixel level and instead average FRET over larger regions of interest 
is considered. If only one excitation scan is used to calculate FRET, then FRET may be calculated 
at pixel level. In addition, by only needing to acquire a single image, transient interactions, that 
might be lost in the time it takes to excite multiple times, are able to be captured. The use of a 
two-photon excitation (as opposed to single-photon excitation) minimizes damage to the 
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sample and reduce fluorophore bleaching. Two-photon excitation allows delicate, biological 
samples to be measured multiple times with minimal damage. 
Spectral imaging is beneficial because it means that a full fluorescence spectra at single 
nanometer resolution is collected for each measurement. The resulting “mixed” spectra are 
deconvoluted (i.e. unmixed) with spectra obtained from cells expressing either donor alone or 
acceptor alone. Assuming that the mixed spectra is a linear combination of the contributions of 
each individual spectra, factors are determined that scale the fluorescence of the donor in the 
presence of acceptor and acceptor in the presence of donor to fit the measured composite 
spectra. By separating out the individual component spectrums from an overall composite 
spectrum, any contribution of the donor to the acceptor spectrum or the acceptor to the donor 
spectrum is removed. The result of spectrally unmixing fluorescent images in a FRET 
spectrometry experiment is the generation of 2D fluorescent intensity maps which locate the 
donor and acceptor signal within the sample being measured.  In addition, supplementary 
spectrum (such as auto-fluorescence, background light, or additional fluorescent markers) may 
also be unmixed and considered in the analysis. By considering the entire fluorescent spectrum 
(as opposed to just a peak intensity or band of wavelengths), spectral imaging allows for the 
calculation of FRET closer to the true theoretical underpinnings of the theory. Specifically, that 
FRET represents the fraction of excitations transferred from donors to unexcited acceptors per 
total donor excitations. Using a single, two-photon excitation and spectral imaging, enough 
information is captured so that FRET (Eapp) may be calculated for each pixel within a fluorescent 
microscopic image using FRET spectrometry. The specific equations involved will be discussed in 
greater detail in Chapter 2. 
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A variation on FRET spectrometry, termed fully quantitative spectral imaging (FSI), 
expanded on the FRET spectrometry technique to include the use of a second excitation 
wavelength (King et al., 2016; Stoneman et al., 2017). Like FRET spectrometry, FSI uses the first 
excitation wavelength to specifically excite the donor which would then transfer its energy to a 
nearby acceptor. A second excitation wavelength is then chosen to primarily excite the 
acceptor. The second excitation allows for the calculation of the fluorescence of the acceptor in 
the absence of donor. The fluorescence of the acceptor alone can then be used to back-
calculate the fluorescence of the donor emission within the sample in the absence of acceptor. 
The details of this technique will be discussed in greater detail in Chapter 2 and 3. The benefit 
of obtaining the fluorescence of the acceptor in the absence of donor and the fluorescence of 
the donor in the absence of acceptor is two-fold. The first advantage is that by assuming that 
the fluorescence of a fluorescent molecule will increase linearly with concentration, a standard 
curve can be constructed which relates fluorescence intensity to concentration. This standard 
curve can be used in every measurement to calculate the concentrations of the donor and 
acceptors within each sample. In addition, the back-calculation of the donor in the absence of 
acceptor requires a correction for any direct excitation of the acceptor. This allows for the 
calculation of Eapp between a donor and acceptor even when there is significant direct 
excitation of the acceptor. Although the ability to correct for direct excitation of the acceptor 
expands the application of FSI to systems where the donor and acceptor spectrum significantly 
overlap, it also comes with a tradeoff. Specifically, if two excitation wavelengths are used in the 
calculation of Eapp then two excitation scans must be collected to calculate FRET. If two 
excitation scans are needed, then the time it takes to acquire those two scans allows molecular 
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diffusion to occur such that the molecules imaged in the first scan are different from those 
measured in the second scan (King et al., 2016; Patowary et al., 2015). Specifics of the theory 
and calculation of Eapp will be discussed further in Chapters 2 and 3. 
Quantitative microspectroscopic imaging (Q-MSI) (Corby et al., 2017) follows up on the 
technique of FSI and FRET spectrometry (King et al., 2016; Raicu and Singh, 2013) and 
incorporates the use of a fluorescent marker to identify sub-cellular structures. The third 
fluorescent marker is easily unmixed from the composite spectra and generates a 2D 
fluorescence intensity map of the desired sub-cellular structure. Sub-cellular regions of interest 
(ROIs) can then be selected within the unmixed 2D fluorescence intensity map representing the 
location of the sub-cellular structure being analyzed. The ROIs selected on the fluorescent 
marker intensity map are applied as a mask to the 2D fluorescent intensity maps generated 
through the unmixing of the composite spectrum in FRET spectrometry to specifically calculate 
Eapp within the sub-cellular region of interest. This technique is particularly helpful when the 
localization of the fluorescent donor and acceptor molecules is not apparent from visual 
analysis alone.  
This thesis seeks to explore the function of the NS3 protease and helicase domain 
through its interaction with a novel compound which inhibits both functions. Next, 
fluorescently labeled HCV NS3 and a fluorescently labeled oligonucleotide is used to calculate 
FRET in vitro  using several different techniques including Q-MSI. After which Q-MSI is applied in 
vivo to the homo and hetero interactions of HCV NS3, DDX3, DDX1, DDX5, RIG-I, MDA5, LGP2, 
and MAVS. A greater understanding of the function of the NS3 protein in the maintenance of 
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HCV and the inhibition of the innate immune system could inspire new therapies aimed at 
working with the immune system. In addition, a further understanding of the protein:protein 
interactions of the innate immune system proteins could lead to a greater understanding of the 
protein’s role in preventing disease and allow therapies to be developed which enhance the 
innate immune system function. 
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Chapter 2 Literature review  
Viruses are small and lack the 
necessary components for independent life 
and therefore viruses are dependent on a host 
to replicate. Viruses are able to infect all 
Kingdoms of Life including bacteria, Archaea, 
plants, and humans (Breitbart and Rohwer, 
2005). A viral genome encodes viral proteins 
which can typically be separated into 
structural and non-structural components. The 
structural components provide the packaging 
for the virus. All viruses have at least a 
structural capsid (protein coat) which 
surrounds and protects the genetic material during transmission. This protein coat can be made 
up of several different proteins which fit together to form a cohesive layer. Some viruses also 
have an envelope which surrounds the capsid and aids in transmission (Figure 2-1). There can 
be several different proteins involved in making one envelope structure.  
The structural proteins surround the genetic material and aid in the transmission of the 
virion. The genetic material contained in the virion may be either DNA or RNA. In viruses like 
hepatitis C virus (HCV) or human immunodeficiency virus (HIV), the RNA genome encodes for 
the production of non-structural proteins which make up some of the machinery necessary for 
Figure 2-1 The structure of an enveloped 
virus. The envelope coats the virus and aids in 
transmission. A capsid is sometimes present 
and serves to protect the viral genome. The 
viral genome can be made of DNA or RNA and 
transmits the genetic information necessary 
for replication. This figure was adapted with 
permission. This work is licensed under the 
Creative Commons Attribution 3.0 Unported 
License. To view a copy of this license, visit 
http://creativecommons.org/licenses/by/3.0/ 
or send a letter to Creative Commons, PO Box 
1866, Mountain View, CA 94042, USA. 
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viral replication. This machinery include enzymes such as polymerases, helicases, integrases, 
and proteases, as well as accessory proteins. The additional enzymes and materials (such as 
ATP) required for replication are derived from the host cell. Viruses require assistance from the 
host and many viruses (including HIV and HCV) co-opt host enzymes to aid in viral replication 
(Gelderblom, 1996; Lodish et al., 2000).  
An additional function of some viral non-structural proteins is to evade the host immune 
response. In order to replicate, many viruses have the ability to mute the host’s immune 
response. Some ways viral proteins achieve this are by direct interaction with intracellular 
immune system proteins, cleavage of key proteins involved in signal transmission, or through 
disguising their genomes to better resemble host components (i.e. adding a 5’ 7-methly-
guanylate RNA cap or 2’ O-methylation) (Hale et al., 2010; Lucas et al., 2001; Picard-Jean et al., 
2013) 
There are many different viruses which infect humans and cause illness ranging from the 
common cold to chicken pox and cold sores. Some viruses cause a disruption in homeostasis 
(and subsequently the onset of sickness) through cell lysis or disruption of cell activities. Lytic 
viruses rupture and kill the cell host and if enough cells die, the host suffers. Non-lytic viruses 
can transmit to other organisms without killing the cell, but the presence of viral infection can 
disrupt cell processes and inhibit normal function by inducing an immune response which shuts 
down host protein translation and function. The symptoms associated with virus infection; 
fever, vomiting, diarrhea, malaise, and rash, are often caused by the host immune response 
attempting to rid the body of the virus. Some viruses are able to replicate without inducing an 
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immediate immune response and these viruses can establish persistent infections that are 
difficult or impossible to cure. Persistent viral infections may be harmless or silently deadly. In 
addition, some viruses (including those that replicate without immune detection) have been 
linked to cancer (Bowie and Unterholzner, 2008). 
2.1 Helicases 
Helicases are enzymes indispensable to all living organisms and many viruses. Almost all 
biological functions involving RNA or DNA include at least one helicase. Helicases are motor 
proteins fueled by ATP hydrolysis which are able to bind and translocate directionally along 
nucleic acids. Some helicases also have the ability to unwind and/or remodel the nucleic acid 
(Patel and Donmez, 2006). Defective helicases are linked to many diseases such as cancer, 
neurodegenerative diseases, and developmental defects (Abdelhaleem, 2004; Hanada and 
Hickson, 2007; Nakayama, 2002). 
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Helicases are comprised of six super-families. Superfamilies 3-6 form large hexameric 
rings and are obligate oligomers (Figure 2-2B) whereas superfamilies 1 and 2 can work as 
monomers (Figure 2-2A). One functional difference between the obligate oligomers and those 
which are monomers, arises from the presence or absence of a complete ATP binding site. 
Helicases, such as DnaB, form hexameric rings because each sub-unit has only half of the ATP 
binding site necessary for ATP hydrolysis. These ATP binding domains are termed RecA-like 
domains due to their similarity to E.coli’s RecA protein which is involved in DNA recombination. 
Each monomer in a hexameric helicase contains only one RecA-like domain and oligomerization 
is necessary to create a functional ATP binding site. In contrast, helicases from superfamilies 1 
and 2 contain tandem RecA-like domains and therefore are able to function as monomers 
(Fairman-Williams et al., 2010; Jankowsky et al., 2011; Ye et al., 2004). Despite the ability of SF 
Figure 2-2: Helicases belong to several super families (SF). (A) SF 1 and SF2 contain 
tandem RecA-like domains and are able to function as monomers. (B) SF3, 4, and 5 
are obligate oligomers who form hexameric rings. Altered with permission from the 
RNA helicase database (Jankowsky et al., 2011). 
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1 and 2 helicases to function as monomers, there is evidence that some helicases become 
better enzymes when they oligomerize. These include UvrD and RecBCD which form a homo or 
hetero-dimer respectively. Other helicases show functional cooperativity when multiple 
helicases are loaded onto one strand. These helicases have increased processivity as more 
helicases bind (Patel and Donmez, 2006). 
Helicases can be classified as either DNA or RNA helicases based on their preferential 
substrate. Some specifically prefer RNA or DNA whereas others target DNA-RNA duplexes. DNA 
helicases are involved in cellular processes such as DNA replication, recombination and repair 
and also encoded by DNA viral genomes such as the herpes simplex virus (Chattopadhyay et al., 
2006). RNA helicases are involved in RNA metabolism, innate immune signaling, and are 
encoded by many RNA viruses that replicate in the cytoplasm, such as hepatitis C virus. Many 
RNA helicases are DExD/H box proteins and belong to superfamily 2. The name derives from the 
single letter amino acid code describing their highly conserved ATPase site located in motif II. 
The DExD/H box proteins are further classified into sub-groups based on subtle differences in 
their conserved amino acid motifs. Examples of the different sub-groups include DEAD-box 
(DDX) and DEAH-box (DHX) proteins (Bird et al., 1998; Fairman-Williams et al., 2010). Despite 
the sequence similarity of their catalytic core, the function of these DExD/H box proteins is 
diverse and the specificity of function determined by sites outside of the amino acid motif after 
which they are named (Rocak and Linder, 2004; Subramanya et al., 1996). 
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2.2 Hepatitis C virus 
Hepatitis C virus (HCV) is a blood borne pathogen which is able to reproduce after 
entering hepatocytes. It was identified in 1988 and blood donor testing began in 1990 
(Houghton, 2009). By 1992, most of the blood supply was considered free of HCV, yet those 
who received blood transfusions prior to 1992, were at significant risk for having the disease    
(Lauren Gravitz, 2011; QL Choo et al., 1989). Today, about 170 million people are infected 
worldwide with baby boomers and intravenous drug users being the populations most likely to 
be infected. The hepatitis C virus causes a slowly progressing liver disease that if left untreated 
causes cirrhosis, hepatocellular carcinoma, and liver failure (Ansaldi et al., 2014). 
HCV is a member of the Flaviviridae family of viruses and has a positive-sense RNA 
genome encoding a single long open reading frame. The RNA encodes for a ~3,000 amino acid 
polyprotein. The poly-peptide is cleaved by host and viral proteases into structural (core, E1, 
Figure 2-3 The HCV genome is comprised of ~ 9.6 kb genome which encodes for both 
structural and non-structural proteins. The structural proteins include Core, E1, and E2. The 
non-structural proteins are p7, NS2, NS3, NS4A, NS4B, NS5A, NS5B. 
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and E2) and nonstructural proteins (p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B) (Figure 2-3) 
(M. Gu and Rice, 2013).  
Structural proteins are processed by host proteases and self-processing begins when 
NS2 (a cysteine protease) cleaves the junction between NS2/NS3 and releases the NS3 N-
terminal serine protease domain to cleave the remaining poly-protein. The NS3 protease 
cleaves the junction between NS3 and NS4A in-cis and then proceeds to cleave the remaining 
NS4B, NS5A, and NS5B in trans (Figure 2-4).  
NS4A is an accessory protein which associates with the NS3 protease and contains the 
membrane anchors necessary to localize it to the ER membrane bound viral replicase complex. 
NS4B is involved in the remodeling of the ER membrane and intercalates into the membrane via 
several trans-membrane regions. NS5A is a zinc-binding phosphoprotein and NS5B is the RNA-
dependent RNA-polymerase with C-terminal membrane anchors (Salam and Akimitsu, 2013; 
Scheel and Rice, 2013). HCV reproduces and evolves rapidly because its RNA-dependent RNA 
polymerase (NS5B) lacks proofreading activity.  Quasi-species evolve in HCV patients, and 
Figure 2-4: The HCV genome is cleaved by both host and viral proteases. Host proteases are 
responsible for cleaving the junctions between the structural proteins; Core, E1, E2, and p7. NS2 
cleaves the junction between NS2 and NS3 in cis. The NS3 protease then cleaves the junction 
between NS3 and NS4 in cis and the junction between the remaining non-structural proteins in 
trans. 
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hepatitis C viruses are now comprised of a diverse set of 7 genotypes (1-7), and several 
subtypes (i.e. 1a, 1b), whose sequences differ by typically 20-25% (Simmonds, 2004). 
2.2.1 HCV viral lifecycle 
Viral entry into the host cell consists of multiple interactions including attachment, 
entry, and fusion. Viral particle uptake occurs via clathrin-mediated endocytosis (Emmanuelle 
Blanchard et al., 2006). Once inside the cytoplasm, the HCV virion fuses with cellular 
endosomes to release the viral RNA into the cell. The IRES (internal ribosomal entry site) found 
in the 5’ UTR (untranslated region) of the HCV genome mediates the translation by recruiting 
viral and host translation initiation factors in a cap-independent fashion. The resulting 
polypeptide is about 3,000 amino acids in length and consists of both structural and non-
structural proteins. The poly protein is further processed by host and viral factors (Chevaliez 
and Pawlotsky, 2006; Kim and Chang, 2013). 
The poly-peptide processing occurs in a membranous replication web closely associated 
with the ER membrane and containing vesicles with HCV non-structural proteins, HCV RNA, and 
lipid droplets. Replication in these webs consists of NS5B making negative sense copies of the 
positive sense RNA genome to produce further positive sense genomes which are the template 
for translation (Scheel and Rice, 2013). Several host proteins are also recruited to the 
membranous webs to aid in HCV replication, including DDX3 which undergoes a dramatic re-
localization to HCV replicase complexes mediated by the HCV structural protein core (Angus et 
al., 2010). 
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The poly-peptide is cleaved initially by host signal peptidases which targets the poly-
protein to the ER membrane and which yields the mature structural viral proteins. The zinc-
dependent NS2 cysteine protease cleaves between the NS2-NS3 juncture in-cis, freeing the NS3 
serine protease to cleave between NS3:NS4A in-cis and then the remaining NS4A-NS4B, NS4B-
NS5A, and NS5A-NS5B in-trans (Scheel and Rice, 2013). 
HCV virions are formed with an icosahedral capsid and have with a host-derived lipid 
membrane embedded with E1 and E2 (envelope 1 and 2) proteins. Inside the lipid bi-layer 
envelope is a nucleocapsid composed of core protein which surrounds the HCV RNA and 
protect it before it moves on to the next host cell (Chevaliez and Pawlotsky, 2006; Kim and 
Chang, 2013). 
2.2.2 Viral Proteins 
Core Protein 
Core protein forms the viral nucleocapsid with the viral RNA in the virion. Core is a 21-
kDa protein that has lipid and RNA binding ability. Core behaves as a membrane protein and 
has two distinct domains, D1 and D2. D1 is a hydrophilic domain with primarily positively 
charged amino acid residues and D2 is a hydrophobic domain with primarily negatively charged 
amino acid residues (Angus et al., 2010). Little is known about how core forms the proposed 
icosahedral nucleocapsid because, so far, it has not been possible to replicate this assembly 
outside of cells. Reconstituted core particles form irregular structures which are much larger 
than those isolated from HCV infection (Gawlik and Gallay, 2014; Kunkel et al., 2001). 
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E1 and E2 Glycoproteins 
E1 and E2 are cleaved from the poly-peptide via host signal peptidases. They contain 
multiple possible glycosylation sites and are often modified by N-linked glycans. These envelope 
glycoproteins are essential for HCV entry and fusion in a host cell and therefore represent a 
good target for anti-viral therapies or vaccines. E1 and E2 exist in heterodimers and the 
formation of this heterodimer is essential for efficient viral entry (Freedman et al., 2016). The 
E1 protein is indispensable for interacting with cell surface receptors and membrane fusion 
(Douam et al., 2014). 
P7 
P7 is a 63 amino acid membrane protein. P7 intercalates into the ER membrane and 
both the N and C terminus are oriented toward the ER lumen. P7 monomers have been 
crystalized as hexamers or heptamers and are believed to function as cation-selective channels. 
Therefore p7 is classified as a viroporin (Gentzsch et al., 2013). Although its role in the life-cycle 
is unclear, it has been proposed that p7 acts as an ion channel pump which helps to maintain a 
pH suitable for viral protein development in the membranous web replicase complex. The 
absence of p7 decreases the infectivity of some HCV strains (Atoom et al., 2014; Dubuisson, 
2007). 
NS2 
The NS2 protein is the HCV N-terminal non-structural protein. It is a cysteine protease 
which cleaves the junction between NS2-NS3 in-cis however it is not required for the replication 
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of HCV subgenomic replicons (Lohmann et al., 1999). There is some thought that NS2 may also 
be involved in viral packaging and release. This is due to several mutational studies which show 
that in the absence of a functional E1 and E2 or core, NS2 is not properly localized to lipid 
droplet replication complexes. In addition, NS2 shows sequence similarity to other viral 
proteins (Welbourn and Pause, 2007) which function in packaging and release of viruses. NS2 is 
a short lived protein that is quickly degraded in the replication complex in a phosphorylation 
dependent manner (Popescu et al., 2011; Welbourn and Pause, 2007). 
NS3 
The NS3 protein is comprised of a covalently linked protease and helicase domain, both 
of which are essential to viral replication (Lin, 2006). The details of NS3 structure and function 
will be discussed in section 2.2.4. 
NS4A 
NS4A is a 54 amino acid protein with an N-terminal hydrophobic alpha helix 
transmembrane segment. The middle part of NS4A is a co-factor for the NS3 serine protease 
and contributes to the proper positioning of the proteolytic cleavage active site. The C-terminal 
portion of NS4A forms an alpha helix at low pH.  The NS4A protein is critical for HCV replication 
and localizes the NS3 protease to the ER membrane via the trans-membrane helices. In addition 
to its activity as a protease co-factor, NS4A also serves to enhance the function of the NS3 
helicase by aiding in the proper positioning of the protease catalytic domain (Beran et al., 
2009). Further, mutations in NS4A cause problems in virus particle assembly indicating diverse 
roles for NS4A throughout the viral life-cycle (Phan et al., 2011). 
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NS4B 
NS4B is a highly hydrophobic 27 kDal protein which contains four transmembrane 
domains. It can exists as a monomer but there is also evidence that it could function as a part of 
larger, multi-protein complexes with NS4A and NS5A or NS3 and NS5B (Neddermann et al., 
1999). NS4B localizes to the ER membrane replication complexes and has been shown to be 
closely associated with lipid rafts, the putative site for replicase formation. Therefore, it is 
hypothesized that NS4B may be a critical protein for establishing the replicase complexes. In 
addition, NS4B has been shown to negatively regulate the NS5B RNA-dependent-RNA (RdRp) 
polymerase activity in-vitro giving further evidence to the idea that NS4B may function in larger 
multi-protein complexes. Lastly, NS4B is a critical component of the HCV induced interferon 
effect with the NS4B mutation Q1737H being found in multiple interferon treatment resistant 
phenotypes (Namba et al., 2004; Sklan and Glenn, 2006).  
NS5A 
NS5A is an RNA binding protein which contains three distinct domains and integrates 
into the membrane via a transmembrane helix.  Domain 1 is essential for replication and has 
been crystallized in multiple configurations, including a dimer. Domains 2 and 3 are unfolded 
and their precise roles have yet to be elucidated (Fridell et al., 2011). NS5A is highly 
phosphorylated with a basal phosphorylation form and a hyper-phosphorylated form. It is 
proposed that the difference in phosphorylation may help regulate its function and its 
interaction with other NS3 non-structural proteins. For example, NS5A can interact with NS5B 
and change its RNA polymerase activity (Shirota et al., 2002). In addition, multiple mutations 
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which confer increased replicative efficiency have been found in the NS5A domain and some 
overlap the phosphorylation sites, inferring that the extent of phosphorylation may control 
replication (He et al., 2006). The inhibition of NS5A is one of the most effective treatments for 
HCV and the NS5A inhibitor, Ledipasvir, is included in the currently prescribed and highly 
effective treatment, Harvoni®. 
NS5B 
NS5B is an RdRp essential for copying the positive sense HCV genome and making a 
molar excess of the template strands necessary for translation. Similar to other RdRps, NS5B 
has a “right hand” formation with a finger, palm, and thumb subdomains. The amino acid 
residues necessary for nucleotidyl transfer are found in the palm domain and recombinant 
NS5B was sufficient to catalyze the formation of full length HCV RNA in vitro. This implies that 
NS5B also has the ability to replicate through the stable secondary and tertiary RNA structures 
found in the untranslated regions of HCV RNA (Ferrari et al., 1999). NS5B lacks proofreading 
activity and is very error prone, thus contributing to the high mutation rate of HCV (Ranjith-
Kumar and Kao, 2006). One of the current HCV treatments, Harvoni®, includes sofusbuvir, a 
NS5B inhibitor.  
2.2.3 Inhibitors 
Up until a few years ago, the standard of care for HCV was a combination of pegylated 
interferon and ribavirin. Although able to completely cure some cases of chronic HCV at an 
efficiency between 40-90% percent depending on genotype, the side effects made treatment 
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difficult for the patient and caused low treatment adherence. In particular, genotype 1 (the 
most prevalent genotype in the United States) is hard to treat with the IFN/RBV regimen and 
only resulted in about a 40% cure rate, even with extended treatment. Side effects to IFN 
treatment include flu-like symptoms, bone marrow depression and autoimmune syndromes 
which contribute to feelings of fatigue, myalgia, depression, loss of appetite, and weight loss. 
Hemolytic anemia is the most common side effect of ribavirin treatment (Gerlach et al., 2003; 
Manns et al., 2006; Santantonio et al., 2005). 
Currently, the best treatment for HCV is a combination therapy made up of direct acting 
antivirals (DAAs). DAAs target the HCV non-structural proteins directly and offer the best 
treatment outcomes (including genotype 1) with the least number of side effects. The first-
generation direct acting anti-virals include telaprevir and boceprevir which target the NS3 
protease. Combination therapy with a protease inhibitor and PEG-IFN/RBV improves the 
sustained virological response (SVR) (i.e. an undetectable viral load for 12 weeks) amongst 
treatment naïve genotype 1 patients to 70%. However, variants resistant to both telaprevir and 
boceprevir develop rapidly and the presence of side-effects, like fatigue and anemia, reduce 
patient compliance and success rates (Aghemo and De Francesco, 2013; Kwo and Vinayek, 
2011; Welsch et al., 2012). 
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A second generation of DAAs was approved by the FDA in 2013 and includes simeprevir, 
a protease inhibitor and sofosbuvir, a nucleotide analog NS5B inhibitor (Figure 2-5).  In 2014, a 
combination therapy including, ledispasvir (NS5A inhibitor) and sofosbuvir was approved and 
marketed under the name Harvoni®. An additional, interferon-free treatment including DAAs 
ombitasvir (NS5A inhibitor), paritaprevir (NS3 protease inhibitor), ritonavir (a booster of 
protease inhibitors which slows their degradation) and dasabuvir (NS5B polymerase inhibitor) 
was also approved. The future of HCV drug discovery continues to explore DAAs capable of 
curing even treatment-resistant HCV phenotypes using an interferon-free regimen with 
reduced side effects. These DAA combinations, in particular those which are able to eliminate 
the need for interferon, have side-effect profiles which are well tolerated and increase patient 
treatment adherence and cure rates (Balistreri, 2016; Götte and Feld, 2016; Qian et al., 2016). 
Figure 2-5 Approved inhibitors currently in use for the treatment of HCV listed in conjunction 
with the protein they target. Combinations of direct acting antivirals are the best treatment 
currently available for HCV and are able to cure most cases, regardless of genotype. 
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2.2.4 HCV NS3:NS4A 
HCV NS3 is a multi-functional protein with an N-terminal serine protease domain and a 
C-terminal helicase/ATPase domain. A covalently linked protease and helicase domain is unique 
to the flaviviridae family of viruses and both enzymatic activities are essential for virus 
propagation, although the functional significance of their linkage is unknown. Helicase and 
protease enzyme activities are able to function independently, yet the presence of the protease 
domain has been shown to alter the activity of the helicase domain and the presence of the 
helicase domain increases the processivity of the protease domain. There is an allosteric 
domain between the protease and helicase and mutational studies within that domain highlight 
its importance to overall function but the cross-talk between the two domains leaves much to 
be discovered (Aydin et al., 2013; Beran and Pyle, 2008; Frick et al., 2004). 
NS3 Protease 
The NS3 protease is a serine protease which contains the His57, Asp81, and Ser139 
catalytic triad indicative of the trypsin/chymotrypsin superfamily of proteases. Mutational 
studies show that the NS3 protease, is indispensable to the cleavage of several sites in the HCV 
poly-protein including cleavage of the NS3/NS4A in cis and the NS4A/NS5B, NS4B/NS5A, and 
NS5a/NS5B sites in trans. Mutations within the catalytic triad of NS3 abolished cleavage at any 
of these four sites but still allowed for the cleavage of any proteins upstream of NS3 in the HCV 
poly-peptide (Bartenschlager et al., 1994; Lin, 2006). 
The NS3 protease enzyme has two beta-barrel motifs that are capped at either end by 
short alpha-helices. The overall structure is stabilized by the presence of a Zinc ion that is 
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coordinated with cysteines. The Zn+2 is essential for proteolytic function. The catalytic triad, 
His57, Asp81, and Ser139, is responsible for the proteolytic cleavage and the NS4A protein, which 
closely associates with the NS3 protease contributes to the proper positioning of the catalytic 
triad. This explains why NS3 protease function is greatly enhanced when NS4A is present 
(Raney et al., 2010). 
The catalytic mechanism for the HCV NS3 protease is similar to all serine proteases. The 
His57 serves as the base which activates the Ser139 nucleophile. The nucleophile may then attack 
the carbonyl atom of the scissile peptide bond and form a tetrahedral intermediate. 
Subsequent breakdown of the tetrahedral intermediate leads to the formation of an acyl-
enzyme intermediate and the N-terminal peptide product. The N-terminal product then 
dissociates, allowing for the division of the acyl-enzyme intermediate, the binding of water, and 
the formation of the C-terminal peptide product. This then allows for dissociation of the 
product and re-association by the next protease substrate (Di Cera, 2009; Fersht and Sperling, 
1973). 
Besides aiding in the poly-peptide processing during HCV replication, HCV NS3 protease 
also has a direct role in inhibiting the innate immune response to HCV infection. HCV infection 
is sensed through multiple pathways that converge on the adaptor protein, mitochondrial anti-
viral signaling protein (MAVS). One way that the NS3 protease is able to disrupt antiviral 
signaling is to cleave MAVS. This abrogates immune signaling and blunts the innate and 
adaptive anti-viral response (Horner et al., 2011; Horner et al., 2012). 
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NS3 Helicase 
The NS3 helicase is classified as a super family 2 helicase based on sequence homology. 
It contains two tandem domains which closely resemble the bacterial recombination enzyme, 
RecA. ATP binds the NS3 helicase between the two RecA-like domains. Domain 1 contains the 
phosphate binding loop present in all Walker A and B motif-containing NTPase proteins (Saraste 
et al., 1990). The phosphate binding loop is responsible for binding the ATP and allowing the 
catalytic base (Glu291) to activate the 
water molecule needed for hydrolysis of 
the ATP. The activated water can then 
attack the ƴ-phosphate on the ATP (Belon 
and Frick, 2009b). 
The purpose of the NS3 helicase is 
to couple the energy liberated through 
ATP hydrolysis to duplex RNA or DNA strand separation (Figure 2-6). The NS3 helicase will bind 
to either RNA or DNA with a low nanomolar dissociation constant. Although the binding of the 
helicase to RNA is not surprising given that HCV is an RNA virus, the helicase’s ability to bind 
and unwind DNA does not have a known function and may indicate a role for NS3 in the cellular 
nucleus (Kasprzak et al., 2007). The helicase binds with a footprint of about 5-7 nucleotides and 
can translocate uni-directionally along single stranded RNA/DNA with the ability to disrupt 
duplex binding. However, the mechanism by which NS3 translocates is unclear and competing 
theories exist (Frick et al., 2006). 
Figure 2-6: HCV helicase translocates 
unidirectionally along single stranded HCV RNA 
displacing the duplex strand. The helicase is 
powered by ATP. 
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The inchworm model maintains that domains 1 and 2 of the helicase move opposite 
each other fueled by the energy of ATP. This movement results in a helicase which literally 
walks along a ssRNA or a ssDNA molecule. Crystal structures done in the presence of a non-
hydrolyzable ATP and ATP transition state analogs give credence to the inchworm mechanism 
(M. Gu and Rice, 2010).  Important in these structures are residues W501 and V432 which form 
“book-ends” along the DNA, locking the NS3 helicase into a positon with a 5 base pair step size. 
W501 sits at the 3’end of the helicase footprint along the nucleic acid, whereas V432 inserts at the 
5’ end. ATP hydrolysis results in a conformational shift which causes domains 1 and 3 to rotate 
relative to one another closing with domain 2. This causes the protein to slide 1 nucleotide. 
Release of ATP allows the enzyme to swing open and the overall movement is 1 nucleotide per 
ATP hydrolyzed (Figure 2-7) (Frick et al., 2006; Pyle et al., 2006; Pyle, 2008; Raney et al., 2010; 
Velankar et al., 1999).   
In contrast to the inchworm model, the Brownian motion ratchet model says that the 
NS3 helicase exists in two states and that the switch between the two states is powered by ATP. 
The first state is a high-affinity state whereby the helicase is strongly attracted to the single 
stranded nucleotide substrate and the second state is a low affinity state, where the helicase is 
only weakly associated, thus allowing it to slide via Brownian motion. The preference for 
Figure 2-7: Inchworm model of HCV NS3 helicase motion. Prior to binding ATP (A) the helicase 
is in an open position with domain 1 swung out from domain 2 by about 27 angstroms. After 
binding ATP, (B) domain 1 swings in to close the gap between domains 1 and 2 to about 15 
angstroms and shifting the complex by one nucleotide. Immediately following hydrolysis, 
domain 2 moves away from domain 1 and the helicase re-assumes an open confirmation (C) 
(Raney et al., 2010).  
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forward motion comes from the ratchet effect where W501 intercalates into the nucleic acid and 
prevents the enzyme from sliding back (Levin et al., 2005). 
2.3 Innate Immune System 
The innate immune system is the first line of defense against invading organisms. Unlike 
the adaptive immune system which remembers pathogens from previous encounters but 
requires time, sometimes multiple days, to become effective, the innate immune system is fast. 
The innate immune system can respond in the first hours after an infection and it doesn’t 
matter if the pathogen is known or completely novel or whether it’s bacterial, viral, or fungal. 
The innate immune system is set up to detect patterns present in pathogens called pathogen 
associated molecular patterns (PAMPs) and to respond immediately (Alberts et al., 2002). 
There are many parts to the innate immune system. One important component is the 
skin and mucous bilayers present in gut and intestinal linings which provide a physical and 
chemical barrier to pathogen entry. If the pathogen is able to breach the epithelial wall and 
reach the tissue or bloodstream, there are several systems including macrophages and the 
complement system set up to recognize the PAMPs and induce an inflammatory response. If a 
pathogen enters a cell, there are multiple protein receptors, such as Toll-like receptors and RIG-
I like receptors, which will recognize PAMPs such as double stranded RNA or DNA, un-capped 
RNA, cyclic-diGMP, flaggelin or lipopolysaccharides present in the cytoplasm. Once an 
intracellular innate immune protein has recognized a PAMP, they induce a signaling cascade 
resulting in the production of interferon and other cytokines (Takeuchi and Akira, 2010). 
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The function of the innate immune system is important not only for immediate 
pathogen recognition and neutralization but also for its role in the adaptive immune response 
and immunological memory (i.e. antibodies). Without the innate immune response, the 
adaptive immune system is significantly hindered. For example, the release of cytokines 
initiated by the innate immune response alerts nearby specialized cells, such as dendritic cells 
(antigen presenting cells), and recruits them to the area of infection.  The innate response is so 
critical that many viruses and other pathogens, such as HCV, seek to disrupt the innate immune 
signaling. The disruption of innate immune signaling effectively slows the response and can 
allow the virus to spread undetected until it is well established in the host (Akira et al., 2006; 
Takeuchi and Akira, 2010). 
2.3.1 RIG-I like receptors (RLRs) 
A subset of the innate immune system intracellular pattern recognition receptors (PRRs) 
are known as the RIG-I like receptors (RLRs).  The RLRs consist of three receptor proteins 
retinoic inducible gene I (RIG-I), melanoma differentiation associated protein 5 (MDA5), and 
laboratory of genetics and physiology protein 2 (LGP2) which belong to the DExD/H family of 
RNA helicases. RLRs reside at low concentrations in the cytoplasm of most cells in the human 
body and aid in detecting intracellular RNA virus infection (Jensen and Thomsen, 2012). The 
RLR’s anti-viral function was first revealed by Yoneyama et al when RIG-I was uncovered during 
a cDNA screen of genes which induced the expression of interferon in response to duplex RNA 
transfection (Yoneyama et al., 2004a). It was determined that RIG-I’s CARDs (capsase activation 
and recruitment domains) are important for transmitting the down-stream signal, and that the 
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helicase domain recognizes dsRNA and regulates the signal transduction in an ATPase 
dependent manner (Yoneyama et al., 2004b). Two additional proteins demonstrating high 
helicase domain sequence similarity to RIG-I were subsequently identified as MDA5 and LGP2. 
Both RIG-I and MDA5 possess CARDs and MDA5 was identified as transmitting a signal similar to 
RIG-I, leading to the activation of interferon (Yoneyama et al., 2005). 
The RLR’s contain a helicase and ATPase to bind and translocate along RNA, a C-terminal 
domain (CTD) to modulate and control this interaction, and, in the case of RIG-I and MDA5, two 
tandem CARDs to transmit the signal downstream. The RLRs are classified as super family 2 
helicases and therefore their helicase domains contain two tandem RecA-like domains 
(Rossman fold with repeating alpha/beta sheet) (Byrd and Raney, 2012; Rao and Rossmann, 
1973).  The presence of tandem RecA-like domains means that the super family 2 helicases (like 
super family 1) form a complete ATP binding site and are able to function as monomers, unlike 
superfamily 3, 4 or 5 helicases which are obligate oligomers (Fairman-Williams et al., 2010; 
Hickman and Dyda, 2005; Korolev et al., 1998; Pyle, 2008). Near the tandem RecA-like domains 
are conserved sequences within the helicase which form a platform for recognition and 
manipulation of nucleic acids.  The helicase domains (hel1 and hel2) are separated by an 
insertion domain at the N-terminal of hel2, termed hel2i (Luo et al., 2011). The RLRs are not 
known to unwind RNA, instead they have been shown to translocate along either single or 
double stranded RNA powered by ATP. The ATPase function is essential for proper downstream 
signal activation (Errett and Gale, 2015a; Myong et al., 2009). 
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The C-terminal domain, present in all three RLRs, is a Zn2+ containing regulatory domain. 
The fold of the CTD is conserved across the RLRs, but the characteristics of the ligand 
recognition groove vary which seems to account for some of the ligand specificity of each 
protein (Cui et al., 2008). Binding studies have shown that the RIG-I CTD binds 5’ ppp dsRNA, 
ssRNA, and blunt-ended dsRNA with the highest affinity for 5’ ppp dsRNA (Lu et al., 2010). 
Whereas, MDA5 and LGP2 CTDs preferentially bind dsRNA and the RNA ends are not as 
important (Bruns and Horvath, 2014; Pippig et al., 2009). The overall CTD binding is primarily 
electrostatic through a basic binding cleft that is not specific to the internal sequence of the 
RNA (Luo et al., 2011). 
Figure 2-8: Schematic of RIG-I like 
receptor function. RIG-I, MDA5, and 
LGP2 exist in an auto-inhibited state in 
the cytoplasm in the absence of RNA 
ligand. Upon RNA ligand binding (1), the 
CARD domains are exposed to allow for 
oligomerization. RIG-I binds in short 
filaments where as MDA5 binds in larger 
oligomers aided by the presence of LGP2 
(2). After oligomerization, localization of 
the RLR filament to the mitochondrial 
membrane induces the formation of a 
MAVs + RLR filament (3) and initiation of 
downstream signaling (4) resulting in the 
production of interferon.  This research 
was originally published in Journal of 
Biological Science. 2017; 292: 9000-
9009. © The American Society for 
Biochemistry and Molecular Biology. 
Adapted for use with permission. 
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Immediately connected to the CTD, is a “pincer” or “bridge” which consists of two 
tandem alpha helices which connect the CTD to the hel2 domain. This RIG-I pincer domain has 
been shown through mutational studies to be imperative for stimulation of interferon in 
response to RNA binding and elimination of the pincer abolishes signaling altogether. Further, 
direct study through ATPase assays shows that deletion of even a portion of the pincer 
significantly reduces the ATPase activity in response to RNA binding. Thus this bridge/pincer, 
although small, transmits information directly from the CTD to the helicase2 domain 
(Kowalinski et al., 2011; Luo et al., 2011). 
The tandem CARDs are present only in RIG-I and MDA5 and are responsible for the 
downstream signaling. The CARDs belong to the Death Domain superfamily and the CARD fold 
consists of six anti-parallel alpha helices. CARD domains are often involved in apoptotic 
pathways or inflammatory responses and may oligomerize into large complexes. The RLRs, RIG- 
I and MDA5, which contain CARD domains induce interferons which may lead to inflammation. 
In addition, the CARDs of MDA5 and RIG-I oligomerize to form larger complexes (Ferrao and 
Wu, 2012; Wu and Hur, 2015). The CARDs of RIG-I form a helical tetramer with a pitch of a 
single card. The CARD-CARD interface is mediated via a series of electrostatic and hydrophobic 
interactions. The RIG-I tandem CARDs have been crystallized in conjunction with MAVS. The 
model suggests that the tandem CARDs are necessary to create a stable tetramer which seeds 
the MAVS filament formation necessary for downstream signaling. (Wu et al., 2013; Wu et al., 
2014; Wu and Hur, 2015) 
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The overall functional model of RIG-I and MDA5 could be thought of as the helicase 
domain forming a base that is covered by two flaps, the CARDs and the C-terminal domain. In 
the absence of RNA ligand, the protein is in an auto-inhibited state. The CARDs fold to block the 
helicase domain from interacting with “self” RNAs through a direct interaction. The C-terminal 
domain then folds on top of the CARD domains and maintains their position blocking the 
helicase domain. The ligand recognition portion of the CTD is still exposed and available to the 
cytosol to scan for PAMPS. In the event of PAMP binding, the CTD swings in to bring the ligand 
into contact with the helicase domain with perfect alignment. The presence of the CTD and 
ligand in connection with the helicase domain clashes with the CARDs and forces them to swing 
up and out to initiate downstream signaling (Kowalinski et al., 2011; Luo et al., 2011). The 
CARDs then oligomerize and re-locate to the mitochondrial membrane where they seed a 
MAVS filament (Luo et al., 2011) (Figure 2-8). The overall function of LGP2 is thought to be in 
accessory to MDA5 function instead of through direct signaling with MAVS due to the lack of 
CARDs (Lässig and Hopfner, 2017). 
2.3.2 RIG-I 
RIG-I (retinoic acid-inducible gene 1), although similar to MDA5 in structure and overall 
function, has distinctive ligand preferences and a unique mode of action. During in vitro 
experiments, RIG-I’s ideal ligand is short, di or tri-phosphorylated double stranded RNA (5’ppp-
RNA) of around 7-10 base pairs (bps). RIG-I also binds short di or tri-phosphorylated single 
stranded RNA and RNAs with an m7-guanosine triphosphate cap. In addition, RIG-I can 
recognize and respond to short U-rich tracts of RNA (Goubau et al., 2014; Schlee et al., 2009). 
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These ligands represent multiple parts of an RNA virus life cycle including incoming RNA and 
replication intermediates. In addition, RNA polymerase III can transcribe tracts of viral DNA to 
5’-ppp RNA which is also recognized by RIG-I (Sharma and Fitzgerald, 2011). Therefore, RIG-I is 
able to recognize both RNA and DNA viruses at multiple points in the viral life cycle. 
RIG-I discriminates between self and non-self RNA primarily through spatial separation. 
RIG-I monitors the cytoplasm and 5’ppp-RNAs are not normally present in the cytosol of healthy 
cells because host mRNAs are capped before exiting the nucleus after transcription. Therefore, 
the presence of 5’ppp-RNA in the cytoplasm could signal a replicating virus. In addition, it was 
recently shown that RIG-I can bind to m-7-guanosine capped RNA but it cannot accommodate 
the 2’O-methylation of the first 5’ nucleotide and therefore self-capped RNAs are excluded 
from RIG-I recognition. Any other cytoplasmic RNA is either cleaved to only a 5’-
monophosphate (like tRNAs) or masked by ribonuclear complexes, as in ribosomal RNA. RIG-I 
ligand preference is tightly regulated to prevent self-RNA recognition (Marques et al., 2006). 
After RIG-I recognizes a viral RNA ligand, RIG-I becomes ubiquitinated which promotes 
CARD oligomerization. In the absence of ligand, the RIG-I 2CARD is phosphorylated which 
sterically prevents ubiquitination further adding to the layers of protection against rogue 
signaling (Jonathan Maelfait and Rudi Beyaert, 2012). The role of the ATPase domain in RIG-I 
signaling is controversial. Given that RIG-I prefers ligands as small as 7bp, there is seemingly no 
need for translocation. However, single molecule studies indicate that RIG-I does translocate 
along RNA. One hypothesis to explain these findings is that RIG-I dissociates from low affinity 
substrates at a rate faster than the rate of ubiquitination, oligomerization, and signaling. But 
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when RIG-I is bound to a high affinity substrate, even in the presence of ATP, it would dissociate 
slower, allowing time for the signaling complex to assemble and initiate the downstream 
response. Therefore, the ATPase function would contribute to RIG-I ligand discrimination 
(Ahmad and Hur, 2015; Myong et al., 2009). 
2.3.3 MDA5 
MDA5 binds long double stranded RNAs with a length greater than 2,000 base pairs. 
Unlike RIG-I, MDA5 seems to have no preference for the type of RNA ends and instead freely 
binds anywhere along the dsRNA. Due to this lack of sequence or end specificity it’s possible 
that MDA5 might be more prone to recognize native cell ligands such as mRNA or tRNA. 
However, long dsRNAs (>2,000 base pairs) are rare in the cytoplasm and when they do occur, 
base pairing is reduced by converting some RNPs to inosine by adenosine deaminase (ADAR1). 
Therefore, because MDA5 binds with highest affinity to RNAs greater than 2,000 base pairs that 
exhibit perfect complementarity, it is less likely that MDA5 would bind to cell-derived RNAs 
which, in general, are shorter than 2,000 base pairs or which lack perfect complementarity 
(Heraud-Farlow and Walkley, 2016; Liddicoat et al., 2015). 
The increased binding stability of MDA5 for long dsRNA is mediated via ATP. MDA5 
mutants deficient in ATP hydrolysis and ATP binding are constitutively active (Louber et al., 
2015). However, it was seen that in the presence of ATP, MDA5 filaments are significantly 
weakened (i.e. MDA5 dissociates more rapidly), in particular at the ends of the RNA, 
presumably due to the ATP hydrolysis and MDA5 translocation activity. This shifts the stable 
MDA5 filament formation towards a preference for long dsRNA and increases the likelihood 
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that MDA5 will dissociate from the short filaments. Therefore, although ATP is not required for 
MDA5 signaling, it is required for MDA5 ligand discrimination. The ATP hydrolysis and ATP 
binding activity limits erroneous MDA5 signaling by decreasing the stability of the MDA5 
proteins on a short RNA strand. This establishes the MDA5 ligand preference for longer double 
stranded RNA (Peisley et al., 2011). 
2.3.4 LGP2 
LGP2 (laboratory of genetics and physiology 2) is the less-understood RIG-I like receptor. 
The structure of LGP2 is similar to RIG-I and MDA-5 in the sense that they all share a 
homologous C-terminal ligand recognition domain and DExD/H box helicase domain. But LGP2 
differs from RIG-I and MDA5 in that it lacks CARDs needed to activate MAVS. The lack of CARDs, 
suggests LGP2 plays a unique role in the innate immune system by signaling PAMP detection 
through a path that does not involve CARDs, but instead involves an interaction with MDA5 
(Bruns and Horvath, 2014; Satoh et al., 2010). It has been shown that LGP2 can form active 
dimers (Murali et al., 2008) and oligomers that interact with MDA5 filaments (Bruns and 
Horvath, 2014). In addition, LGP2 has been shown to negatively regulate RIG-I signaling, 
possibly through substrate sequestration (Rodriguez et al., 2014).  
LGP2 favors double stranded RNA ligands and binds with highest affinity to the ends of 
RNA, however there is no difference in binding affinity for RNA ligands with or without 
5’triphosphates. It is possible that LGP2’s preference for the ends of dsRNA is in direct 
competition with RIG-I’s RNA end preference and this competition is what causes the observed 
hindrance of RIG-I signaling when LGP2 is upregulated. LGP2 enhances MDA5 filament 
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formation and thus MDA5 signaling activity (Bruns et al., 2014; Errett and Gale, 2015b; 
Uchikawa et al., 2016). 
2.3.5 HCV and detection by RIG-I like receptors 
HCV is recognized by the intracellular innate immune response once the viral RNA is 
released into the cytoplasm. Multiple pattern recognition receptors (PRRs), including Toll-like 
receptors (TLRs) and RIG-I like receptors (RLRs), participate in responding to HCV RNA. Loo et al 
showed, using immunofluorescence, that IRF-3 accumulation in the nucleus increases after JFH-
1 infection in Huh7 cells but not in Huh7.5 cells which have a defective RIG-I pathway (Y. Loo et 
al., 2006). Therefore, Loo et al concluded that once the RIG-I like receptors have bound to the 
HCV RNA PAMP (i.e. the 5’ triphosphate and the poly-U/UC region (Saito et al., 2008), they 
initiate a downstream signaling cascade resulting in the production of interferon and other 
cytokines.  
HCV RNA may be recognized at several points in its lifecycle by the RIG-I like receptors. 
Initially, the newly released HCV RNA may be recognized by RIG-I due to its 5’ppp. Once the 
HCV ligand binds to RIG-I, it induces a conformational shift which releases the CARD domains 
for oligomerization and downstream interaction with MAVS. A mutation in the RIG-I CARD 
(T55I) is present in the HCV cured cell line, Huh 7.5, which is used because it is significantly 
more permissive to HCV infection. The T55I mutation does not allow for proper ubiquitination 
of the RIG-I CARD and therefore is able to abrogate RIG-I receptor signaling. The fact that 
blunting RIG-I signaling makes the cell line much more susceptible to HCV infection lends 
credence to the importance of RIG-I in HCV detection (Liu and Gale, 2010). 
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The RLR, MDA5 has also been implicated in HCV PAMP recognition although, due to its 
preference for longer dsRNA, it’s hypothesized to recognize HCV replication intermediates 
produced later in the life cycle (Errett and Gale, 2015a). When cell lines were produced which 
knocked out either RIG-I or MDA5 and then looked at the production of interferon-β, 
interleukin-28, and interleukin-29 in response to HCV RNA transfection, they found that the 
antiviral response was significantly hampered when MDA5 was knocked out. Further, when 
siRNA was expressed which targeted MDA5 in primary hepatocytes infected with HCV genotype 
2a, the cell’s production of interferon-β was decreased. Therefore, it is believed that MDA5 also 
plays a role in HCV detection and that MDA5 and RIG-I sensing may occur at different points in 
the viral life cycle (Cao et al., 2015). 
LGP2 has also, more recently, been implicated in HCV RNA sensing. Knockdown of LGP2 
significantly hampered the interferon response to HCV infection and therefore LGP2 must be a 
positive regulator of HCV infection. Mechanistic studies showed that LGP2 exerted its effect 
somewhere upstream of MDA5 in the interferon signaling cascade and that HCV RNA promoted 
interaction between MDA5 and LGP2, which also enhanced MDA5 interaction with RNA (Hei 
and Zhong, 2017). 
Although HCV RNA is able to trigger RIG-I like receptor signaling and the importance of 
this signaling to cell permissiveness is demonstrated with the Huh 7.5 cell line defective RIG-I 
mutation, most cases of HCV go on to establish a chronic infection. This is possible because HCV 
is adept at evading the host innate immune mechanisms and thereby elongating the time 
between infection and a robust immune response (Liu and Gale, 2010). 
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HCV’s regulation of the RIG-I like receptor pathway is mediated by the NS3:NS4A 
protein. NS3:NS4A contains a covalently linked protease and helicase along with a co-factor 
protein (NS4A) which greatly enhances proteolytic function. NS3:NS4A recognizes and cleaves 
the MAVS RLR adaptor protein near its C-terminus, thus liberating it from the mitochondrial 
surface and abrogating its downstream signaling which leads to activation of IFN and other 
cytokines. Cleavage of MAVS stops all RIG-I like receptor signaling and the prevention of MAVS 
cleavage through mutation of the MAVS cleavage site (C508Y in MAVS) restores the RIG-I like 
receptor function. In addition, the HCV NS3-4A protease is able to cleave the adaptor protein 
for TLR signaling, TRIF, and inhibit detection through the TLR pathway. Taken together, this 
innate immune signaling disruption is enough to effectively block early HCV detection, giving 
the virus a chance to establish a chronic infection in hepatocytes (Horner et al., 2012; Horner, 
2014). 
2.4 Other DExD/H-box proteins 
Proteins in the DExD/H box helicase family are known to be involved in many forms of 
RNA processing such as splicing, transcriptional and translational regulation, as well as mRNA 
export and decay. All members contain a highly conserved RNA binding site and ATPase. 
However, their functions are diverse and, in some cases, do not require nucleic acid unwinding 
(Frick et al., 2004). Thus, it has been proposed that while sometimes these helicases are 
performing the function of unwinding and remodeling nucleic acids, other times, they may be 
rearranging protein complexes or using nucleic acid binding activity to sequester nucleic acids.   
DExD/H box helicases have been discovered that play a role in the host response to pathogenic 
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infection. DDX1, DDX3, DDX5, DDX 6, DDX9, DDX17, DDX41, DDX60, DHX 9, and DHX36 
comprise a short list of the host DExD/H box helicases which also function as PRRs (Jankowsky 
et al., 2011). 
2.4.1 DDX3 
DDX3 has the ability to enhance interferon production in response to viral invasion and 
works downstream of the RLRs. For example, DDX3 was identified in a yeast two-hybrid screen 
as an interacting partner to MAVS and it was shown using an IRF-3 reporter assay that the 
DDX3:MAVS interaction upregulates interferon production (Oshiumi et al., 2010). Therefore, 
DDX3 is a prime target for viral manipulation by human immunodeficiency virus, hepatitis C 
virus, and poxviruses (Oda et al., 2009; Owsianka and Patel, 1999; Yedavalli, Venkat S R K et al., 
2004). Interestingly, DDX3 is also is hijacked by HCV and HIV to participate in viral replication 
(Ariumi et al., 2007; Yedavalli, Venkat S R K et al., 2004). For example, DDX3 binds to the HCV 
core protein and when cells harboring an HCV replicon or infected with full length HCV-1b 
expressed a lentivirus vector encoding a short hairpin RNA against DDX3, both the replicon 
replication and the accumulation of full length HCV RNA were suppressed (Ariumi et al., 2007). 
DDX3 plays contradictory roles in viral replication and host viral detection/signaling by both 
detecting viral invasion and initiating immune signaling and by upregulating production of some 
viruses, like HCV. 
DDX3’s involvement in the IFN production pathway was discovered when Schroder et al 
searched for targets of vaccinia virus protein K7 in order to understand its ability to reduce 
interferon production. Using K7 antibodies to pull down factors in HEK293 cells led to the 
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identification of an unknown protein which was later identified, using peptide mass 
fingerprinting, as DDX3. Two groups simultaneously reported that DDX3 interacts with tank 
binding kinase 1 (TBK1) and I-kappa kappa epsilon (IKKƐ) in response to virus infection and 
encourages the phosphorylation of IRF3 and induction of the interferon promoter. When DDX3 
was silenced via a small interfering RNA, interferon signaling upon vaccinia virus infection was 
reduced (Decker et al., 2008; Schröder, 2011). TBK1 and IKKƐ are at a critical point in the IFN 
induction pathway where signaling from diverse PRRs converge with signaling through MAVS, 
TRIF, and STING. DDX3 association with TBK1 and IkkƐ, makes it a part of this key step. 
Later Schroder et al elaborated on their original findings to show that DDX3 not only 
interacts with TBK1 and IKKƐ, but is also phosphorylated by them. They also showed that there 
is a direct interaction between DDX3 and IRF3 (L. Gu et al., 2013; Schröder, 2011). Soulat et al 
used chromatin immunoprecipitation to demonstrate that DDX3 binds the interferon promoter 
directly when stimulated by virus infection. In all cases, DDX3 had a positive effect on interferon 
induction (Decker et al., 2008). Lastly, Oshiumi et al found, while studying the interaction of 
HCV core protein and DDX3, that DDX3 also associates with MAVS. Reporter assay showed that 
the association of DDX3 and MAV enhanced IFN-β promoter activation and knockdown of DDX3 
with a small interfering RNA decreased the IFN-β promoter activation (Oshiumi et al., 2010). 
2.4.2 DDX1 
DDX1 is an RNA helicase able to unwind duplex RNA and RNA-DNA complexes which 
may play a role in RNA clearance at double-stranded breaks, thereby aiding in template guided 
repair of the genome. More recently, DDX1 has been implicated in innate immunity as an 
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intracellular receptor for dsRNA. DDX1 has been shown to bind poly I:C RNA and knockdown of 
DDX1 decreases interferon signaling (Fullam and Schröder, 2013; Zhang et al., 2011). 
2.4.3 DDX5 
DDX5 is involved in multiple cellular processes which involve alteration of RNA 
secondary structure, including translation initiation, nuclear splicing, and splicesome assembly 
(Fuller-Pace, 2013). DDX5 has also been implicated in HCV replication where it is shown to 
interact with NS5B. Initially it was revealed that over-expression of NS5B caused a re-
localization of DDX5 from the nucleus to the cytoplasm and that infection with infectious JFH1 
particles also caused the same re-localization. Binding studies showed that DDX5 interacts with 
NS5B in two locations on the protein. Further, in cells where DDX5 was knocked down, 
production of the negative sense strand of HCV RNA was reduced, implying a possible role for 
DDX5 in HCV RNA replication (Upadya et al., 2014). 
2.5 FRET Microscopy 
2.5.1 Principles  
The ability to look at sub-cellular structures by labeling structures or proteins of interest 
using fluorescent dyes or fluorescent proteins is useful to understanding the cellular 
environment under different conditions. This is may be achieved by labeling multiple cellular 
components in fixed cells and taking several images targeting a different range of emission 
wavelengths each time to isolate the signal from each fluorescent tag. The resulting images are 
then overlaid and have contributed some beautiful and informative images to the 
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understanding of the sub-cellular environment. However, fixed cells are not alive and therefore 
cannot contribute information as to the dynamic and sometimes transient interactions 
occurring in live cells. In addition, observing the co-localization of proteins using a fluorescence 
microscope does not provide the resolution necessary to confirm or deny an interaction 
because proteins are on the scale of a few nanonmeters wide and the resolution of a 
fluorescent microscope is on the order of hundreds of nanometers (Piston and Kremers, 2007; 
Raicu and Singh, 2013). Instead, FRET microscopy provides an ideal framework to learn more 
about dynamic, intracellular protein:protein interactions. 
                Fluorescence resonance energy transfer (or Förster resonance energy transfer) (FRET) 
(Lakowicz, 2010) can be measured over distances of 0-10 nm (1-100 Angstroms) (Clegg, 1995). 
The fundamental principle of FRET is that a fluorescent donor molecule is put into an excited 
state through absorption of light. That donor molecule may then transfer its energy non-
radiatively to a nearby fluorescent acceptor molecule through long-range dipole-dipole 
interactions. The non-radiative transfer is affected by orientation, environmental factors, and 
distance. Once the acceptor molecule has absorbed the energy from the donor molecule, the 
light emitted by the acceptor molecule can be measured as FRET (Clegg, 1995; Piston and 
Kremers, 2007; Selvin, 1995; Selvin, 2000). This is because the light emitted from the acceptor 
will be directly proportional to the energy transferred from the donor. The transfer efficiency 
(E) can be measured using the relative fluorescence intensity of the donor in the absence (FD) 
and presence (FDA) of the acceptor as: 
𝐄 = 𝟏 − 
𝐅𝐃𝐀
𝐅𝐃
                   (Equation 2-1) 
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One of the most important aspects to a successful FRET experiment is selection of an 
appropriate FRET pair. Ideally, the donor should have a high quantum yield so that it gives off 
the most energy possible from each excitation photon and the acceptor should have the 
highest extinction co-efficient possible to ensure that it is able to absorb the maximum number 
of photons emitted by the donor. Choosing a donor with a high quantum yield and an acceptor 
with a high extinction co-efficient increases the likelihood of a successful energy transfer. 
Additionally, the spectral overlap between the donor emission and the acceptor absorption 
should be at a maximum while minimizing any direct excitation by the acceptor at the donor 
excitation wavelength (Bajar et al., 2016; Shaner et al., 2005).  
In addition, the location and orientation of the fluorescent tags on the proteins or other 
sub-cellular regions of interest need to be positioned in such a way that productive FRET can 
occur between the fluorescent tags. Since FRET is only easily measurable within a small range of 
1-10 nm, if two proteins interact, but form a complex where the orientation of the fluorescent 
tags are diametrically opposed, no FRET may be observed. Further, the tagging of a protein 
surface may block an association that would otherwise take place under native conditions. 
Therefore, great care must be taken not to obscure the putative interaction site. The 
interaction site may be known through x-ray crystallography, through known mutations which 
cause a loss of interaction or it may be predicted through molecular modeling. The fluorescent 
tags should then be placed outside of the interaction site so as not to block an interaction 
(Jares-Erijman and Jovin, 2006; Snapp, 2005). 
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The above mentioned obstacles also highlight an important property of all FRET 
measurements. Specifically, the absence of FRET cannot conclusively say that two proteins do 
not interact because the selection of the fluorescent tags may not be optimal or the location of 
the tags may be obscuring interaction sites. Only the presence of FRET and the intensity of FRET 
can render information as to the interaction of two proteins. Each FRET experiment must be 
optimized to achieve the best signal (Piston and Kremers, 2007). 
When FRET occurs the donor is excited and transfers energy to an acceptor. There are 
several different approaches to calculating FRET which rely on three basic components of 
fluorescence resonance energy transfer. The first approach focuses on the decrease in donor 
emission intensity when some of the donor emission energy is non-radiatively transferred to a 
nearby acceptor. The second approach focuses on the increase (sensitization) of acceptor 
emission intensity when an acceptor receives energy from a nearby donor.  The third approach 
focuses on the property that, when a donor interacts with an acceptor, this causes a decrease 
in the fluorescence lifetimes of the interacting donors because FRET provides additional 
pathways through which the donor may lose energy and therefore the total fluorescence 
lifetime of the donor is decreased. These three effects decrease of the donor, enhanced 
(sensitized) emission of the acceptor, and reduced lifetime of the donor, make up the basis for 
several FRET analysis techniques which will be briefly discussed (Raicu and Singh, 2013). 
2.5.2 FRET calculation using filter based measurements 
 Two ways to calculate FRET, as adapted by Lakowicz (Lakowicz, 2010) and Hoppe 
(Hoppe et al., 2002) are based on whether they depend on the decrease of the donor intensity 
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due to quenching or the increase of the acceptor intensity due to sensitized emission. The first 
method is defined based on a decrease of the donor intensity due to fluorescence quenching 
(Equation 2-2), and the second is defined based on the increase of the acceptor emission 
intensity due to sensitized emission (Equation 2-3).  
𝑬𝒂𝒑𝒑 = (𝟏 −
𝑭𝑫𝑨(𝝀𝑫
𝒆𝒙𝝀𝑫
𝒆𝒎)
𝑭𝑫(𝝀𝑫
𝒆𝒙𝝀𝑫
𝒆𝒎)
)               (Equation 2-2)
        
𝑬𝒂𝒑𝒑 =
ɛ𝑨(𝝀𝑫
𝒆𝒙)
ɛ𝑫(𝝀𝑫
𝒆𝒙)
(
𝑭𝑨𝑫(𝝀𝑫
𝒆𝒙𝝀𝑨
𝒆𝒎)
𝑭𝑨(𝝀𝑫
𝒆𝒙𝝀𝑨
𝒆𝒎)
− 𝟏)              (Equation 2-3) 
In equation 2-2, 𝐹𝐷(𝜆𝐷
𝑒𝑥𝜆𝐷
𝑒𝑚) is the donor fluorescence of the sample in the absence of acceptor 
and 𝐹𝐷𝐴(𝜆𝐷
𝑒𝑥𝜆𝐷
𝑒𝑚) is the donor fluorescence in the presence of acceptor. In equation 2-3, the 
ɛ𝐴(𝜆𝐷
𝑒𝑥) is the extinction coefficient of the acceptor at the donor excitation wavelength and 
ɛ𝐷(𝜆𝐷
𝑒𝑥) is the extinction coefficient of the donor at the donor excitation wavelength.  
𝐹𝐴𝐷(𝜆𝐷
𝑒𝑥𝜆𝐴
𝑒𝑚) is the acceptor fluorescence in the presence of donor and 𝐹𝐴(𝜆𝐷
𝑒𝑥𝜆𝐴
𝑒𝑚) is the 
acceptor fluorescence in the absence of donor. 
 The application of equation 2-2 is confounded by determination of the 
fluorescence of the donor in the absence of acceptor (𝐹𝐷(𝜆𝐷
𝑒𝑥𝜆𝐷
𝑒𝑚)). Some techniques (i.e. 
acceptor photo-bleaching and FRET spectrometry) are able to calculate (𝐹𝐷(𝜆𝐷
𝑒𝑥𝜆𝐷
𝑒𝑚) indirectly 
and therefore may be applied to fluorescent microscopic images where the direct 
measurement of (𝐹𝐷(𝜆𝐷
𝑒𝑥𝜆𝐷
𝑒𝑚) is impossible. These techniques will be discussed later. However, 
in the specific case of an in vitro titration of a donor with an acceptor that is measured using a 
spectrophotometer, the starting fluorescence intensity of the donor (before any titrant is 
added) is a close approximation to the 𝐹𝐷(𝜆𝐷
𝑒𝑥𝜆𝐷
𝑒𝑚) throughout the titration if the starting 
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volume is large relative to any titrant added.  In this specific case, the starting point in the 
titration is defined as 𝐼𝐴𝑙𝑜𝑛𝑒
𝐷 (𝜆𝐷
𝑒𝑥𝜆𝐷
𝑒𝑚) which is analogous to 𝐹𝐷(𝜆𝐷
𝑒𝑥𝜆𝐷
𝑒𝑚)  and is directly 
measured. Each subsequent addition of titrant is defined as 𝐼𝐷𝐴(𝜆𝐷
𝑒𝑥𝜆𝐷
𝑒𝑚) which is analogous 
to 𝐹𝐷𝐴(𝜆𝐷
𝑒𝑥𝜆𝐷
𝑒𝑚) or donor in the presence of acceptor when excited at the donor excitation 
wavelength and measured at the donor emission wavelength.  If the quantities 
𝐼𝐴𝑙𝑜𝑛𝑒
𝐷 (𝜆𝐷
𝑒𝑥𝜆𝐷
𝑒𝑚) and 𝐼𝐷𝐴(𝜆𝐷
𝑒𝑥𝜆𝐷
𝑒𝑚) are substituted into equation 2-2, then equation 2-4 
results: 
       𝑭𝑭𝑹𝑬𝑻 = 𝟏 −
𝑰𝑫(𝝀𝑫
𝒆𝒙𝝀𝑫
𝒆𝒎)
𝑰𝑨𝒍𝒐𝒏𝒆
𝑫 (𝝀𝑫
𝒆𝒙𝝀𝑫
𝒆𝒎) 
   (Equation 2-4) 
  
 Another way to calculate FRET as defined by Hoppe (Hoppe et al., 2002)  (equation 
2-3) is sometimes called three-filter acceptor “sensitized emission” because it focuses on the 
energy gained by the acceptor rather than energy lost by the donor.  Acceptor sensitized 
emission is due to energy transfer from the donor. This is determined using equation 2-3 from 
the ratio of the acceptor fluorescence intensity in the presence of donor 𝐹𝐴𝐷(𝜆𝐷
𝑒𝑥𝜆𝐴
𝑒𝑚) and the 
acceptor fluorescence intensity in the absence of donor 𝐹𝐴(𝜆𝐷
𝑒𝑥𝜆𝐴
𝑒𝑚) and the extinction co-
efficients of the donor and acceptor respectively ɛ𝐴(𝜆𝐷
𝑒𝑥) and the ɛ𝐷(𝜆𝐷
𝑒𝑥). 
 Three-filter sensitized emission involves the use of three filter sets which collect 
three images. The three images are donor excitation and donor emission, 𝐹(𝜆𝐷
𝑒𝑥𝜆𝐷
𝑒𝑚) or 𝐼𝐷, 
acceptor excitation and acceptor emission, 𝐹(𝜆𝐴
𝑒𝑥𝜆𝐴
𝑒𝑚) or 𝐼𝐴, and donor excitation and acceptor 
emission, 𝐹(𝜆𝐷
𝑒𝑥𝜆𝐴
𝑒𝑚), or 𝐼𝐹.  The collection 𝐼𝐷 , 𝐼𝐴, and 𝐼𝐹  assumes that there is negligible 
transmission of acceptor emission into the donor emission filter when excited at the donor 
54 
 
excitation wavelength and negligible transmission of the donor emission  into the acceptor 
emission filter when excited at the acceptor excitation wavelength or that the following 
conditions are met: 
𝑭𝑨(𝝀𝑫
𝒆𝒙𝝀𝑫
𝒆𝒎) = 𝟎               (Equation 2-5) 
𝑭𝑫(𝝀𝑨
𝒆𝒙𝝀𝑨
𝒆𝒎) = 𝟎               (Equation 2-6) 
Another assumption made in three-filter sensitized emission is that the contributions of 
excitation light or fluorescence emission for any given fluorophore are linearly related and can 
be propagated from one filter set to another using scalar factors. 
 To solve for equation 2-3 using a microscope, a correction must be applied for any 
donor emission which may overlap with the acceptor emission spectrum. Specifically, 
𝐹𝐴𝐷(𝜆𝐷
𝑒𝑥𝜆𝐴
𝑒𝑚) and 𝐹𝐴(𝜆𝐷
𝑒𝑥𝜆𝐴
𝑒𝑚) must be corrected for any donor spectral contamination. In 
addition, 𝐹𝐴(𝜆𝐷
𝑒𝑥𝜆𝐴
𝑒𝑚) (fluorescence of the acceptor in the absence of donor) when measured in 
a microscope, must be determined in the presence of donors.  Assuming the acceptor 
fluorescence is not modified by the presence of the donor when the acceptor is excited at the 
acceptor’s excitation then,  
𝑭𝑨𝑫(𝝀𝑨
𝒆𝒙𝝀𝑨
𝒆𝒎) = 𝑭𝑨(𝝀𝑨
𝒆𝒙𝝀𝑨
𝒆𝒎)              (Equation 2-7) 
If it is assumed that the emission of the acceptor at one wavelength is proportional to the 
emission of the acceptor at another wavelength and equation 2-7 is used then the fluorescence 
of the acceptor alone in the presence of donor can be determined using equation 2-8. 
𝑭𝑨(𝝀𝑨
𝒆𝒙𝝀𝑨
𝒆𝒎) = 𝜶𝑭𝑨𝑫(𝝀𝑨
𝒆𝒙𝝀𝑨
𝒆𝒎) = 𝜶𝑰𝑨             (Equation 2-8) 
The α co-efficient is measured in a sample containing only acceptor. The α is defined as: 
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𝜶 = 
𝑭𝑨(𝝀𝑫
𝒆𝒙𝝀𝑨
𝒆𝒎)
𝑭𝑨(𝝀𝑨
𝒆𝒙𝝀𝑨
𝒆𝒎)
               (Equation 2-9) 
With any given FRET pair, the emission of the donor often overlaps with the emission of the 
acceptor such that the signal collected at the acceptor emission upon donor excitation 
(𝐹(𝜆𝐷
𝑒𝑥𝜆𝐴
𝑒𝑚), or 𝐼𝐹) contains fluorescence from both the donor and the acceptor (equation 2-
10). 
𝑭(𝝀𝑫
𝒆𝒙𝝀𝑨
𝒆𝒎) = 𝑭𝑨𝑫(𝝀𝑫
𝒆𝒙𝝀𝑨
𝒆𝒎) + 𝑭𝑫𝑨(𝝀𝑫
𝒆𝒙𝝀𝑨
𝒆𝒎) =  𝑰𝑭          (Equation 2-10) 
To correct for the donor emission within the acceptor emission wavelength another correction 
(β) can be determined such that: 
𝑭𝑫𝑨(𝝀𝑫
𝒆𝒙𝝀𝑨
𝒆𝒎) = 𝜷𝑭𝑫𝑨(𝝀𝑫
𝒆𝒙𝝀𝑫
𝒆𝒎) = 𝜷𝑰𝑫          (Equation 2-11) 
Where the β is determined from a sample expressing solely donor. The β is defined as: 
𝜷 = 
𝑭𝑫(𝝀𝑫
𝒆𝒙𝝀𝑨
𝒆𝒎)
𝑭𝑫(𝝀𝑫
𝒆𝒙𝝀𝑫
𝒆𝒎)
             (Equation 2-12) 
By substituting the equations for the α and β corrections into the equation for sensitized 
emission, equation 2-3  results in equation 2-13, as defined by Hoppe: 
𝑬𝒂𝒑𝒑 =  
ɛ𝑨(𝝀𝑫
𝒆𝒙)
ɛ𝑫(𝝀𝑫
𝒆𝒙)
(
𝑭(𝝀𝑫
𝒆𝒙𝝀𝑨
𝒆𝒎)−𝜷𝑭𝑫𝑨(𝝀𝑫
𝒆𝒙𝝀𝑫
𝒆𝒎)
𝜶𝑭𝑨(𝝀𝑨
𝒆𝒙𝝀𝑨
𝒆𝒎)
− 𝟏)           (Equation 2-13) 
The fluorescence intensities can be collected using three filter sets, 𝐼𝐷 , 𝐼𝐴, and 𝐼𝐹. Therefore 
equation 2-13 becomes: 
𝑬𝒂𝒑𝒑 =  
ɛ𝑨(𝝀𝑫
𝒆𝒙)
ɛ𝑫(𝝀𝑫
𝒆𝒙)
(
𝑰𝑭−𝜷𝑰𝑫
𝜶𝑰𝑨
− 𝟏)            (Equation 2-14) 
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2.5.3 Acceptor photo-bleaching 
One of the challenges which arises with the calculation of Eapp using any of the methods 
which rely on the donor decrease upon energy transfer (equation 2-2) is how to calculate the 
fluorescence of the donor alone in a sample containing both donor and acceptor. Acceptor 
photo-bleaching is one method which attempts to solve this problem by bleaching the acceptor 
irreversibly (Jovin et al., 2005). If the acceptor molecule is bleached irreversibly, the donor will 
no longer be quenched and its fluorescence restored. The ratio between the donor before 
quenching and the donor after quenching is a measure of how much energy was transferred 
between the donor and acceptor or FRET.  
𝐅𝐑𝐄𝐓 =
𝑭𝒑𝒐𝒔𝒕
𝑫 −𝑭𝒑𝒓𝒆
𝑫
𝑭𝒑𝒐𝒔𝒕
𝑫                                              (Equation 2-15) 
Where 𝑭𝒑𝒐𝒔𝒕
𝑫  is the fluorescence of the donor after acceptor photo-bleaching and 𝑭𝒑𝒓𝒆
𝑫  is 
the fluorescence of the donor before photo-bleaching. 
Several problems exist for acceptor photo-bleaching, particularly in live cell 
measurements. Photo-bleaching the acceptor takes minutes, and therefore can only be done in 
fixed cells or with immobilized proteins. The time it takes to bleach the acceptor is ample time 
for molecular diffusion in a cell and the structure of live dynamic complexes will shift in that 
time. In addition, the process is irreversible, meaning that each cell can only be measured once. 
Lastly, it can be difficult to specifically target the acceptor and not also cause some bleaching to 
the donor (Karpova et al., 2003). 
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2.5.4 Fluorescence lifetime measurements  
Fluorescence lifetime imaging (FLIM) is based off the model that all fluorescent 
molecules exhibit an exponential decay of intensity and that the rate of this decay is affected by 
the surrounding environment of the fluorescent molecule. Interactions with nearby quenchers 
will change the decay rate of the molecule. When the donor molecule is quenched through 
interaction with an acceptor, the rate of the donor decay will be decreased (Berezin and 
Achilefu, 2010).  
 𝐅𝐑𝐄𝐓 =  𝟏 −
𝛕𝐃𝐀
𝛕𝐃
                                              (Equation 2-16) 
Where ƬDA is equal to the fluorescence of the donor in the presence of acceptor and ƬD is equal 
to the fluorescence of the donor in the absence of acceptor (Hoppe et al., 2002). 
Therefore, FRET can be measured through the decrease in fluorescence decay time in 
the presence of acceptor. One advantage of FLIM is that it relies only on the fluorescence of the 
donor and therefore is immune to some of the problems discussed above such as the effect of 
direct excitation of the acceptor at the donor excitation wavelength. Limitations to FLIM include 
the nanosecond time scale over which images need to be collected which requires expensive 
equipment not available to many labs. In addition, the fluorescence lifetimes of fluorescent 
molecules are also affected by factors such as pH and the changing environment of a cell can 
cause pH fluctuations which shorten fluorescent lifetimes or local environmental conditions can 
cause fluorescent molecules to exhibit multiple fluorescent decays. All of these factors can 
induce artifacts which make data interpretation difficult (Becker, 2012). 
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2.5.5 Optical Microspectroscopy 
Optical microspectroscopy is similar to sensitized emission in that it relies on the 
calculation of donor and acceptor contributions to a composite donor and acceptor spectrum. A 
major component of optical microspectroscopy is that it employs spectral imaging. Spectral 
imaging means that the whole emission spectrum is collected allowing for separation of the 
donor and acceptor spectrum not just at the peak of emission, but also at the tails of the 
fluorescent spectra. This allows for better discrimination between donor and acceptor signal 
and may be able to pick up on more subtle spectra shifts which are missed when only the peak 
values are collected. In addition, the technique allows for the calculation of the relative amount 
of donor and acceptor fluorescence. Furthermore, it is possible to take images at two excitation 
wavelengths and to accurately correct for direct excitation of the acceptor or any donor bleed 
through in the measurement. One of the drawbacks to the method using two successive 
excitations is the time it takes to switch from one wavelength to another, which causes 
molecular diffusion to scramble the information between scans. In other words, the molecules 
imaged in the first scan are distinct from those measured in the second scan (Chen et al., 2007; 
Leavesley et al., 2013; Raicu et al., 2009; Raicu et al., 2005; Raicu and Singh, 2013). 
In a typical fluorescent optical microspectroscopy experiment, there are several 
fluorophores present in the sample being measured. In order to separate the component 
spectra from the overall composite spectrum, spectral unmixing must be employed. Spectral 
unmixing separates the relative contribution from each fluorophore for every pixel of an image. 
In order to achieve this, elementary spectrum of each fluorescent spectrum contributing to the 
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overall composite spectrum are first collected using samples containing each fluorophore 
individually. The acquisition of elementary spectra must be obtained using the same conditions 
employed for the measurement of the composite sample. 
The underlying assumption of spectral unmixing is that the composite spectrum is made 
up of a linear combination of each contributing elementary spectra as defined below: 
𝑺𝒎(𝝀𝒆𝒙,𝒊 𝝀𝒆𝒎) =  𝜮𝒍[𝒌
𝒍(𝝀𝒆𝒙,𝒊)𝒔
𝒍(𝝀𝒆𝒎)]                     (Equation 2-17) 
Where i (=1,2) is the excitation wavelength index and l is the summation index for the 
different spectra present in the composite spectra. The overall spectral contributions from each 
fluorophore in the composite spectra can then be determined using a linear algebra matrix to 
calculate the individual contributions of the elementary spectra to each point in the measured 
composite spectra.  
The coefficients, defined as kx (where x equals the contributing elementary spectra (i.e. 
donor in the presence of acceptor (DA), acceptor in the presence of donor (AD), etc)) equal to 
the fluorescent contributions of each fluorescent species present in the composite spectra can 
then be extracted using a least squares minimization method previously described (Biener et 
al., 2013; Raicu et al., 2005; Raicu and Singh, 2013). 
2.5.7 FRET Spectrometry 
FRET spectrometry uses the technique of spectral imaging and applies it to the problem 
of calculating not only the presence or absence of FRET but also the spatial dynamics of a 
supermolecular protein complex in living cells. In one version of FRET spectrometry, unlike 
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other techniques, spatial information can be gained without the burden of a second excitation 
wavelength (Raicu and Singh, 2013). To achieve this, the selection of fluorescent FRET pairs is of 
paramount importance because it is essential that there is no direct excitation of the acceptor 
at the excitation wavelength. Wildtype GFP and a yellow fluorescent protein are one example 
of a pair which meet this criteria. To eliminate the dependence on acceptor emission, FRET 
spectrometry relies on the measurement of the donor quenching using equation 2-2 for the 
calculation of Eapp.  
    𝐸𝑎𝑝𝑝 = 1 −
𝐹𝐷𝐴
𝐹𝐷
                         (Equation 2-2)                    
  
In equation 2-2, FD is defined as the total fluorescence of the donor in the absence of acceptor 
and FDA is defined as the fluorescence of the donor in the presence of acceptor. To solve for FDA, 
deconvolution (unmixing) of the emission spectra for the fluorescence of the donor is necessary 
(equation 2-17). When the composite spectrum is deconvoluted, it yields two quantities (kDA 
and kAD) which are equal to the maximum emission intensity for donor in the presence of 
acceptor and for acceptor in the presence of donor respectively (Biener et al., 2013).  The 
quantity kDA can then be used to determine the total number of donor photons emitted per unit 
time by integrating the fluorescence spectra, IDA(λem) = kDAiD(λem) over all emission wavelengths 
(equation 2-18). 
𝑭𝑫𝑨 = 𝒌𝑫𝑨 ∫ 𝒊𝑫(𝝀𝒆𝒎)𝒅𝝀𝒆𝒎 = 𝒌
𝑫𝑨𝒘𝑫          (Equation 2-18) 
61 
 
where 𝑖𝐷(𝜆𝑒𝑚) is the emission intensity of the donor spectrum measured in a sample only 
expressing donor and normalized to the maximum value and 𝑤𝐷 is the integral of the 
elementary spectra of the donor. 
Similarly, the 𝑘𝐴𝐷 value extracted from unmixing can be used to determine the total number of 
acceptor photons emitted per unit time by integrating the fluorescence spectrum IAD(λem) = 
kADiA(λem) over all emission wavelengths. 
𝑭𝑨𝑫 = 𝒌𝑨𝑫 ∫ 𝒊𝑨(𝝀𝒆𝒎)𝒅𝝀𝒆𝒎 = 𝒌
𝑨𝑫𝒘𝑨           (Equation 2-19) 
Where 𝑖𝐴(𝜆𝑒𝑚) is the emission intensity of the acceptor spectrum measured in a sample only 
expressing acceptor and normalized to the maximum value and 𝑤𝐴 is the integral of the 
elementary spectra of the acceptor. The term FAD will be used at a later point. 
The term FD  in equation 2-2 is calculated by assuming that light energy is conserved. In 
other words, FD is equal to the fluorescence of the donor in the presence of the acceptor (FDA) 
and the energy lost to FRET through the interaction of the donor and the acceptor (FD(RET)). 
𝑭𝑫 =  𝑭𝑫𝑨 +  𝑭𝑫(𝑹𝑬𝑻)                                  (Equation 2-20) 
To solve for FD(RET), a relationship between FD(RET) to FA(RET) must be derived. The quantum 
yield of the donor (QD) is a ratio of the number of donor emissions per total donor excitations. If 
the total number of excitations is termed  NRET , then the quantum yield defines how many of 
those total excitations would be emitted by the donor if no RET occurred according to equation 
2-21.  
𝑵𝑹𝑬𝑻𝑸𝑫 = 𝑭𝑫(𝑹𝑬𝑻)            (Equation 2-21) 
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However, once the photons have transferred from donor to acceptor, only a fraction of those 
(defined as the quantum yield of the acceptor which is the total number of photons emitted by 
the acceptor per total number of acceptor excitations, QA) will be emitted by the acceptor as 
photons according to equation 2-22. 
𝑵𝑹𝑬𝑻𝑸𝑨 = 𝑭𝑨(𝑹𝑬𝑻)            (Equation 2-22)  
 
If NRET from equation 2-22 is substituted into equation 2-21, equation 2-23 results (Raicu et al., 
2009): 
𝑭𝑫(𝑹𝑬𝑻) =
𝑸𝑫
𝑸𝑨
 𝑭𝑨(𝑹𝑬𝑻)                               (Equation 2-23) 
To solve for FA (RET) in equation 2-21, the following equation which relates the 
fluorescence of the acceptor in the presence of donor is equal to the direct excitation of the 
acceptor plus the energy gained from FRET.   
𝑭𝑨𝑫 =  𝑭𝝀𝒆𝒙
𝑨 +  𝑭𝑨(𝑹𝑬𝑻)                           (Equation 2-24) 
where FAD  is defined by equation 2-19.  
If there is no direct excitation of the acceptor (as would be the case for carefully chosen FRET 
pairs) then equation 2-24 may simplify to:  
𝑭𝑨𝑫 =  𝑭𝑨(𝑹𝑬𝑻)                               (Equation 2-25) 
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Since FAD is a measurable quantity (equation 2-19) and FAD = FA(RET), then FD(RET) becomes a 
measurable quantity through its relationship to FA(RET) shown above in equation 2-23. 
By substituting equation 2-18 in for FAD and equation 2-23 in for FD(RET) in equation 2-20, the 
following equation 2-26 results. 
𝑭𝑫 = 𝒌𝑫𝑨𝒘𝑫 +
𝑸𝑫
𝑸𝑨
 𝑭𝑨𝑫                                   (Equation 2-26) 
Next equations 2-18, 2-19, and 2-26 may be substituted into equation 2-2 to yield equation 2-
27. 
𝑬𝒂𝒑𝒑 = 𝟏 −
𝒌𝑫𝑨𝒘𝑫
𝒌𝑫𝑨𝒘𝑫+
𝑸𝑫
𝑸𝑨
 𝒌𝑨𝑫𝒘𝑨 
                          (Equation 2-27) 
    
Equation 2-27 can be rearranged to yield equation 2-28. 
𝑬𝒂𝒑𝒑 =
𝟏
𝟏+ 
𝑸𝑨
𝑸𝑫
𝒌𝑫𝑨
𝒌𝑨𝑫
𝒒𝑫
𝒘𝑨
           (Equation 2-28)     
   
The term QD is defined as the quantum yield of the donor and the term QA is defined as the 
quantum yield of the acceptor. Both known quantities which can be found in the literature for 
commonly used fluorescent probes. The term wD and wA are the integrals of the donor and 
acceptor respectively and these are measured and calibrated for each experiment. 
By calculating FRET using a single wavelength, the FRET spectrometry technique (Raicu 
and Singh, 2013) eliminates the need for a second excitation. By eliminating the second 
excitation wavelength, the molecular diffusion which may occur between scans does not occur 
and the analysis can be completed on a pixel level as opposed to an average over an area. This 
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pixel level information gives better spatial resolution of the complex(es) by allowing the 
creation of an image which shows a pixel by pixel distribution of Eapp values throughout the cell. 
In addition, it produces many more data points in one area because now instead of averaging 
the Eapp over a region of interest, you can extract a wide number of Eapp values over the region 
of interest and thus get a better idea as to the full dynamic range of complexes present within 
the area. 
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Chapter 3 Methods 
3.1 Molecular Cloning 
3.1.1 pCMV-YFP-LGP2 
LGP2 (DHX58) human cDNA ORF clone (Origene NM_024119) was amplified with PCR from the 
PCMV3-RC204837 (Origene, Inc) backbone using primers (Integrated DNA Technologies, 
Coralville, IA) which contain HindiIII and XhoI restriction sites. 
Forward 5’-CGC GCG AAG CTT ATG GAG CTT CGG TCC TAC CAA TGG GAG G-3’  
Reverse 5’-GCG CGC CTC GAG TCA CTC CAG GGA GAG GTC CGA CAA GTT C-3’  
The PCR product was then cut with HindiIII and XhoI restriction enzymes and ligated into a 
similarly treated PCMV6-AN-mYFP (Origene-PS100050) plasmid. 
The resulting plasmid expresses a YFP protein connected to LGP2 via a two amino acid linker. 
3.1.2 PCMV-CFP-LGP2 
LGP2 (DHX58) human cDNA ORF clone (Origene NM_024119) was amplified with PCR from the 
PCMV3-RC204837 (Origene, Inc) backbone using primers (Integrated DNA Technologies) which 
contain HindiIII and XhoI restriction sites. 
Forward 5’-CGC GCG AAG CTT ATG GAG CTT CGG TCC TAC CAA TGG GAG G-3’  
Reverse 5’-GCG CGC CTC GAG TCA CTC CAG GGA GAG GTC CGA CAA GTT C-3’  
66 
 
The PCR product was then cut with HindiIII and XhoI restriction enzymes and ligated into a 
similarly treated PCMV6-AN-mCFP (Origene-PS100052) plasmid. 
The resulting plasmid expresses a CFP protein connected to LGP2 via a two amino acid linker. 
3.1.3 PCMV-YFP-DDX1 
DDX1 human cDNA ORF clone (Origene NM_004939) was amplified using primers (Integrated 
DNA Technologies) which contain HindiIII and XhoI restriction sites. 
Forward: 5’-CGC GCG AAG CTT ATG GCG GCC TTC TCC GAG AT-3’ 
Reverse: 5’- GCG CGC CTC GAG TCA GAA GGT TCT GAA CAG CTG GTT AG-3’ 
The PCR product was then cut with HindiIII and XhoI restriction enzymes and ligated into a 
similarly treated PCMV6-AN-mYFP (Origene-PS100052) plasmid. 
The resulting plasmid expresses a YFP protein connected to DDX1 via a two amino acid linker. 
3.1.4 PCMV-YFP-DDX3 
DDX3 human cDNA ORF clone (Origene NM_001356) was amplified with using primers 
(Integrated DNA Technologies) which contain HindiIII and XhoI restriction sites. 
Forward: 5’CGC GCG AAG CTT ATG AGT CAT GTG GCA GTG GAA AAT 3’ 
Reverse: 5’GCG CGC CTC GAG TCA GTT ACC CCA CCA GTC AAC CCC CTG 3’ 
The PCR product was then cut with HindiIII and XhoI restriction enzymes and ligated into a 
similarly treated PCMV6-AN-mYFP (Origene-PS100052) plasmid. 
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The resulting plasmid expresses a YFP protein connected to DDX3 via a two amino acid linker. 
3.1.5 PCMV-YFP-DDX5 
DDX5 human cDNA ORF clone (Origene NM_004939) was amplified with using primers 
(Integrated DNA Technologies) which contain HindiIII and XhoI restriction sites. 
Forward: 5’- CGC GCG AAG CTT ATG TCG GGT TAT TCG AGT GAC C- 3’ 
Reverse: 5’- GCG CGC CTC GAG TTA TTG GGA ATA TCC TGT TGG C-3’ 
The PCR product was then cut with HindiIII and XhoI restriction enzymes and ligated into a 
similarly treated PCMV6-AN-mYFP (Origene-PS100052) plasmid. 
The resulting plasmid expresses a YFP protein connected to DDX5 via a two amino acid linker. 
3.1.6 PCMV-CFP-NS3:NS4A 
NS3:NS4A was cut from p28-His-NS3:NS4A-His (Frick et al., 2004) plasmid using NheI and XhoI. 
The resulting DNA fragment was gel purified and ligated into PCMV-AN-CFP-scNS3 which was 
also cut with NheI and XhoI. The resulting plasmid expresses a CFP protein connected to 
NS3:NS4A via an eight amino acid linker. 
3.1.7 pCMV-CFP-SCNS3 
SinglechainNS3 (scNS3) was amplified from clone p28-scNS3-1b(con1) (Frick et al., 2010) 
plasmid using primers (Integrated DNA Technologies) which contain HindiIII and XhoI restriction 
sites. 
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Forward: 5’- CGC GCG AAG CTT ATG GGC AGC AGC CAT CAT – 3’ 
Reverse: 5’-CGC GCG CTC GAG GAC GGA GCT CGA ATT CGG-3’ 
The PCR product was then cut with HindiIII and XhoI restriction enzymes and ligated into a 
similarly treated PCMV6-AN-mCFP-LGP2 vector. 
The resulting plasmid expresses a CFP protein connected to scNS3 via an eight amino acid 
linker. 
3.1.8 pCMV-CFP-NS3-HEL1B 
The NS3 helicase domain from genotype 1b open reading frame was cut from p24a-
NS3h1b(con1) (Belon and Frick, 2009a) plasmid using NheI and XhoI. The resulting DNA 
fragment was gel purified and ligated into PCMV-AN-CFP-scNS3 which was also cut with NheI 
and XhoI. The resulting plasmid expresses a CFP protein connected to NS3h via an eight amino 
acid linker. 
3.1.9 pCMV-CFP-NS3 
The open reading frame encoding the NS3 protease and helicase domain from genotype 1b was 
cut out of p280FL-NS3(1b-con1) (Neumann-Haefelin et al., 2008) plasmid using the restriction 
enzymes NheI and XhoI. The resulting full length NS3 DNA fragment was gel purified and ligated 
into PCMV-AN-CFP-scNS3 which was also cut with NheI and XhoI. The resulting plasmid 
expresses a CFP protein connected to NS3FL via an eight amino acid linker. 
3.1.10 PCMV-CFP-NS3-PRO 
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A stop codon was inserted in the linker after protease and before the helicase domain in PCMV-
CFP-scNS3 (above) using the following primers. 
 
Forward: 5’-GCTGGGGCATCTAGCGGGCTGCCGTGTGCACCCGAGGGGTTGCG-3’ 
Reverse: 5’-CGCAACCCCTCGGGTGCACACGGCAGCCCGCTAGATGCCCACAGC-3’ 
 
Agilent-QuickChange II Site Directed Mutagenesis Kit was used to make the mutation. After 
amplification, the parental methylated strand was degraded using DpnI.   The resulting 
amplicon was transformed into competent E.coli and transformants expressing the pCMV-CFP-
NS3-Pro were selected for using the amplicillan resistance marker. The resulting transformants 
were purified and sequenced to confirm presence of the stop codon. 
3.1.11 P24-CFP-NS3HEL 
The open reading frame encoding CFP-NS3h was excised from pCMV-CFP-NS3h (created above) 
using EcoRI. The resulting DNA fragment was gel purified and ligated into a similarly treated 
Pet24d vector (Novagen, Inc.) 
3.1.12 P24-YFP-NS3HEL 
The YFP open reading frame was amplified via PCR primers which contained NdeI and NheI 
restriction sites from the vector PCMV6-AN-mYFP (Origene-PS100052). The amplicon was 
digested with NdeI and NheI and ligated into a plasmid p24a-NS3h(con1) (Belon and Frick, 
2009a) which was similarly treated. 
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3.1.13 pCMV-YFP-RIG-I 
Vector was purchased from GeneCopoeia (Rockville, MD, Product # EX-T0237-M15). 
3.1.14 pCMV-CFP-RIG-I 
Vector was purchased from GeneCopoeia (Rockville, MD, Product # EX-T0237-M32). 
3.1.15 pCMV-YFP-MDA5 
Vector was purchased from GeneCopoeia (Rockville, MD, Product # EX-T0707-M150). 
3.1.16 pCMV-CFP-MDA5 
Vector was purchased from GeneCopoeia (Rockville, MD, Product # EX-T0707-M32). 
3.1.17 pCMV-GFP2-MAVS 
Vector was created and purchased via VectorBuilder with a two amino acid linker between the 
fluorescent protein and MAVS. 
3.1.18 EF1-mVenus-MDA5 
Vector was created and purchased through VectorBuilder and contains a 15 amino acid linker 
between the venus and MDA5. 
3.1.19 pCMV-GFP2-LGP2 
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LGP2 was cut from pCMV-YFP-LGP2 plasmid using HindiIII and XhoI. The resulting DNA fragment 
was gel purified and ligated into PCMV-AN-GFP2 which was also cut with HindiIII and XhoI. The 
resulting plasmid expresses a GFP2 protein connected to LGP2 via a two amino acid linker. 
3.1.20 pCMV-GFP2(T203I)-MAVS 
A point mutation was made in the GFP2-MAVS vector (above) purchased through GenScript 
such that the residue T203 in GFP2 was mutated to T203I. Genscript made the mutation. 
3.1.21 pCMV-Sapphire 
The vector expressing pCMV-Sapphire was designed and purchased through VectorBuilder. 
3.1.22 pCMV-GFP2  
The vector expressing pCMV-GFP2 was designed and purchased through Genscript. 
3.2 Protein Purification 
YFP-NS3h and CFP NS3h purified proteins used for calibration curves and FRET binding assays 
were purified from BL21(DE3) E.coli containing either pET24-CFP-NS3h or pET24-YFP-NS3h. HCV 
NS3h, scNS3, and NS3FL were purified from BL21(DE3) E.coli containing either pET24-NS3h, 
pET24-scNS3, or pET24-NS3FL. The method used for purification was exactly as previously 
described in detail (Frick et al., 2010; Ndjomou et al., 2015). 
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3.3 Enzyme Assays 
3.3.1 Helicase  
Molecular beacon-based helicase assays (Belon and Frick, 2008) were performed in the 
presence of 50 nM NS3, 12.5 nM helicase substrate, and a dilution series of 12 different HPI 
concentrations from 1 to 100 µM. The slopes immediately following ATP addition were 
analyzed to determine unwinding rates per the method previously described (Hanson et al., 
2012; Ndjomou et al., 2015). 
3.3.2 Protease  
HCV NS3 depsipeptide cleavage assays were performed with the RET-S1 substrate (Anaspec), 
which is based on the NS4A/NS4B cleavage site.  Each 20 µl assay contained 50 mM Tris–HCl pH 
7.0, 50% glycerol, 2% CHAPS, 30 mM DTT, 5% DMSO, and 0.5 µM RET-S1 substrate.  When NS3 
lacking a covalently tethered NS4A was used, reactions were supplemented with 6 µM pep4AK 
(Anaspec). Reactions were first performed with various concentrations of each NS3 protein to 
determine its specific activity.  A unit of enzyme was defined as the amount needed to cleave 
0.05 µM of substrate/min. To determine the inhibitory potential of HPI with each enzyme, 
reactions were performed with 1 unit of each enzyme with various concentrations of HPI. 
Reactions containing HPI were performed in the presence of a 16-pt two-fold dilution series of 
HPI starting at 100 µM. Assays were performed in duplicate, and rates normalized to reactions 
performed in the absence of HPI.  Initial rates of substrate cleavage were then plotted verses 
HPI concentration and fitted to a concentration response equation to calculate the 
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concentration of HPI needed to reduce initial rates by 50% using GraphPad Prism (v.6). 
(Ndjomou et al., 2015) 
3.3.3 Protein:DNA titrations 
The interaction between DNA oligonucleotides and fluorescent fusion proteins was 
monitored in vitro using a Cary Eclipse Spectrophotometer (Agilent). The fluorescent moieties 
used to label DNA were “MAX” (N-hydroxysuccinimide ester) and hexachlorofluoroscein (HF). 
Oligonucleotides were obtained from Integrated DNA Technologies (IDT). The sequences for the 
fluorescently labeled DNAs are below. 
5’-MAX-ATG GTT CTG AGG GTG GCG GTA CTA-3’  
5’- HF-TGG CGA CGG CAG CGA GGC-3’ 
The fluorescently tagged protein (YFP-NS3h) was purified as described above in section 3.2. 
Titrations were performed in 1.25 mM MgCl2, 12.5 mM MOPS (pH 6.5), and with various 
concentrations of fluorescent proteins which ranged from 50 to 300 nM per titration. Starting 
volumes were 500 µL and titrations were performed in a cuvette. The fluorescent protein was 
titrated with fluorescent DNA and a full emission spectrum was collected for 2 excitation 
wavelengths upon each addition of DNA. 
 The data for the titration between YFP-NS3h and HF-DNA was analyzed assuming 
that observed fluorescence intensity at a given set of wavelengths is equal to the concentration 
of the free acceptor [A], the free donor [D], and the donor acceptor complex [AD] times co-
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efficients (bA, bD, or bAD) describing a linear relationship between the fluorescent brightness 
(where brightness is equal to the extinction co-efficient of the fluorescent molecule (ɛ) 
multipled by the quantum yield of the fluorescent molecule (Q)) and the concentration of a 
species as described by equation 3-1.  
𝑰𝒐𝒃𝒔 = 𝒃
𝑨[𝑨] +  𝒃𝑫[𝑫] + 𝒃𝑨𝑫[𝑨𝑫𝒏]             (Equation 3-1) 
Equation 3-1 has too many unknown variables to be solved directly and therefore the 
application of equation 3-1 requires that simplifying assumptions be made dependent on 
specifics of each experiment. The simplying assumptions will be discussed as they apply to the 
application of equation 3-1 to the analysis of the titration of YFP-NS3h with HF-DNA in Chapter 
5. 
In equation 3-1, the A:D complex is described using the stoichiometry coefficient “n,” where n is 
the number of helicase (donors) bound to the DNA (acceptor), as indicated by the chemical 
equation below: 
ADn  A + nD                (Equation 3-2) 
It is important to note here that the above model makes the simplifying assumption that there 
is only one form of donor acceptor complex formed when “n” donors bind to one acceptor 
(ADn) without positive or negative cooperativity. Specifically, this is a 1:1 binding model where 
the acceptors and donors are assumed to be bound as a dimer made up of one acceptor and 
any “n” number of bound donors. 
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The equilibrium dissociation constant describing equation 3-2 (Kd) is defined as the 
concentration of the free acceptor [A] and the free donor [D] (modified by the co-efficient “n” 
to represent that multiple donors may be bound to one acceptor) divided by the total 
concentration of bound donor and acceptor [ADn] at equilibrium.  
𝑲𝑫 = [𝑨][𝒏𝑫]/[𝑨𝑫𝒏]              (Equation 3-3) 
The total free donor and total free acceptor can be calculated by assuming the following 
relationships:  
[𝑫] = [𝑫]𝑻 − [𝑨𝑫𝒏]               (Equation 3-4) 
[𝑨] = [𝑨]𝑻 − [𝑨𝑫𝒏]               (Equation 3-5) 
Where [D]T and [A]T are the total amount of donor and acceptor present at any point in the 
titration, which are known quantities. 
These assumptions allow for the calculation of the concentration of the A:D complex at each 
point in the titration from the Kd and the n, using equation 3-6: 
[𝑨𝑫𝒏] =
([𝑫]𝑻+𝒏[𝑨]𝑻+𝑲𝒅)−√([𝑫]𝑻+𝒏[𝑨]𝑻+𝑲𝒅)𝟐−𝟒∗[𝑫]𝑻∗𝒏[𝑨]𝑻
𝟐
                     (Equation 3-6) 
Substituring equations 3-4 through 3-6 into equation 3-1 yields: 
𝒊𝒐𝒃𝒔 = 𝒊
𝑨 [𝑨 −
([𝑫]𝑻+𝒏[𝑨]𝑻+𝑲𝒅)−√([𝑫]𝑻+𝒏[𝑨]𝑻+𝑲𝒅)𝟐−𝟒∗[𝑫]𝑻∗𝒏[𝑨]𝑻
𝟐
] +  𝒊𝑫 [𝑫 −
([𝑫]𝑻+𝒏[𝑨]𝑻+𝑲𝒅)−√([𝑫]𝑻+𝒏[𝑨]𝑻+𝑲𝒅)𝟐−𝟒∗[𝑫]𝑻∗𝒏[𝑨]𝑻
𝟐
] +
𝒊𝑨𝑫[
([𝑫]𝑻+𝒏[𝑨]𝑻+𝑲𝒅)−√([𝑫]𝑻+𝒏[𝑨]𝑻+𝑲𝒅)𝟐−𝟒∗[𝑫]𝑻∗𝒏[𝑨]𝑻
𝟐
]                            (Equation 3-7)  
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The titration data for the YFP-NS3h titrated with HF-DNA were fit to equation 3-7 using 
non-linear regression in GraphPad Prism V.5.  
The data for the titration of YFP-NS3h with MAX-DNA was fit using the following 
equation previously defined in Raicu et al (Raicu and Singh, 2013). 
𝑬𝒂𝒑𝒑 =
𝟏
𝑫𝑻
∙ ([𝑫] ∙ 𝟎 + [𝑨𝑫] ∙ 𝑬𝑨𝑫)               (Equation 3-8) 
where DT is the total donors present, [D] is the concentration of total free donors, [AD] is the 
concentration of donor:acceptor complexes and EAD is the pairwise FRET efficiency of the 
donor:acceptor complex.  
Equation 3-8 assumes  there is no fluorescence of the free monomers and therefore the 
equation can be simplified to: 
𝑬𝒂𝒑𝒑 =
[𝑨𝑫]
𝑫𝑻
∙ 𝑬𝑨𝑫                            (Equation 3-9) 
The concentration of complex ([AD]) can be solved for using equation 3-6 and the titration data 
for the YFP-NS3h titrated with MAX-DNA were fit to equation 3-9 using non-linear regression in 
GraphPad Prism V.5. 
To calculate FRET efficiency between the fluorescently labeled protein (YFP-NS3h) and 
the fluorescently labeled oligonucleotide (MAX-DNA), three different FRET techniques were 
used. The three methods were designed to analyze the energy lost by the donor in the 
presence of acceptor. In the first method, peak intensity values at donor emission (i.e. intensity 
at 525 nm recorded with the donor alone (𝐼𝐴𝑙𝑜𝑛𝑒
𝐷 (𝜆𝐷
𝑒𝑥𝜆𝐷
𝑒𝑚) and the intensity at 525 nm recorded 
in the presence of both door and acceptor (𝐼𝐷(𝜆𝐷
𝑒𝑥𝜆𝐷
𝑒𝑚) were used.  For a full explanation of the 
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terms used please see section 2.5.3. Equation 2-4 (reproduced below) was used to calculate 
FFRET.  
    𝐹𝐹𝑅𝐸𝑇 = 1 −
(𝐼𝐷(𝜆𝐷
𝑒𝑥𝜆𝐷
𝑒𝑚)
(𝐼𝐴𝑙𝑜𝑛𝑒
𝐷 (𝜆𝐷
𝑒𝑥𝜆𝐷
𝑒𝑚) 
          (Equation 2-4) 
Where 𝐼𝐷(𝜆𝐷
𝑒𝑥𝜆𝐷
𝑒𝑚 ) was the fluorescence intensity recorded at 525 nm (slit width 10 nm) upon 
excitation at 480 nm (slit width 10 nm) and recorded in the presence of acceptor and 
𝐼𝐴𝑙𝑜𝑛𝑒
𝐷 (𝜆𝐷
𝑒𝑥𝜆𝐷
𝑒𝑚) is the same value recorded in the absence of acceptor. 
 The second method was designed to separate the contributions of the donor and 
acceptor spectra from the composite spectra and to account for any background fluorescence 
(see section 2.5.6).  Using spectral unmixing, FD is obtained from unmixing the spectrum of 
donor alone to obtain kD. Then the kD value was multiplied by the normalized spectral integral 
of the spectrum of the donor alone to account for all the photons contained within the full 
donor spectrum.  The FDA values were obtained by unmixing spectra recorded in the presence of 
various amounts of acceptor to obtain kDA. Then the kDA values were also multiplied by the 
normalized spectral integral of the spectrum of the donor alone to account for all the photons 
contained within the full donor spectrum. This generated FDA values for each point in the 
titration. Eapp was then calculated using equation 2-1: 
 𝐸𝑎𝑝𝑝 = 1 −
𝐹𝐷𝐴
𝐹𝐷
                           (Equation 2-1) 
 The third method was used to simulate what would need to be done in a 
microscope when imaging cells expressing fluorescent proteins. It is important to note that 
direct measurements of FD are not possible to obtain when cells expressing fluorescent proteins 
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are imaged.  FD values were therefore back calculated from FAD and FDA values obtained from 
spectral unmixing using gamma ratios and the quantum yields of the donor and acceptor per 
equation 3-10. Equation 3-10 will be discussed in section 3.5.5. 
𝑭𝑫(𝝀𝒆𝒙,𝟏) =  𝑭
𝑫𝑨(𝝀𝒆𝒙,𝟏) +  
𝑸𝑫
𝑸𝑨
𝑭(𝝀𝒆𝒙,𝟏,𝝀𝒆𝒙,𝟐)          (Equation 3-10) 
Eapp was then calculated using the calculated FDA values and the back-calculated FD values using 
equation 2-1:  
𝐸𝑎𝑝𝑝 = 1 −
𝐹𝐷𝐴
𝐹𝐷
              (Equation 2-1)  
3.4 Cell-based Assays  
3.4.1 HCV subgenomic replicon assays.  
 All subgenomic replicon containing Huh-7.5 cells were isolated and maintained as 
previously described (Ndjomou et al., 2012). To assess the ability of each compound to inhibit 
HCV replication, Huh7.5 cells harboring HCV Rluc subgenomic replicons were seeded at 10 x 103 
cells per well in 96-well plates and incubated 4-5 hours to allow the cells to attach to the plate. 
Two-fold serial compound dilutions were made in dimethyl sulfoxide (DMSO), and diluted into 
media, such that the DMSO final concentration was 0.5% after adding dilutions to cells. 
Compounds and cells were incubated at 37 °C in 5% CO2. After 3 days, Renilla luciferase was 
measured using Promega’s Renilla luciferase assay kit. Quantitative reverse transcriptase PCR 
using Taqman probes specific to conserved sequences in the HCV 5’UTR was used to measure 
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relative RNA levels as previously described (Ndjomou et al., 2012). PCR data were normalized to 
RNA levels observed in cells incubated with DMSO only (Ndjomou et al., 2015). 
3.4.1.1 Combination studies 
Two-fold serial dilutions, starting at ~4 times the EC50 values obtained in concentration-
response assays with each compound alone, were prepared in 96-well plates.  50 μl of each 
dilution of the first compound to be tested (at twice the final compound concentration) was 
added horizontally and 50 μl of each dilution of the second compound was added vertically to 
make a 1x final concentration of each compound. After 3 days at 37 °C, luciferase activity was 
measured. At least four separate experiments (in triplicate) were performed for each 
combination (Ndjomou et al., 2015). 
3.4.1.2 In-vivo assay data analysis 
 Half-maximal inhibitory concentrations were calculated from concentration response 
curves using non-linear regression to fit data to a log(inhibitor) vs. normalized response 
equation with variable slope. The effects of drug-drug combinations were evaluated using the 
MacSynergy II (http://www.uab.edu/medicine/peds/macsynergy) (Prichard and Shipman, 
1990).  MacSynergy II uses the Bliss independence model to estimate synergy and/or 
antagonism.  Additive inhibition is calculated in MacSynergy using the equation Z = X + Y (1-X), 
where X and Y correspond to the inhibitory effects of compound 1 and 2 respectively, and Z is 
the effect produced when the two compounds are combined.  Resulting values are then 
subtracted from the normalized inhibition observed at each drug combination to estimate 
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synergy (positive values) or antagonism (negative values). Synergy/antagonism values 
calculated using the MacSynergy II Excel spreadsheet at the 95% confidence levels were plotted 
in three dimensions using DeltaGraph 6 (Redrock Software) (Ndjomou et al., 2015). 
3.4.2 Cell Viability Assays.  
To assess compound effects on Huh-7.5 or BHK DenV-Rluc cell viability, cells were plated 
and treated as above for compound inhibitory activity and the effect of compound on cell 
viability was tested using the CellTiter-Glo luminescent cell viability kit (Promega) (Ndjomou et 
al., 2015). 
3.4.3 Transfection with plasmids 
HEK293T cells were grown to 90% confluence in 10-cm cell culture dishes in 37 °C and 
5% CO2 in complete Hyclone (Hyclone labs, Logan, UT) Dulbecco’s Modified Eagle Medium 
(DMEM)/High Modified Media with 4,500 mg/l glucose, 110 mg/l sodium pyruvate 
(ThermoFisher Scientific). The media was supplemented with 10% fetal bovine serum (FBS), 1X 
non-essential amino acids, and 1X penicillin/streptomycin (ThermoFisher Scientific).  
The HEK293T cells were trypsinized, and diluted to 1.0 x 10 5 cells per mL. Then 2 mL (2.0 x 10 5 ) 
cells were seeded to 35 mm petri dishes, with a 14 mm diameter Microwell, No. 1.5 coverglass 
(0.16-0.19mm) poly-D-lysine coated glass bottom culture dishes (MatTek Corp., Ashland, MA) 
and allowed to grow for 24 hours in 37C under 5% CO2.   
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Aliquots of 1.5 ug of each plasmid was diluted in 600 uL of serum free DMEM growth media 
with 5 uL of Turbofect Transfection Reagent (Thermoscientific #R0531). The mixture sat at 23 °C 
for 1 hour.  The mixture was then added to the cells in the glass bottom culture dishes and the 
dishes were returned to 37°C and 5% CO2 for 24 hours to express the recombinant fluorescent 
protein construct (Corby et al., 2017). 
3.4.4 Intracellular protease assays  
A MAVS-based reporter assay was used for cell-based protease assay. 293T cells were 
co-transfected with plasmids encoding NS3 and the plasmid TRIP-RFP-NLS- IPS (Charles M. Rice, 
Rockefeller University), which encodes the “TagRFP” red fluorescent protein (RFP, Evrogen, 
Inc.) and a SV40 nuclear localization signal (NLS) fused to residues 462–540 of MAVS (aka IPS). 
Cells were imaged as described below (Corby et al., 2017). 
3.4.5 Transfections with polyinosinic–polycytidylic acid (Poly I:C)  
 
Four hours prior to imaging, either 200 μl of poly I:C (5 ng/μl) in DMEM plus TurboFect 
(1:100 dilution) or 200 μl of serum free DMEM plus TurboFect (1:100 dilution) was added to the 
dishes containing transfected cells. The plates were then returned to the 37 °C, 5% CO2 
incubator for 4 hours (Corby et al., 2017) 
3.4.6 ISRE Assays 
3.0 x10 4 of HEK 293T cells per well were plated per well of a 24-well plate. After 12 h at 
37 °C, 0.5 μg of the pISRE-luc (Agilent Technologies, Inc., product #219092) plasmid expressing 
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firefly luciferase under control of and interferon stimulated regulatory element (IRSE) was co-
transfected along with either 0.5 μg of plasmid expressing YFP alone or YFP-RIG-I, YFP-MDA5, or 
YFP-LGP2 using TurboFect (as above). After 24 h at 37 °C, luciferase activity was measured using 
the Firefly Luc One-Step Flow Assay Kit (Pierce) (Corby et al., 2017). 
3.5 Microscopy 
3.5.1 Choosing FRET pairs  
Initial experiments used the cyan fluorescent protein (CFP) and the yellow fluorescent 
protein (YFP) as the chosen FRET pair. This pair requires the use of a correction for direct 
excitation (explained below) due to the excitation of YFP at the 840 nm CFP peak excitation 
wavelength (Figure 3-1). This correction for direct excitation requires two excitation 
wavelengths and the time required between the two measurements allows enough time for 
Figure 3-1: Comparison of fluorescent protein spectrums. (A) Normalized absorption cross 
section of YFP and CFP with arrow indicating the YFP absorption present at the CFP excitation 
peak. This YFP absorption requires a correction for direct YFP excitation whenever a YFP and 
CFP pair is used. (B) Normalized absorption cross section of YFP and wild-type GFP (which has 
a similar absorption spectrum to GFP2).  Arrow indicates that the peak GFP absorption 
corresponds to no YFP absorption, therefore negating the need for a correction of direct 
excitation of the acceptor at the donor peak excitation wavelength. (C) Normalized 
absorption cross section of Venus and wild-type GFP (which has a similar absorption 
spectrum to GFP2).  Arrow indicates that the peak GFP absorption corresponds to no Venus 
absorption, therefore negating the need for a correction of direct excitation of the acceptor 
at the donor peak excitation wavelength. 
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molecular diffusion. Therefore, only average Eapps (FRET efficiencies) over the regions of interest 
were considered in the analysis of this data.  
To move away from the calculation of average Eapps and toward the generation of pixel 
level Eapps, the tags were switched to enhanced green fluorescent protein 2 (GFP2) and YFP or 
Venus. GFP2 is very similar to Clonetech’s enchanced green fluorescent protein (eGFP) molecule 
which incorporates mutations which allow it to fold at 37 °C and increases overall stability. The 
difference between GFP2 and Clonetech’s eGFP exists in just two amino acid changes. The GFP2 
protein incorporates an A206K mutation which prevents the inherent dimerization which all 
fluorescent proteins are prone to (von Stetten et al., 2012; Zacharias et al., 2002) and it also 
returns the eGFP S65T mutation to the wild-type S65 which gives the GFP2 molecule an 
Figure 3-2: Alignment of wild-type GFP (avGFP), Clonetech’s eGFP, and GFP2 protein 
sequences. The GFP2 protein retains all the characteristics of Clonetech’s eGFP molecule 
with the exception of two mutations. Clonetech eGFP includes a mutation at position 66 (in 
this alignment, S66T)) which alters eGFP excitation spectra to prefer a predominantly 475 
nm (960 nm-two photon) excitation. Additionally, eGFP retains the wildtype A207 (in this 
alignment) which means that eGFP is prone to dimerization. Both mutations are indicated 
by arrows in the alignment. The GFP2 protein retains the original wild-type GFP S66, thereby 
giving the GFP2 protein an excitation spectra very similar to wild-type GFP and a preference 
to the 395 nm (800 nm-two photon) excitation. The GFP2 protein also incorporates an 
A207K mutation, which significantly reduces protein dimerization.  
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excitation spectra practically identical to wild-type GFP with a peak excitation at about 395 nm 
(Heim et al., 1995) (Figure 3-2).  
By using the GFP2 protein, which exhibits a large Stokes shift, in conjunction with either 
YFP or Venus fluorescent protein, the donor can be excited at about 395 nm and completely 
avoid direct excitation of the acceptor (Figure 3-1). This eliminates the need for a direct 
excitation of the acceptor correction and allows for the calculation of Eapps (FRET efficiencies) at 
pixel level instead of an average over a larger region of interest. This is preferable because it 
allows for the generation of pixel level FRET maps which can more precisely locate the origin of 
FRET interactions and increases the amount of FRET data present in each region of interest 
from one averaged value to tens or hundreds of values depending on the size of the region of 
interest.  
3.5.2 Imaging set up and Mito-Tracker staining 
The cell medium contains the pH indicator, phenol red. To remove phenol red prior to 
imaging, the cell medium was removed using aspiration and replaced with pre-warmed serum-
free DMEM lacking phenol red. To stain mitochondria, cell medium was again removed, and 
cells were stained in 1 ml of 25 ng/ml MitoTracker-Red (ThermoFisher Scientific) in pre-warmed 
serum-free DMEM lacking phenol red for 15 minutes. Cell medium was removed using 
aspiration and replaced with pre-warmed serum-free DMEM lacking phenol red (Corby et al., 
2017).  
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3.5.3 Collection of microscopic images  
Plates containing cells were removed from the incubator and washed once with pre-
warmed serum-free DMEM lacking phenol red. Then two milliliters of pre-warmed serum-free 
DMEM lacking phenol red was added to each plate for imaging. The images were collected at 
room temperature using a two-photon inverted microscope (Nikon Eclipse TiTM (Nikon 
Instruments Inc., Melville, NY). The microscope is equipped with an OptiMiS scanning/detection 
head (Aurora Spectral Technologies, Grafton, WI) which was modified to include a line scan 
protocol (Biener et al., 2013) which allows for the detection of larger signals. In addition, the 
OptiMiS system includes the ability to switch between excitation wavelengths while 
maintaining the same power (Stoneman et al., 2017). Fluorescent excitation was achieved 
through use of a mode-locked laser (MaiTaiTM, Spectra Physics, Santa Clara, CA).  The mode-
locked laser is tunable between 690 nm and 1040 nm and produces 100 femtosecond pulses 
with a 7 nm full-width-half-maximum.  
The laser was focused using an infinity-corrected oil-immersion objective with 100X 
magnification (Nikon Instruments, Inc.) The fluorescence detection occurred through a 
transmission grating whereby the light was collected on a cooled electron multiplying CCD 
(EMCCD) camera (iXon X3 897; Andor Technologies, Belfast, UK). The spectrum is separated as a 
function of pixel position on the EMCCD array allowing for the collection of spatial, physical 
dimensions (X and y) and 200 wavelengths simultaneously.  The 200 wavelengths collected 
range from approximately 200 nm to 600 nm with a maximum spectral resolution of about 1 
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nm. Custom software was written in C++ and developed by the Raicu lab at University of 
Wisconsin-Milwaukee.  
Before each experiment, a spectral calibration is performed using 10 µM uranine and 
rhodamine standards which assigns each wavelength to a known camera pixel. Two-photon 
images were collected for each plate of 293T cells expressing either singly transfected CFP or 
YFP tagged proteins or a combination of CFP (donor) and YFP (acceptor) tagged proteins.  
3.5.4 Un-mixing of spectral images 
The first step in spectral un-mixing requires the generation of elementary spectra. The 
spectra obtained from those cells singly expressing either CFP or YFP tagged proteins was used 
to generate the elementary donor and acceptor spectrums, respectively. Cells expressing no 
fluorescently tagged protein but stained with a MitoTracker-red dye were used to determine 
the elementary spectra of the MitoTracker.  
To generate the composite spectrum, a “FRET” scan was performed on the cells 
expressing the combination of CFP and YFP tagged proteins using the peak excitation of the 
donor (λ ex1 = 840 nm). To generate an image primarily exciting and targeting the acceptor 
fluorescence in the presence of donor, a second scan is taken at the acceptor peak excitation (λ 
ex2 = 960 nm). This second scan can be termed the “acceptor scan.” About 15-30 field of views 
at 100X magnification were collected for each dish analyzed. The FRET scan and the acceptor 
scan are taken sequentially for each field of view and the image acquisition time is about 10 
seconds for each excitation scan and about 40 seconds to change the wavelength between the 
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FRET and acceptor scans. The total image acquisition time is therefore about 60 seconds to 
collect two sets of images each containing 440 x 300 pixels and 20 wavelengths per pixel. The 
average laser power used during the measurements was about 200 mW per line for both the 
FRET and acceptor scans and the power was held constant through the modified OptiMiS 
system previously described in section 3.5.3. (Corby et al., 2017; Stoneman et al., 2017) 
The composite spectra was deconvoluted (un-mixed) (Raicu et al., 2005) at pixel level 
through the assumption that the composite spectra is a linear combination of each of the 
elementary spectra per equation 2-17. In these experiments, the contributing spectra are donor 
in the presence of acceptor (l=DA), acceptor in the presence of donor (l=AD), and in some cases, 
Mitotracker (l=M). In addition, a background, wavelength-independent component which is 
nearly constant is also included (l=B). 
The coefficients equal to the fluorescent contributions of each of the above mentioned 
fluorescent species (kDA, kAD, kM) were extracted using a least-squares minimization method 
previously described (Biener et al., 2013).  
3.5.5 Eapp (FRET) calculation 
The calculation of Eapp (FRET) begins with the calculation of the total number of photons 
detected for donors, acceptors, and (in some experiments) MitoTracker (Raicu et al., 2005). The 
abundance coefficients (kDA, kAD, kM) for the donor, acceptor, and MitoTracker are multiplied by 
the spectral integral (denoted by w with various superscripts) for each donor, acceptor, and 
MitoTracker signal collected over the wavelengths analyzed via the following equations: 
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𝑭𝑫𝑨(𝝀𝒆𝒙,𝒊) =  𝒌
𝑫𝑨(𝝀𝒆𝒙,𝒊) ∗  𝒘
𝑫                                   (Equation 3-11) 
𝑭𝑨𝑫(𝝀𝒆𝒙,𝒊) =  𝒌
𝑨𝑫(𝝀𝒆𝒙,𝒊) ∗  𝒘
𝑨                                   (Equation 3-12) 
𝑭𝑴(𝝀𝒆𝒙,𝒊) =  𝒌
𝑴(𝝀𝒆𝒙,𝒊) ∗  𝒘
𝑴                             (Equation 3-13) 
The calculation of FDA, FAD, and FM allow for the generation of fluorescence intensity maps 
where the total fluorescent intensity at each pixel is equal to the total number of photons of 
the specific spectra contribution at each pixel. These maps were then used to generate regions 
of interest focused on the fluorescence intensity of the protein or marker of interest (Figure 3-
3).  
The FDA, FAD, and FM values were used to calculate the average donor fluorescence in the 
absence of FRET and the average acceptor fluorescence in the absence of FRET (i.e. direct 
excitation of the acceptor) using the previously derived (Mishra et al., 2016; Patowary et al., 
2015; Stoneman et al., 2017) equation: 
𝑭𝑫(𝝀𝒆𝒙,𝟏) =  𝑭
𝑫𝑨(𝝀𝒆𝒙,𝟏) +  
𝑸𝑫
𝑸𝑨
𝑭(𝝀𝒆𝒙,𝟏,𝝀𝒆𝒙,𝟐)          (Equation 3-10) 
Figure 3-3 Fluorescence intensity map of the donor (A), acceptor (B), and Mito-Tracker (C). 
When whole cells were selected, the donor intensity map (A) was used in conjunction with 
the acceptor intensity map (B) to select whole cell regions of interest expressing both donor 
and acceptor proteins.  When the mitochondria were targeted, the Mito-Tracker intenstiy 
map (C) was used to circle mitochondrial regions of interest. 
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𝑭𝑨(𝝀𝒆𝒙,𝟐) =  
𝑭(𝝀𝒆𝒙,𝟏,𝝀𝒆𝒙,𝟐)
𝝆𝑨− 𝝆𝑫
           (Equation 3-14)          
Where  
𝝆𝑨 =  
г𝝀𝒆𝒙,𝟏,𝑨
г𝝀𝒆𝒙𝟐,𝑨
              (Equation 3-15)  
             𝝆𝑫 =  
г𝝀𝒆𝒙,𝟏,𝑫
г𝝀𝒆𝒙𝟐,𝑫
               (Equation 3-16) 
 𝑭𝑨(𝝀𝒆𝒙,𝟏) =
г𝝀𝒆𝒙,𝟏,𝑨
г𝝀𝒆𝒙𝟐,𝑨
∗  𝑭𝑨(𝝀𝒆𝒙,𝟐)             (Equation 3-17)  
 𝑭𝑫(𝝀𝒆𝒙,𝟐) =
г𝝀𝒆𝒙,𝟐,𝑫
г𝝀𝒆𝒙𝟏,𝑫
 ∗  𝑭𝑫(𝝀𝒆𝒙,𝟏)             (Equation 3-18) 
 𝑭(𝝀𝒆𝒙,𝟏,𝝀𝒆𝒙,𝟐) = 𝑭
𝑨𝑫(𝝀𝒆𝒙,𝟏) − 𝝆
𝑨𝑭𝑨(𝝀𝒆𝒙,𝟐)            (Equation 3-19) 
 
Figure 3-4: Calculation of the gamma ratio for CFP and YFP. The peak emission of CFP when 
excited at both excitation wavelengths (840 nm and 960 nm) generates the 𝐹𝐷(𝜆𝑒𝑥, 1) and 
the 𝐹𝐷(𝜆𝑒𝑥, 2) used in the gamma ratio calculation for the donor (A). The peak emission of 
the YFP when excited at both excitation wavelengths generates the 𝐹𝐴(𝜆𝑒𝑥, 1)and the 
𝐹𝐴(𝜆𝑒𝑥, 2)used in the gamma ratio calculation for the acceptor (B).  
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The ρD is the ratio between the emission peak of the donor at excitation wavelength 1 and 
excitation wavelength 2 and ρA is the ratio between the emission peak of the acceptor at the 
excitation wavelength 1 and the excitation wavelength 2 (Figure 3-4).  
 
The average FRET efficiency (Eapp) over the circled regions of interest could then be calculated 
using the following equation which defines FRET as the ratio of the donor intensity in the 
presence of acceptor (quenched due to FRET) and the total donor fluorescence in the absence 
of FRET using equation 2-2 shown below. 
𝐸𝑎𝑝𝑝 = 1 −
𝐹𝐷𝐴(𝜆𝑒𝑥,1)
𝐹𝐷(𝜆𝑒𝑥,1)
     (Equation 2-2) 
3.5.6 Donor and acceptor concentration calculation  
To calculate the total concentration of the donor-tagged proteins and the acceptor 
tagged proteins in the dual-expressing cell samples, the values for FD (λ ex,1) and FA (λ ex, 2) were 
applied to a standard curve of fluorescence intensity. The standard curve was generated using a 
ten-fold dilution series of purified CFP-NS3h (donor) and YFP NS3h (acceptor) which were 
imaged under the exact same conditions as the 293T cells. Calibration curves were generated 
by plotting FD (λ ex,1) vs. CFP-NS3h and FA (λ ex, 2) vs YFP NS3h. The slopes of the calibration 
curves therefore correspond to the number of fluorescence counts per µM of solution. A value 
of 958 counts/µM and 5,317 counts/µM were found for the donor and acceptor respectively. 
The pixel-level concentrations were averaged over the whole region of interest to obtain the 
average concentration of donor and acceptor molecules (Corby et al., 2017). 
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3.5.7 Pixel level FRET calculation 
Pixel level FRET calculation allows for the collection of more Eapp values per unit area and thus a 
more detailed analysis of sub-cellular regions where many oligomeric complexes may be 
interacting and generating a population of different FRET efficiencies. If the selection of FRET 
pairs is carefully made such that the acceptor is not directly excited by the laser light used to 
excite the donor then the calculation of pixel level FRET becomes possible because the 
correction for direct excitation of the acceptor at the first excitation wavelength is no longer 
necessary and there is no time lost between excitations (Raicu et al., 2009). If there is no direct 
excitation of the acceptor at the donor excitation wavelength then the fluorescence at 
excitation wavelength 1 becomes zero and equation 2-28 (derived in Section 2.5.6) may be used 
to calculate Eapp.  
𝐸𝑎𝑝𝑝 =  
1
1+ 
𝑄𝐴
𝑄𝐷
𝑘𝐷𝐴
𝑘𝐴𝐷
𝜔𝐷
𝜔𝐴
                           (Equation 2-28) 
Once pixel level Eapp values are calculated, the Eapp values are organized into histograms 
based on selected regions of interest. The histograms may have several unique peaks which can 
indicate the presence of varying combinations of donor and acceptors within a larger 
oligomeric complex. To understand the predominant peaks and features over all pixels 
collected into histograms by selected regions of interest, the predominant peak from each 
histogram was recorded and a meta-histogram of all the histogram peaks was generated. This 
meta-histogram represents the dominant oligomeric configurations within the larger 
population (Stoneman et al., 2017).  
92 
 
Chapter 4  A Novel Inhibitor Can Inhibit Both Helicase and Protease Activities of 
HCV NS3 Protease/helicase 
The hepatitis C virus (HCV) NS3 protein is a protease and helicase/ATPase. All three 
activities are essential for HCV replication and therefore all three activities are potential drug 
targets but currently, only protease inhibitors are approved as drugs. Previously, a set of HCV 
helicase inhibitors were designed based on the yellow dye, primuline. One of these inhibitors 
(HPI PubChem CID #50930749) had the ability to inhibit the helicase and the protease domains 
but not the ATPase domain in vitro. Further, HPI was able to inhibit HCV sub genomic replicons 
in Huh 7.5 cells (Ndjomou et al., 2012). Based on the ability of HPI to inhibit both sub-genomic 
replicons in cells and the protease domain and helicase domain in in vitro assays, it is 
hypothesized that HPI interacts in the allosteric groove between the NS3 protease and helicase 
domains and therefore, is able to make contacts which inhibit both activities. 
This study strives to understand the mechanism of action of HPI through both in vivo 
and in vitro assays.  We examine how HPI inhibits HCV sub-genomic replicons of differing 
genotypes and how HPI inhibition is affected by the presence of first generation linear protease 
inhibitors and second generation macro-cyclic protease inhibitors in HCV sub-genomic 
replicons. To precisely target the putative HPI binding site, HCV full length proteins harboring 
several mutations in both the NS3 protease domain and the allosteric domain between the 
protease and helicase were tested in an in vitro proteolytic cleavage assay in the presence of 
HPI. In addition, full length HCV NS3 and NS3 with a covalently linked 4A protein were tested in 
the in vitro protease assay with HPI.  
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4.1 HPI is specific to HCV genotypes 1b, 3a, and 4a  
HPI was previously shown to inhibit both the protease and helicase activities of NS3 in 
vitro and was shown to have activity against Huh 7.5 cells stably expressing HCV sub-genomic 
replicons with a renilla luciferase reporter from genotype 1b (Ndjomou et al., 2012). One 
explanation for this broad inhibition would be if HPI non-specifically bound to HCV NS3. To test 
this, an HPI dilution series was applied to cells stably expressing an HCV subgenomic replicon 
with renilla luciferase reporter from genotype 2a, cells stably expressing a renilla luciferase 
tagged dengue virus replicon and to cells stably expressing the HCV genotype 1b sub-genomic 
Figure 4-1: HPI is specific to HCV genotypes 1b, 3a, and 4a. A sub-genomic HCV replicon for 
gentotypes 1b and 2a with a Renilla luciferase (R-luc) reporter and a Dengue virus sub-genomic 
replicon with an R-luc reporter was expressed in cells. The cells were treated with HPI and the 
R-luc activity measured after treatment (A). The EC50 was calculated and HCV 2a and Dengue 
virus were insensitive to HPI. HCV 1b was sensitive to HPI with an EC50 of 12 µM (A). Cells were 
also transfected with sub-genomic replicons from HCV 1bm 2a, 3a, and 4a. RT-qPCR was 
performed and RNA levels quantified. Again, HCV genotype 2a was insensitive to HPI, whereas 
HCV genotypes 1b, 3a, and 4a were sensitive to the drug (B).  
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replicon. Similar to previous experiments, HPI showed activity against HCV sub-genomic 
replicon 1b with an EC50 of about 12µM with no effect on cell viability. However, it showed no 
activity against genotype 2a or dengue virus even in concentrations up to 100 µM (Fig 4-1A) 
(Ndjomou et al., 2015). 
Next to see the effect on a wider range of HCV genotypes, a real-time polymerase chain 
reaction assay was performed on Huh 7.5 cells with sub-genomic replicons from genotypes 1b, 
2a, 3a, and 4a. The replication of HCV RNA was significantly inhibited for genotypes 1b, 3a, and 
4a with EC50s of 9µM, 4.4 µM, and 3.7 µM respectively. But HCV genotype 2a was again shown 
to be insensitive to HPI with concentrations up to 100 µM (Figure 4-1B). HPI is specific to 
genotypes 1b, 3a, and 4a and therefore it is unlikely that HPI is binding non-specifically to HCV 
NS3 (Ndjomou et al., 2015).  
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4.2 Effect of HPI on NS3 harboring mutations between the protease and helicase 
domains 
Due to the ability of HPI to inhibit both the helicase and protease function, it’s possible 
that HPI makes contacts in the allosteric groove between the helicase and protease domain. 
Molecular modeling further indicated that this may be the case. To test this, HPI was tested in a 
peptide cleavage assay against the activity of a recombinant NS3 with a covalently tethered N-
terminal 4A protein (scNS3). In addition to this wild-type protein, HPI was also tested against 
the activity of the recombinant scNS3 with mutations in the predicted HPI binding site (S483A, 
M485A, and V524A) and in or near the binding site for peptido-mimetic inhibitors (F438A, 
Q526A, and H528A) (Figure 4-2A). The activity of these mutations has previously been 
Figure 4-2 Evaluation of putative HPI 
binding site. The HPI binding site was 
modeled along with residues in and around 
that binding site (A). Residues in the HPI 
binding site and those in the neighboring 
protease domain were mutated and 
expressed in a recombinant scNS3 helicase. 
The mutant scNS3 helicases were tested in a 
protease cleavage assay to determine the 
effect of HPI on protease activity when 
expressing the different binding site 
mutations. The results indicate that residue 
M485 is likely blocking the HPI binding site 
and that mutating that residue to an alanine 
increases the sensitivity of HCV NS3 to HPI 
(B).  To determine whether or not HCV NS3 
could accommodate HPI and a protease 
inhibitor, a crystal structure of the enzyme 
bound to Grazoprevir was used and HPI was 
integrated into the model (C). The model 
shows that HCV NS3 can accommodate both 
Grazoprevir and HPI. 
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characterized (Aydin et al., 2013) and they were all found to retain the ability to bind and 
unwind nucleic acids as well as cleave peptides and ATP.  
The inhibitory potential of HPI was tested with the wild-type scNS3 and the scNS3 
proteins with various mutations in an HCV peptide cleavage assay. In this assay, the M485A 
mutation had the largest effect on the ability of HPI to inhibit NS3 protease catalyzed peptide 
hydrolysis. When M485 is replaced with a smaller alanine residue, the protein was much more 
sensitive to inhibition by HPI. A difference of about 5-fold in comparison to wild-type scNS3.  It 
is possible that the smaller alanine allows HPI greater access to the NS3 putative HPI binding 
site. Both the mutations in the peptido-mimetic inhibitor binding site did not change the 
sensitivity of NS3 to HPI, implying that HPI binds in a way that is different from peptido-mimetic 
inhibitors (Figure 4-2B) (Ndjomou et al., 2015).  Peptido-mimetic inhibitors have previously 
been shown to be affected by the Q526A and H528A mutations (Howe et al., 1999).  
4.3 Effect of HPI on the activity of scNS3 and NS3:NS4A 
To further understand the mechanism of action of HPI against HCV NS3, HPI was tested 
against different recombinant HCV NS3 proteins using the peptide cleavage assay. The scNS3 
protein (discussed above) which contains a covalently linked NS4A peptide on the N-terminal 
protease, the NS3 full-length version, and the NS3 full-length version with the addition of 
exogenous NS4A peptide to enhance protease function. Surprisingly, scNS3 was much more 
sensitive to HPI with a Ki below 10 µM whereas the Ki for NS3 + 4A was closer to 70 µM. The 
NS3 full-length protein without the 4A peptide was the least sensitive to HPI with a Ki around 
100 µM (Figure 4-2B) (Ndjomou et al., 2015).   
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4.4. Synergy between HPI and macrocyclic protease inhibitors in sub -genomic 
replicons 
The combined effect of HPI and protease inhibitors was tested using HCV sub-genomic 
replicons stably expressed in Huh 7.5 cells. To determine the EC50 for each compound (HPI, 
telaprevir, boceprevir, grazoprevir, and danoprevir) a serial dilution of each compound was 
applied to the HCV replicon cells and after 72 hours of treatment, the R.luc activity was 
measured. The resulting EC50 values are reported in Table 4-1. In addition, cell viability assays 
were performed and the concentrations of compounds necessary to reduce the cell viability by 
half (CC50) was always much greater than the concentration required to inhibit replicon activity 
(R.luc signa) by 50% (EC50) (Table 4-1).  
Compound EC50 (µM) CC50 (µM) 
HPI 15 ±  4 >100 
Telaprevir 0.81 ±  0.4 45 ±  4 
Boceprevir 0.64 ±  0.1 >100 
Danoprevir 0.002 ±  0.0005 >100 
Grazoprevir 0.00076 ±  0.00013 54 ±  5 
Table 4-1 The ability of HPI and other direct acting antivirals to inhibit the HCV genotype 1b 
subgenomic replicons and Huh7.5 cell viability. HPI and other direct acting antivirals were 
applied to Huh7.5 cells harboring HCV genotype 1b subgenomic replicons. The EC50 values are 
equal to the concentration of each compound needed to reduce the HCV-1b-subgenomic 
replicons by 50% relative to cells treated with DMSO alone. CC50 values are the concentration 
of compound necessary to reduce cell viability by 50%. 
98 
 
Using the calculated EC50 values, concentrations were determined above and below the 
EC50 for each compound. These concentrations were then applied in different combinations to 
the HCV sub-genomic replicon cells. The expected additive inhibition from the combination of 
each drug was determined via the Bliss Independence Model. The Bliss Independence Model 
assumes that each drug will inhibit according to its individual inhibitory potential at a given 
concentration and will not be affected by the other drug. Therefore, the combination of two 
drugs should result in the same total inhibition as if both drugs were applied independently and 
Figure 4-3: Interactions between HPI and other protease inhibitors. Points in line 
with the plane represent the inhibition which would be expected if the two 
inhibitors functioned additively as defined by the Bliss independence model. Any 
signal above the plane in the Z direction represents inhibition seen that is greater 
than what would be expected from additive inhibition alone.  Data were analyzed 
using MacSynergy II (Prichard & Shipman, 1990). 
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each of the drug’s inhibitory ability was added. If, there is a significant deviation from this 
expected additive inhibition, it can be assumed that there is some interaction between the two 
drugs. If the inhibition with a combination of two drugs is greater than the expected additive 
inhibition, then the effect is said to be synergistic.  
No difference from expected additive inhibition (defined as the plane in Figure 4-3 
three-dimensional plots) was observed for the combination of HPI with linear protease 
inhibitors, telaprevir and boceprevir. Limited synergy was observed when HPI was used in 
conjunction with danoprevir. Modest synergy was observed when HPI was applied in 
conjunction with grazoprevir (Figure 4-3) (Ndjomou et al., 2015). 
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4.5 Significance of the experimental results on the mechanism for HPI mode of 
inhibition 
In this study, HPI (which inhibits both helicase unwinding and protease-catalyzed 
peptide cleavage) was shown to have activity specific to HCV genotypes 1b, 3a, and 4a (Figure 
4-1).  HPI appears to behave differently than current peptido-mimetic protease inhibitors 
because it is able to inhibit the helicase function in addition to the protease function. Despite 
the fact that second-generation macrocyclic protease inhibitors were designed to make 
contacts in both the protease and helicase domain, they are still not able to inhibit helicase 
function.  HPI is proposed to bind in the allosteric site between the protease and helicase 
domains (Figure 4-2C).   
Figure 4-4 HCV NS3 can cleave substrates in cis and in trans. HCV NS3 helicase first 
cleaves itself in cis to free its C-terminal from the polypeptide (A). It is proposed that this 
cleavage occurs when the protein is in a closed conformation with the protease domain 
sitting close to the helicase domain.  HCV NS3 assumes an extended conformation to 
cleave all other downstream targets in trans (B). In the extended conformation, the NS3 
protease domain is swung away from the helicase domain.  
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By binding in the allosteric site between the protease domain and helicase domain, HPI 
may affect the conformation of the NS3 protein. The conformation of the protein is thought to 
have biological significance in the processing of the HCV polypeptide. Host and viral proteases 
cleave the HCV polypeptide.  HCV NS3 protease is important for cleaving the junction between 
itself and 4A in cis and then cleaving all other downstream non-structural proteins in trans (see 
figure 2-4 in the methods). In order to cleave both in cis and in trans, HCV NS3 must adopt 
different conformations. To cleave in cis it is thought that the HCV NS3 protease domain swings 
inward and the overall protein adopts a “closed” conformation, To cleave in trans, the NS3 
protease domain must swing out away from the helicase domain to reach the additional 
downstream cleavage sites in the HCV polypeptide (Figure 4-4). Macrocyclic protease inhibitors 
have been proposed to alter this equilibrium by making contacts in the helicase domain in 
addition to the protease domain and this characteristic is one of the reasons why the 
macrocyclic protease inhibitors are much better direct acting anti-virals (inhibit more genotypes 
and are more active against telaprevir resistant variants) (Schiering et al., 2011).  
Modeling and protease cleavage assays with HPI suggest that HPI may also be able to 
alter the equilibrium between the closed and open conformation by binding in the allosteric 
site between the helicase and protease domains (Figure 4-2). The M485 residue is located in 
the allosteric groove between the protease and helicase domains. When it was mutated to 
alanine, the resulting protein was much more sensitive to HPI implying that the methionine is 
somehow reducing the interaction of HPI with NS3 and that HPI is indeed binding in this 
allosteric site. In addition, scNS3 showed much greater sensitivity to HPI in the peptide cleavage 
assay than either full length NS3 or NS3 with exogenous 4A peptide added. All scNS3 proteins 
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crystallized have been in a compact conformation (Saalau-Bethell et al., 2012; Yao et al., 1999). 
In our lab, it has been seen that scNS3 frequently runs faster on a size exclusion column than 
the smaller protein NS3 and therefore it’s possible that scNS3 is favoring the closed 
conformation and that full length NS3 favors a more open conformation thus slowing its 
migration. Given that HPI was significantly more potent against the scNS3, it is possible that HPI 
binds the NS3 protein when it’s in the closed conformation and is able to lock it in the close 
conformation. This hypothesis is modeled in Figure 4-5.  
Lastly, the combination of HPI with macro-cyclic protease inhibitors danoprevir and 
particularly grazoprevir showed a synergistic interaction over and above what would be 
expected from additive inhibition alone. Since the macro-cyclic protease inhibitors have been 
shown to make contacts in both the protease domain and the allosteric domain, it’s possible 
that this synergistic interaction is due to HPI locking NS3 into a closed conformation and 
Figure 4-5 Proposed hypothesis for the mechanism of action of HPI. HPI is proposed to bind 
HCV NS3 in the closed conformation only and to make contacts in the allosteric groove 
separating the helicase and protease domain effectively shifting the equilibrium towards the 
closed conformation and limiting the ability of the NS3 protease to cleave downstream 
substrates.  Once HPI has bound to the closed conformation, it may facilitate the binding of 
the macrocyclic protease inhibitors (such as Grazoprevir) which make contacts in the both 
the helicase and protease domains, further locking the protein in a closed conformation.  
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allowing the protease inhibitors better access to both the protease and helicase domains in 
which to make contacts (Figure 4-4). (Ndjomou et al., 2015) This study is the first time that the 
two different functions of NS3 were targeted with different compounds simultaneously. 
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Chapter 5 Interactions between NS3 helicase and nucleic acids  
Measuring the interaction of the NS3 helicase with oligonucleotides can be 
accomplished by monitoring the decrease of the intrinsic protein fluorescence upon 
oligonucleotide binding because the binding of DNA/RNA to the NS3 helicase causes a 
concentration dependent decrease in the intrinsic protein fluorescence (340 nm) when the 
protein is excited at 280 nm. To show this effect, 150 nM YFP labeled NS3 helicase (YFP-NS3h) 
was titrated with a hexachlorofluoroscein labeled 18-nucleotide DNA strand (HF18). At each 
point in the titration, the mixture was excited at 280 nm and the fluorescent spectrum collected 
from 300 nm to 700 nm. The 340 nm fluorescence decreases with each subsequent HF18 
Figure 5-1: NS3 helicase binding monitored through the quenching of the intrinsic protein 
fluorescence. HCV NS3 binding can be measured through monitoring the quenching of the 340 
nm intrinsic protein fluorescence. ( (A) 150 nM YFP tagged NS3h was titrated with an 18 base 
nucleic acid tagged with a hexachlorofluoroscein fluorophore (HF-18). The mixtures were excited 
at 280 nm and the emission spectra recorded. The decrease of the 340 nm fluorescence, along 
with the decrease of the YFP donor and the increase in concentration of the acceptor HF-18 are 
noted with arrows. (B) Fluorescence at 340 nm was plotted  versus total DNA concentration. Data 
were fit to equation 3-7 using a Kd of 36 with a 95% confidence interval of 8.7 to 64 and an “n” of 
3.9 with a 95% confidence interval of 3.2 to 4.6 and iD of 0.43 with a 95% confidence interval of 
0.41 to 0.43, iDA of 0.11 with a 95% confidence interval of 0.09 to 0.13 and an iA of 0. 
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addition (Figure 5-1A). The 280 nm excitation not only excites the intrinsic protein fluorescence 
but also the YFP and the HF and therefore, it is also possible to see the quenching of the YFP 
(donor) at 525 nm and the increase of the HF (acceptor) at 556 nm. The decrease of the 340 nm 
fluorescence (Figure 5-1B) which is caused by the intrinsic protein fluorescence of the protein 
when excited at 280 nm was fit to equation 3-7: 
𝑖𝑜𝑏𝑠 = 𝑖
𝐴 [𝐴 −
([𝐷]𝑇+𝑛[𝐴]𝑇+𝐾𝑑)−√([𝐷]𝑇+𝑛[𝐴]𝑇+𝐾𝑑)2−4∗[𝐷]𝑇∗𝑛[𝐴]𝑇
2
] +  𝑖𝐷 [𝐷 −
([𝐷]𝑇+𝑛[𝐴]𝑇+𝐾𝑑)−√([𝐷]𝑇+𝑛[𝐴]𝑇+𝐾𝑑)2−4∗[𝐷]𝑇∗𝑛[𝐴]𝑇
2
] +
𝑖𝐴𝐷[
([𝐷]𝑇+𝑛[𝐴]𝑇+𝐾𝑑)−√([𝐷]𝑇+𝑛[𝐴]𝑇+𝐾𝑑)2−4∗[𝐷]𝑇∗𝑛[𝐴]𝑇
2
]                  (Equation 3-7) 
The observed fluorescence intensity at 340 nm is equal to a linear combination of the free 
acceptor [A] which is YFP-NS3h, the free donor [D] which is an 18 nucleotide DNA labeled with 
an HF, and the donor acceptor complex [AD)]. Each of these terms is multiplied by a co-efficient 
(iA, iD, or iAD) representing the fluorescence intensity of each observed at 340 nm which should 
be linearly related to the amount of acceptor, donor, or acceptor donor complex present. The 
co-efficient iA represents the fluorescence of the acceptor (HF-DNA) at 340 nm, the co-efficient 
iD represents the fluorescence of the donor (YFP-helicase) at 340 nm and the co-efficient iAD 
represents the fluorescence of the donor: acceptor complex at 340 nm.  
 In this experimental set up where fluorescence intensity at 340 nm is being measured, it 
was assumed that iA is zero because there is no observed fluorescence of the acceptor (HF-
DNA) at the 340 nm emission wavelength. For the titration of YFP-NS3h with HF-DNA, the best-
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fit Kd value was 36.4 ± 30 nM (8.7 nM to 64.1 at the 95% confidence interval ) and the calculated 
“n” is 3.9 ± 0.7 (3.2 to 4.5 nM at the 95% confidence interval). 
5.1 Measuring the interaction of HCV NS3 with oligonucleotides u sing FRET: A 
comparison of  three different FRET calculation techniques 
 Another way that HCV NS3 helicase interactions with oligonucleotides can be 
measured is through fluorescently labeling the helicase and the oligonucleotide with a 
complimentary FRET pair and measuring FRET between the donor and acceptor flourophore. A 
titration of YFP labeled NS3h with a “MAX” fluorophore labeled single stranded DNA (MAX-
DNA) was performed. (Figure 5-2A). Elementary spectra of the YFP-NS3helicase and the MAX 
labeled DNA were collected at 480 nm and 525 nm excitations. Before the addition of any MAX-
DNA, 500 µl of 50 nM of YFP NS3 helicase was excited at 480 nm to generate the emission 
spectrum for donor alone. Next 500 µM MAX-DNA was added in 1 µl increments to a final 
concentration of 54 nM MAX-DNA. For each point in the titration, emission spectra were 
collected for both the 480 nm and 525 nm excitations using a slit width of 10 nm. (Figure 5-2B 
and 5-2C).  
 To calculate the FRET between YFP-NS3h and the MAX-DNA, three different FRET 
calculation techniques were employed. The first technique calculated FFRET used the previously 
defined equation 2-4: 
    𝐹𝐹𝑅𝐸𝑇 = 1 −
𝐼𝐷(𝜆𝐷
𝑒𝑥𝜆𝐷
𝑒𝑚)
𝐼𝐴𝑙𝑜𝑛𝑒
𝐷 (𝜆𝐷
𝑒𝑥𝜆𝐷
𝑒𝑚) 
                (Equation 2-4) 
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To calculate FFRET using equation 2-4, the fluorescence of the titration before any addition of 
acceptor was measured to obtain the 𝐼𝐴𝑙𝑜𝑛𝑒
𝐷 (𝜆𝐷
𝑒𝑥𝜆𝐷
𝑒𝑚) value. The emission of the donor in the 
presence of acceptor ((𝐼𝐷(𝜆𝐷
𝑒𝑥𝜆𝐷
𝑒𝑚)) was measured at each point in the titration. FFRET was 
calculated for each point in the titration using the values measured. 
 A second technique was employed which uses spectral unmixing  to separate the 
contributions of the donor and acceptor spectra from the composite spectra (see section 2.5.6 
and section 3.3.4 for further explanation of the technique). Through the use of spectral 
unmixing, the kD coefficient was determined from the starting sample which contained only 
donor (i.e. the starting point in the titration). Then the kD was multiplied by the spectral integral 
of the donor alone spectra to obtain an FD value which represents all the donor photons across 
the full donor spectrum. This FD was obtained from the spectrum of the donor alone (i.e. the 
first point in the titration before any addition of titrant). After each subsequent addition of 
acceptor, mixtures were allowed to equilibrate, and an FDA value was calculated by using the kDA 
coefficient generated from unmixing and multiplying it by the spectral integral of the donor 
only spectrum to obtain all the donor photons across the full donor emission spectra.The 
constant FD value and each FDA value was then used in equation 2-2 to calculate an Eapp value 
for each point in the titration. 
𝐸𝑎𝑝𝑝 = 1 −
𝐹𝐷𝐴
𝐹𝐷
                             (Equation 2-2) 
 It is important to note that direct measurement of FD is not possible to obtain in 
some fluorescence microscopy experiments, such as cells transfected with a plasmid expressing 
a fluorescent protein. To simulate what would needed to be done in a microscope, the third 
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FRET calculation technique applied to the titration data back-calculated FD values from FAD and 
FDA values obtained from spectral unmixing using gamma ratios and the quantum yields. In this 
experiment, the gamma ratio of the donor was calculated to be 0.0002 and the gamma ratio of 
the acceptor was calculated to be 0.0550. The quantum yield of the donor (YFP) is 0.61 and the 
quantum yield of the acceptor (MAX) is 0.2.  When equation 3-19 is substituted into 3-10 the 
following equation 5-1 results: 
            𝑭𝑫(𝝀𝒆𝒙,𝟏) =  𝑭
𝑫𝑨(𝝀𝒆𝒙,𝟏) +  
𝑸𝑫
𝑸𝑨
𝑭(𝝀𝒆𝒙,𝟏,𝝀𝒆𝒙,𝟐) − 𝝆
𝑨 𝑸
𝑫
𝑸𝑨
∙ 𝑭𝑨(𝝀𝒆𝒙,𝟐) (Equation 5-1) 
where 𝑭𝑨(𝝀𝒆𝒙,𝟐) is defined by equation 3-14. 
Eapp was then calculated using the same FDA values calculated in technique two and the back-
calculated FD values using equation 2-2. 
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All three techniques were used to calculate FRET values for each point in the titration. A 
graph overlaying the results of the titrations (Figure 5-2D). The curves were fit to equation 3-9. 
The Kd,  EAD , and ET  yielding the best fits are reported in Table 5-1.  
Figure 5-2: Titration of a YFP labeled NS3 helicase with a MAX fluorophore labeled single-
stranded DNA. (A) Schematic showing the proposed interaction of YFP NS3helicase with MAX 
labeled DNA. (B)The 480 nm excitation targets the YFP which is expected to have a peak 
emission of about 525 nm. Emission spectra for each addition of MAX labeled DNA were 
collected for the 480 nm excitation up to a final MAX-DNA concentration of 54 nM. (C) The 
second excitation of 525 nm targets the MAX fluorophore, which is expected to emit at 557 nm. 
Emission spectra for each addition of MAX labeled DNA were collected for the 525 nm excitation 
up to a final MAX-DNA concentration of 54 nM. (D) Overlay of FRET calculated for each point in 
the titration using three different FRET calculation techniques. 
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All three different FRET calculation techniques employed resulted in similar curve fits.
 
Table 5-1: Results of FRET calculation using each FRET calculation technique for the YFP-NS3h 
to MAX-DNA titration.  
 
The first two techniques require that the starting donor concentration be known. This is 
possible with an in vitro titration where the starting point in the titration is known and 
represents the donor in the absence of any acceptor. However, in cell microscopy where 
fluorescent proteins are expressed, it is not possible to directly measure the concentration of 
donor molecules in each cell measured. Therefore, the concentration of the donor needs to be 
back-calculated. The equation which back-calculates the fluorescence of the donor in the 
absence of acceptor under circumstances where it cannot be measured directly is equation 3-
10. Equation 3-10 was used to back-calculate the fluorescence of donor in the YFP-NS3helicase 
+ MAX-DNA titration in the absence of acceptor (FD) for each point in the titration. This is the 
same procedure used to back calculate FD in FRET spectrometry (discussed in Section 3-5) and 
applied to live cell fluorescence microscopy. The results are similar to those determined 
without back-calculating the donor alone fluorescence. 
  
Kd
± 95% 
confidence 
interval DT
± 95% 
confidence 
interval EDA
± 95% 
confidence 
interval
1-(DA/D) 1.82 1.3 to 2.3 6.7 5.9 to 7.6 0.64 0.63 to 0.66
1-(FDA/FD) 1.9 1.4 to 2.4 6.8 6.1 to 7.6 0.67 0.65 to 0.69
1-(FDA/FDcalc) 4.27 1.6 to 6.9 6.4 2.9 to 9.9 0.72 0.66 to 0.78
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Chapter 6 The N-terminal membrane anchor domain of NS4A is needed  to localize 
the hepatitis C virus NS3 protease to biologically active foci  
The hepatitis C virus (HCV) encodes a multifunctional NS3 protein which contains a 
covalently linked protease and helicase domain. Important to NS3 proteolytic function is the 
peptide cofactor, NS4A, which is only 54 amino acids in length, yet acts as a key player in HCV 
replication. One way NS4A aids in viral replication is by tethering NS3 to the endoplasmic 
reticulum and mitochondrial membranes. NS4A consists of 3 domains; an acidic C-terminal 
domain, an NS3 cofactor domain, and an N-terminal membrane anchor. Prior research suggests 
that the anchor domain is required to tether NS3 and form HCV replicase complexes (Andrew 
Kohlway et al., 2014).    
To test the localization of NS3 in cells in the presence and absence of NS4A, four 
eukaryotic expression plasmids were generated that encoded recombinant proteins in which all 
or part of NS3 and NS4A were fused to a mCFP fluorescent protein.  In the first, only the NS3 
helicase domain (mCFP-NS3h) was fused to mCFP.  In the second, mCFP was fused with full-
length NS3 (mCFP-NS3).  In the third, mCFP was fused to NS3 and only the NS3 cofactor domain 
of NS4A (lacking the membrane anchor and C-terminus, i.e. mCFP-scNS3), and in the fourth, 
mCFP was fused to NS3 and full length NS4A (mCFP-NS3:NS4A). The aligned protein sequences 
for the NS3 variants are shown in Figure 6-1. If the NS4A membrane anchor domain is required 
for the localization of the NS3 protein to foci, then removal of this domain should cause the 
protein to be diffuse throughout the cell.  If the anchor domain is not required for the 
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localization of NS3 to foci, then removal of the domain should not affect the sub-cellular 
localization. 
To test the activity of the recombinant NS3, scNS3, or NS3:NS4A variants, each variant 
was co-expressed in HEK293T cells with an NS3 protease substrate tagged with a red 
fluorescent protein (RFP) connected to a nuclear localization signal (RFP-NLS-MAVS). When the 
protease substrate is cleaved, the RFP-tagged nuclear localization signal is exposed causing the 
RFP to re-localize to the nucleus. If the protease substrate is not cleaved, then the nuclear 
localization signal is not exposed and the RFP remains in the cytoplasm. This system allows for 
the activity of the NS3 protease to be measured in live cells. If the membrane anchor domain is 
necessary for the activity of NS3, then removal of this domain should change the biological 
activity of the NS3 protein. If the membrane anchor domain is not necessary for the activity of 
NS3, then removal of the domain should not change the biological activity of the protein. 
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6.1 The NS4A membrane anchor is necessary to localize the NS3 complex to sub -
cellular foci 
The recombinant CFP tagged NS3 variants were expressed alone in HEK 293T cells for 24 
hours after transfection. The cells were excited at 840 nm using a two-photon laser excitation 
and imaged at 100X magnification. Details of the microscopic image collection can be found in 
Section 3.5.3.  A full 200 wavelength emission spectra was collected for each image but only the 
image corresponding to the CFP emission peak of 485 nm was used.  
Figure 6-1: Alignment of cyan fluorescent protein tagged NS3 recombinant protein sequences. 
The following protein sequences were taken from eukaryotic expression vectors expressing 
variants of CFP tagged HCV NS3. The alignment includes CFP-NS3h, CFP-NS3, CFP-scNS3, and 
CFP-NS3:NS4A. For a more detailed description of each protein expression vector, see Chapter 
3: Methods.  
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CFP-NS3h lacks the protease domain and all of the NS4A co-factor. As expected, the 
images of CFP-NS3h show it diffuse throughout the cytoplasm of the cell (Figure 6-2 A.1-A.3). 
CFP-NS3 contains both the helicase and the protease domain but lacks any portion of the NS4A 
co-factor. It was expected that CFP-NS3 would be diffuse throughout the cell as seen in Figure 
6-2 B.1-B.3. CFP-scNS3 contains the helicase, protease, and a portion of NS4A but lacks the 
NS4A membrane anchor and, similar to the other two constructs, CFP-scNS3 is diffuse 
throughout the cell (Figure 6-2 C.1-C.3). CFP-NS3:NS4A contains the helicase, protease, and the 
Figure 6-2: CFP-NS3 variants expressed in HEK 293T cells. Recombinant CFP-NS3 
variants were expressed in HEK293T cells for 24 hours. Post 24 hours transfection, the 
cells were imaged by exciting the CFP at 840 nm with a two-photon laser and a 
magnification of 100X. CFP-NS3h contains only the helicase domain is diffuse 
throughout the cell (A.1-A.3). CFP-NS3 contains the protease and helicase domain and 
is diffuse throughout the cell (B.1-B.3). CFPscNS3 contains the protease domain 
covalently linked to the NS4A protease co-factor domain in addition to a helicase 
domain and it is diffuse throughout the cell (C.1-C.3). The CFP-NS3:NS4A contains the 
complete NS3 + NS4A co-factor including the membrane anchors and it is localized to 
distinct foci in the cell (D.1-D.3). 
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entire NS4A domain. This construct forms visible foci in the cytoplasmic region of the cell 
(Figure 6-2 D.1-D.3). It is likely that these foci are targeted to ER or mitochondrial membranes 
because that is where the HCV replicase complex is known to form (Andrew Kohlway et al., 
2014; Lindenbach and Rice, 2005).  
6.2 The NS3 protease co-factor domain of NS4A is necessary for proteolytic 
cleavage of an NS3 substrate but the portion encoding the membrane anchor is not 
necessary for protease activity.   
Each of the recombinant CFP-NS3 constructs were co-expressed in HEK293T cells with a 
plasmid expressing the RFP-NLS-MAVS protease substrate. The constructs were allowed to 
express for 24 hours after transfection. Then the cells were excited at 840 nm to target CFP and 
980 nm to target RFP using a two-photon laser excitation and imaged at 100X magnification. A 
full 200 wavelength emission spectra was collected for each image but only the peak emission 
for CFP (485 nm) and RFP (584 nm) and was used for the image analysis.  
CFP-NS3-helicase is lacking the protease domain and the entire 4A co-factor. Therefore, 
it is not expected to localize in the cell or to be able to cleave the RFP-NLS-MAVs protease 
substrate. Images show that the RFP tagged substrate appears to be in small groups throughout 
the cytoplasm and CFP-NS3h is diffuse in the cytoplasm (Figure 6-3 - Row B). The CFP-NS3 
contains both the helicase and protease domain but lacks NS4A. The NS3 lacking NS4A can 
cleave protease substrates in vitro as seen in Figure 4-2B. But in cells, CFP-NS3 is diffuse 
throughout the cell and appears unable to cleave the RFP-NLS-MAVs substrate which remains in 
the cytoplasm (Figure 6-3 Row C). The CFP-scNS3 contains the helicase and protease domain 
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along with the protease interacting portion of NS4A. This protein is diffuse throughout the cell 
but is proteolytically active. In the cells co-expressing CFP-scNS3 and RFP-NLS-MAVS, the RFP is 
localized to the nucleus (Figure 6-3-Row D). Lastly, the CFP-NS3:NS4A contains the helicase and 
protease domain and the complete NS4A protein including the membrane anchors. This protein 
is located in sub-cellular foci and the RFP-NLS-MAVS substrate can be see localized to the 
nuclear region of the cell.  When CFP-NS3:NS4A was co-expressed with the cleavage resistant 
mutant (MAVs C508Y), the RFP was located in the cytoplasm. (Figure 6-3 Row E and F).  
Figure 6-3 : CFP-NS3 encodes a 
functional protease when 
expressed in HEK 293T cells. 
RFP-NLS-MAVs contains an RFP 
attached to a nuclear 
localization signal (NLS) and the 
NS3 cleavage site of MAVs. 
When NS3 cleaves MAVs, the 
NLS is exposed and the RFP 
molecule moves to the nucleus 
of the cell. When RFP-NLS-
MAVs is expressed alone or in 
conjunction with CFP-NS3 
helicase or CFP-NS3 lacking the 
4A co-factor, it is in the 
cytoplasm (Rows A-C). When 
RFP-NLS-MAVS is expressed 
with CFP-scNS3 or CFP-
NS3:NS4A which both contain 
the protease and the 4A co-
factor, the RFP localizes to the 
nucleus (Row D and E). When 
CFP-NS3:NS4A is expressed in 
conjunction with a cleavage 
resistant RFP-NLS-MAVs 
(C508Y) the substrate is not 
cleaved and the RFP remains in 
the cytoplasm of the cells (Row 
F). 
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6.3 Significance of the requirement of the NS4A co -factor for proteolytic cleavage 
in cells and the necessity of the NS4A anchor domain to localize NS3  
 Previous data has shown that the NS4A anchor domain is necessary to localize the NS4A 
to replicase complexes in the cell (Andrew Kohlway et al., 2014). The results reported here 
confirm this finding. Only the NS3 which contained the full NS4A, including membrane anchors, 
localized to sub-cellular foci in the cell. This means that there are likely no other membrane 
anchors in NS3 or NS4A which could localize the protein. It also means that this sub-cellular 
localization is not a requirement for proteolytic cleavage (Figure 6-3 Rows D and E). Given that 
NS3 protease has multiple sub-cellular targets (NS3 poly-peptide, TRIF, and MAVS) it makes 
sense that localization to the replicase complexes is not a requirement of protease function. 
CFP-NS3 contains the protease domain and in vitro experiments with a similar construct 
lacking NS4A still show protease activity. However, when the NS4A domain is absent in the 
constructs expressed in cells, the protease is unable to cleave the MAVS substrate. It could be 
that the NS3 protease lacking NS4A is not a very active protease and the lower concentrations 
of NS3 protease and substrate in cells do not allow for efficient cleavage. It could also mean 
that the NS4A molecule somehow affects the local pH environment which is not an issue in a 
controlled in vitro experiment where pH is constant throughout, but is an issue in the sub-
cellular environment where local pH values may be different. It’s possible that this shift in local 
pH could affect the ability of the protease to cleave efficiently in cells in the absence of NS4A.  
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Chapter 7 The Hepatitis C virus helicase interacts with the human pattern 
recognition receptor LGP2 
Hepatitis C virus encodes a multi-functional non-structural protein, NS3, which contains 
a covalently linked protease and helicase domain. A linked protease and helicase is unique to 
flaviviridae viruses and the purpose behind linking the two activities is unclear. There is some 
evidence that the activity of the protease is enhanced when the helicase domain is present and 
the activity of the helicase domain is enhanced when the protease domain is present (Aydin et 
al., 2013; Beran and Pyle, 2008; Frick et al., 2004). However, this cross-domain activity 
enhancement does not necessarily explain why their activities are linked.  
NS3 plays multiple roles in the HCV viral life cycle. One of the most important functions 
of NS3 protease is to disrupt innate immune signaling in response to HCV infection (Errett and 
Gale, 2015b; Horner et al., 2012; Liu and Gale, 2010). The innate immune system is an essential 
first line of defense against invading organisms. Almost every cell in the body is equipped with a 
set of innate immune system receptor proteins that recognize and respond to viral nucleic 
acids. These receptor proteins, including the RIG-I like receptors and the Toll-like receptors, 
signal through key adaptor proteins which initiate down-stream signaling and the production of 
interferon. The NS3 protease cleaves the adaptor proteins mitochondrial anti-viral signaling 
protein (MAVS) and TIR-domain containing adaptor inducing interferon-β (TRIF). This cleavage 
effectively abrogates RIG-I like receptor signaling and Toll-like receptor signaling in the cell 
(Akira et al., 2006; Alberts et al., 2002; Horner et al., 2012). 
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It is possible that NS3 helicase aids in the cleavage of the innate immune adaptor MAVS 
by helping to localize the NS3 protease domain to MAVS through interaction with one of the 
RIG-I like receptors. Since all the RIG-I like receptors and HCV NS3 are DExD/H box helicases 
who are known to oligomerize into higher order complexes and they have the same ligand 
preference (HCV RNA), it’s possible that they could oligomerize with each other, either through 
a direct protein-protein interaction or through a shared interaction on RNA. This interaction 
would aid in localizing NS3 near MAVS for cleavage and provide one possible explanation for 
linking the protease and helicase functions in HCV.  
To test for possible interactions of NS3 with the RIG-I like receptors, pairs of fluorescent 
fusion proteins were designed to be used in live-cell FRET imaging assays. The assays were 
performed with Cyan fluorescent protein (CFP) as the donor and yellow fluorescent protein 
(YFP) as the acceptor. These fluorescent proteins were attached to each of the RIG-I like 
receptor proteins and to domain deletion variants of the HCV NS3 protein. Each recombinant 
protein was designed to maintain its enzymatic activity and sub-cellular localization.  
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Details of the live cell FRET imaging assay used can be found in section 3.5. Briefly, cells 
expressing the recombinant fluorescent fusion proteins were imaged on an inverted 
microscope and excited using a two-photon laser. A full 200-wavelength emission spectra was 
collected on an EMCCD camera (Figure 7-1A). Two excitation wavelengths were used for each 
field of view. The first excitation wavelength targets the donor and generates the “FRET” image. 
The second targets the acceptor and generates the “acceptor” image (Figure 7-1 B.1 and B.2) 
Figure 7-1 Quantitative Micro-spectroscopic imaging of donor and acceptor labeled 
recombinant fluorescent fusion proteins in live cells. Cells expressing fluorescent 
fusion proteins were imaged on an inverted microscope and excited using a two-
photon laser. Full 200 wavelength spectrums were collected on an EMCCD camera (A). 
Each plate of cells rendered multiple field of views and each field of view was excited 
at two wavelengths, one to target the donor (B.1) and one to target the acceptor (B.2). 
The resulting emission spectra were unmixed to render the contributions of each 
elementary component to the overall composite spectra (C). Regions of interest were 
selected and the intensity maps of the individual elementary component intensities (C) 
were used to compute average FRET and average donor and acceptors concentrations 
over the regions of interest. 
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The emission spectra were unmixed using a method of least squares to produce the donor and 
acceptor contributions to the composite spectrum. On some of the images, the cells were also 
stained with Mito-Tracker-Red. In this case, a third component (Mito-Red) was un-mixed from 
the composite spectra (Figure 7-1C). These images were then used to compute the average Eapp 
(FRET efficiency) for the selected sub-cellular regions of interest. In addition, average donor and 
acceptor concentrations were calculated for each region of interest.  
7.1 Recombinant fluorescent RNA helicases are biologically active when expressed 
in HEK293T cells 
Plasmids were generated which encoded the following fluorescent fusion proteins; CFP-
NS3h, CFP-NS3, CFP-scNS3, CFP-NS3:NS4A, YFP-RIG-I, YFP-MDA5, and YFP-LGP2. (Figure 6-1 and 
Figure 7-2). All of the fluorescent fusion proteins were designed to be expressed under the 
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Figure 7-2: Protein sequence alignment of YFP RIG-I, YFP MDA5, and YFP LGP2. 
The following protein sequences were taken from eukaryotic expression vectors 
expressing YFP-RIG-I, YFP-MDA5, and YFP-LGP2. For a more detailed description of 
each protein expression vector, see Chapter 3: Methods.  
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control of a cytomegalovirus promoter (CMV) when transfected into HEK 293T cells. Each 
fluorescent protein tag was attached to the N-terminus of the protein of interest.  
HCV NS3:NS4A contains the NS3 protein which has the covalently linked protease and 
helicase domain along with the NS4A protein. The NS4A protein is a protease co-factor in 
addition to containing membrane anchors necessary for proper sub-cellular localization to the 
ER membrane. When the CFP-NS3:NS4A plasmid was expressed in HEK293T cells, the CFP-
NS3:NS4A was localized to foci, indicating that the NS4A membrane anchors were functional 
and securing the protein in specific sub-cellular locations (Figure 6-2 D.1-D.3).  
To further assess the function of the fluorescently tagged NS3 protein, the proteins 
were expressed in conjunction with an RFP tagged protease substrate containing a nuclear 
localization signal (RFP-NLS-MAVS). Prior to cleavage, the RFP-NLS-MAVS is present in the 
cytoplasm. When the substrate is cleaved by the functional NS3 protease, the nuclear 
localization signal is exposed and the RFP re-localizes to the nucleus. The RFP-NLS-MAVS was 
co-transfected along with the NS3 variants and the location of the RFP molecule was assessed 
in each case. CFP-NS3:NS4A and CFP-scNS3 both contain the protease domain and the protease 
co-factor NS4A and both of them were able to cleave the RFP-NLS-MAVS substrate evidenced 
by the re-localization of the RFP protein to the nucleus of the cell. To confirm that NS3 
specifically was cleaving the MAVS substrate, a RFP-NLS-MAVS substrate bearing an NS3 
cleavage resistant mutation was also co-transfected with the CFP tagged NS3 proteins (RFP-
NLS-MAVS (C508Y)). The cleavage resistant mutant was unable to be cleaved and remained in 
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the cytoplasm, showing that the cleavage of the MAVS substrate is specific to a functional NS3 
protease cleavage site (Figure 6-3 A-E and Figure 7-3 A-B).  
The RIG-I like receptors, RIG-I and MDA5, exert their signaling capability through their C-
terminal tandem CARD domains. To avoid these crucial interacting domains, the RIG-I like 
receptors were all tagged on the N-terminus. Previous research has shown that RIG-I like 
receptors tagged on the N-terminus retain their ability to signal and interact with ligand 
(Rehwinkel et al., 2010; Sanchez David et al., 2016). However, tagging with fluorescent proteins 
can sometimes cause proteins to enter the nucleus that may not otherwise be able to enter the 
Figure 7-3: Recombinant fluorescent 
fusion proteins retain biological 
activity when expressed in HEK293T 
cells. A plasmid expressing CFP-
NS3:NS4A was co-expressed with RFP-
NLS-MAVS (A) or RFP-NLS-MAVS 
expressing a NS3 cleavage site 
mutation (C508Y) (B) in HEK 293T cells. 
After 24 hours the cells were imaged at 
100X with two excitation wavelengths 
of 840 nm to target the CFP and 1000 
to target the RFP (A and B). Plasmids 
expressing the YFP tagged RLRs were 
expressed in HEK 293T cells and 
imaged after 24 hours (C-E).  Plasmids 
expressing YFP tagged RLRs were co-
expressed with a plasmid expressing 
the ISRE promoter with a luciferase 
reporter. After 24 hours, the luciferase 
activity was measured along with the 
YFP fluorescence in each well. 
Luciferase activity was normalized to 
YFP fluorescence.  
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nucleus. Un-tagged RIG-I like receptors are known to function in the cytoplasm and to confirm 
that the fluorescently tagged RIG-I like receptors localize to the cytoplasm each fluorescently 
tagged receptor was expressed alone in HEK 293T cells. The resulting YFP tagged proteins were 
all localized to the cytoplasm of the cells (Figure 7-3 C-E). To assay the signaling capability of the 
YFP tagged RIG-I like receptors, YFP alone, YFP-RIG-I, YFP-MDA5, and YFP-LGP2 were all co-
expressed with a second plasmid encoding firefly luciferase under the control of a promoter 
regulated by an interferon-stimulated response element (ISRE). When YFP alone was co-
expressed with the ISRE plasmid, very little luciferase activity was measured. However, when 
YFP-RIG-I and YFP-MDA5 were co-expressed with the ISRE plasmid, both showed the ability to 
stimulate the ISRE promoter. YFP-LGP2 also showed the ability to stimulate the ISRE promoter 
to a greater degree than the YFP vector alone. However, because LGP2 lacks the CARDs 
necessary for direct down-stream signaling, it is likely that this increase is due to the over-
expressed YFP-LGP2 interacting and stimulating the endogenous RIG-I and MDA5 proteins in 
the HEK293T cells (Figure 7-3 F). 
7.2 FRET analysis of interaction between HCV NS3 helicase domain and RLRs  
To screen for and analyze the interaction of the RIG-I like receptors with HCV NS3, a fully 
quantitative FRET technique was employed. This FRET method analyzes the interactions of 
protein ensembles in live cells and allows for the calculation of donor and acceptor 
concentrations (for more details on the FRET technique, see methods section 3.5) (Patowary et 
al., 2015; Stoneman et al., 2017). To specifically target sub-cellular regions of interest (in this 
study, HCV NS3:NS4A foci and mitochondria), a variation on the fully quantitative FRET 
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technique was developed which allowed for the selection of sub-cellular regions of interest 
using one of the fluorescent images or the addition of a third fluorescent tag. This variation on 
fully-quantitative spectroscopic imaging (FSI) (King et al., 2016; Stoneman et al., 2017) was 
termed quantitative micro-spectroscopic imaging (Q-MSI) (Corby et al., 2017).   
 Cells co-transfected with CFP tagged NS3 variants and YFP tagged RLRs were each 
imaged at two-excitation wavelengths (in this case 840 nm and 960 nm). The elementary 
spectrum of the CFP (Figure 7-4 A) and the YFP (Figure 7-4 B) were used to de-convolute (un-
mix) the composite CFP:YFP spectrum (Figure 7-4 C and D) into the individual CFP and YFP 
contributions (Figure 7-4 E,F, and G). The second excitation is necessary to calculate donor and 
acceptor concentrations (Figure 7-5 A-C) and to correct for the direct excitation of YFP at the 
CFP excitation wavelength of 840 nm. Each excitation scan collects about 200 images with a 1 
nm resolution and requires about 10 seconds. To change the excitation wavelength between 
excitation scans takes about 40 seconds. So the average time to collect two images at two 
different excitation wavelengths is approximately 60 seconds. This time delay allows for 
molecular diffusion and limits the analysis of the images to the calculation of FRET averages 
over specific sub-cellular regions of interest. However, this trade-off is necessary when using 
CFP:YFP as a FRET pair because YFP is excited at the 840 nm excitation wavelength used to 
excite CFP. The un-mixed images at each excitation wavelength were used to calculate the 
average FRET over regions of interest. The average intensities of the un-mixed donor and 
acceptor images over the same regions of interest were compared to standard curves of CFP 
and YFP to determine CFP and YFP protein concentrations (Figure 7-5 A-C) (for details see 
methods section 3.5).  
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Figure 7-4 Analysis of FRET helicase interactions using whole cell regions of interest. HEK 
293T cells were transfected with either CFP-LGP2, YFP-LGP2, or both CFP-LGP2 and YFP-LGP2. 
After 24 hours of expression, the cells were imaged at two excitation wavelengths (840 nm 
and 960 nm). The CFP-LGP2 alone cells generated the CFP spectrum (A), the YFP-LGP2 alone 
cells generated the YFP spectrum (B) and these elementary spectra were then used to de-
convolute the composite spectra at 840 nm (C) and at 960 nm (D) excitation. This de-
convolution yielded the donor (E) intensity map, the acceptor intensity map (F) and the 
acceptor concentration intensity map (G). These intensity maps were then used to calculate 
the average Eapp for each region of interest. The same technique was applied to the analysis 
of the interactions of CFP-NS3:NS4A with each of the YFP tagged RIG-I like receptors (H and I). 
Similarly, the interaction of CFP-LGP2 with each of the YFP tagged RIG-I like receptors was 
analyzed (J and K). 
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Figure 7-5: Sub-cellular average concentrations over selected regions of interest in the 
analysis of helicase interactions. The concentrations of the donor and acceptor were 
calculated for the cells co-expressing CFP-NS3-4A and each of the YFP tagged RIG-I like 
receptors by using the un-mixed donor and acceptor intensity maps and applying a 
standard curve either CFP or YFP protein fluorescence respectively. The concentrations 
of donor and acceptor within any given cell were overall within the same range (A-C). 
The same technique was used to calculate the donor and acceptor concentrations in 
the cells co-expressing CFP-LGP2 and each of the YFP tagged RIG-I like receptors. Again 
the average concentrations over selected regions of interest were roughly equal for 
each set of cells measured (D-F).  
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Figure 7-6: HEK 293T cells were transfected with each of the NS3 domain deletion mutants. 
A selected image of the 485 nm emission from the cells expressing each of the CFP-NS3 
variants is shown here (A-D).  CFP-NS3:NS4A was localized to foci within the cell (A) whereas 
each of the other NS3 variants lacking the membrane anchors were diffuse throughout the 
cell’s cytoplasm (B-D). 293T cells were co-transfected with each of the NS3 domain deletion 
constructs and YFP tagged LGP2. The Eapp for each combination was determined using Q-MSI 
and the scatter plot shows the average Eapp calculated for each cell analyzed. The average Eapp 
± the S.D. and the number of cells (regions of interest analyzed were: NS3h: 0.045 ± 0.029 
(n=96), NS3: 0.063 ± 0.035 (n=78), scNS3: 0.068 _/- 0.045 (n=79), and NS3-4A: 0.054 ± 0.027 
(n=74). The significance of the difference between groups was calculated using the one-wave 
ANOVA (F3,323)=7.814, p<0.0001). A Tukey post-hoc was used  and revealed that the Eapp of 
the NS3h group was significantly lower than that of the NS3 or scNS3 groups (*p<0.004). A 
histogram shows the number of cells expressing each Eapp value (bin width 0.05).  
130 
 
Q-MSI was first used to analyze cells transfected with CFP-NS3:NS4A and either YFP-RIG-
I, YFP-MDA5, or YFP-LGP2. In this case, the regions of interest were whole cells that were 
successfully transfected with both CFP and YFP constructs and therefore expressing both a CFP 
and YFP signal. When CFP-NS3:NS4A was co-expressed with either YFP-RIG-I or YFP-MDA5, the 
range of Eapp values straddled zero with some small positive and negative Eapp values calculated. 
However, when CFP-NS3:NS4A was co-expressed with YFP-LGP2, the calculated Eapp values 
were all above zero and reached as high as 20% (Figure 7-4 H and I).  
A similar set of transfections was performed using CFP-LGP2 as the donor and either 
YFP-RIG-I, YFP-MDA5, or YFP-LGP2 as the acceptor. Again, whole cell regions of interest were 
selected where both cells were successfully transfected with both donor and acceptor and 
expressing both CFP and YFP signal. When CFP-LGP2 was co-expressed with both YFP-RIG-I and 
YFP-MDA5, the average Eapp values over whole cells was approximately zero. When YFP-LGP2 
was used as the acceptor, most cells had some FRET. The average Eapp values for CFP-LGP2 and 
YFP-LGP2 cells was about 12% with values as high as 30% (Figure 7-4 J-K).  
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To further explore the possible NS3:LGP2 interaction, three domain deletion mutants of 
NS3:NS4A were used. CFP-NS3:NS4A expresses the full length NS3, including both the helicase 
and protease domain, and the full length NS4A protein including both the protease co-factor 
and the membrane anchors (Figure 6-3-row E and Figure 7-6 A). The first domain deletion 
mutant (CFP-scNS3) eliminates the membrane anchors from the NS4A and covalently attaches 
the protease co-factor domain to the N-terminal protease domain of NS3. This protein retains 
the ability to cleave protease substrates but does not localize to foci in the cell due to the lack 
of membrane anchors (Figure 6-3-row D and Figure 7-6 B).  The next NS3 mutant lacks the NS4A 
Figure 7-7: Concentrations of CFP tagged NS3 variants and YFP-LGP2 when co-
expressed in HEK293T cells. The concentrations for the donor and acceptor in each 
cell co-expressing either CFP-NS3h, CFP-NS3, CFP-scNS3, or CFP-NS3:NS4A co-
expressed with YFP LGP2 was analyzed by using the unmixed donor and acceptor 
intensity maps and calculating the average donor or acceptor intensity over a region 
of interest. This intensity was then compared to a standard curve of either CFP or YFP 
protein to calculate the final concentration of donor or acceptor (respectively) in the 
cell. (A-D).  
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co-factor completely (CFP-NS3) and is therefore not able to cleave MAVs in cells and is 
distributed diffusely throughout the cytoplasm (Figure 6-3-row C and Figure 7-6 C). The last NS3 
domain deletion mutant (CFP-NS3h) only contains the NS3 helicase domain. It is also unable to 
cleave the MAVs substrate and is diffuse throughout the cytoplasm (Figure 6-3-row B and 
Figure 7-6 D). A fourth domain deletion mutant (CFP-scNS3pro) which contained only the NS3 
protease domain along with the NS4A protease cofactor domain was also generated. However, 
when it was expressed in cells it not only lacked the ability to cleave MAVs, it was also 
aggregated in the cytoplasm of the cells. Given that CFP-scNS3pro lacked NS4A membrane 
anchors, it should have been diffuse throughout the cell and should not have formed sub-
cellular foci. Since CFP-scNS3-pro was forming foci in the cell and because it was unable to 
cleave the RFP-NLS-MAVs substrate, it was concluded that CFP-NS3pro was not folding correctly 
and therefore not a reliable mutant to consider in this study (Figure 7-7A-B).  
 
Figure 7-8: Representative images of CFP-NS3-protease expressed in cells. A 
plasmid expressing CFP-scNS3-pro was generated and expressed in HEK293T 
cells. CFP-scNS3-pro contains the 4A protease co-factor domain covalently 
linked to the NS3 protease domain. (A) After 24 hours of expression the cells 
were imaged by exciting at 840 nm. A representative image of 485 nm 
emission is shown. (B) CFP-scNS3-pro was co-transfected with RFP-NLS-MAVs. 
After 24 hours of expression the cells were imaged by exciting ta 840 nm.  A 
representative image overlay of the 485 nm emission and the 584 nm emission 
to target the CFP and RFP respectively is shown. 
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Each of the different domain deletion mutants of NS3 (excluding CFP-NS3pro) was 
transfected along with YFP-LGP2 and whole cell regions of cells displaying both CFP and YFP 
signals were selected. Average calculations of donor and acceptor were calculated for each ROI 
and found to be roughly equal within a given well (Figure 7-8). Despite the differences in the 
properties of each of the deletion mutants, they all retained an ability to interact with LGP2. 
This suggests that the interaction is occurring, at least in part, through the NS3 helicase domain. 
The range of Eapp values for the set of NS3 deletion mutants ranged from around 5% to as high 
as 30%. The CFP-scNS3 construct displayed the highest average Eapps (Figure 7-6 E and F). 
The previous experiments exploring the interaction of NS3 and LGP2 were all done by 
averaging Eapp over a whole cell region. This approach could be lowering the apparent Eapp 
values by averaging over regions of the cell where NS3 or LGP2 is not present (i.e. the nucleus) 
and therefore not able to interact.  This is noticeably problematic in the cells expressing CFP-
NS3:NS4A because the NS4A membrane anchors tethers the NS3 protein into specific sub-
cellular foci. To localize the Eapp analysis to the NS3:NS4A foci, the CFP-NS3:NS4A foci were 
selected in cells co-expressing each of the YFP tagged versions of the RLRs. The CFP-NS3:NS4A 
foci were defined as the bright CFP regions visible in the kDA intensity map of cells co-expressing 
CFP-NS3:NS4A and any one of the YFP tagged RLRs (Figure 7-9 A and B). This analysis approach 
yielded similar Eapp values to those seen in the whole-cell analysis (Figure 7-4 H and I). The Eapps 
calculated for the cells co-expressing CFP-NS3:NS4A and YFP-RIG-I or YFP-MDA5 were 
essentially zero with small Eapp values straddling zero. The Eapps calculated in the cells co-
expressing CFP-NS3:NS4A and YFP-LGP2 were still noticeably higher than those in the YFP-RIG-I 
or YFP-MDA5 expressing cells. Over 400 sub-cellular regions in cells co-expressing CFP-
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NS3:NS4A and YFP-LGP2 were analyzed and results were remarkably reproducible, always 
yielding an average of about 5% Eapp (Figure 7-9 C and D). The concentrations of the donor and 
acceptor were also calculated for the NS3:NS4A regions of interest (Figure 7-9 E-G).  
Figure 7-9: Sub-cellular NS3:NS4A region analysis of NS3 helicase interaction with RIG-I like 
receptors. HEK293T cells were co-transfected with plasmids encoding CFP-NS3:NS4A and 
either YFP-RIG-I, YFP-MDA5, or YFP-LGP2. After 24 hours, the cells were imaged and analyzed 
via Q-MSI. The sub-cellular NS3:NS4A regions was selected on the 2D spatial distribution map 
of CFP-NS3:NS4A fluorescence (A). This selection created a mask which could be applied to 
the 2D spatial distribution map of the YFP tagged RLRs (B).  The average E
app
 values along 
with average donor and acceptor concentrations were calculated over each NS3:NS4A region. 
The scatter plot (C) shows the E
app
 value calculated for each ROI. The average E
app
 ± S.D. and 
the number of ROIs analyzed (n) are: RIG-I: 0.009 ± 0.10 (n=83), MDA5: 0.004 ± 0.024 (n-71), 
LGP2 (set 1): 0.050 ± 0.038 (n=180) and LGP2 (set 2): 0.044 ± 0.033 (n=222). A one-way 
ANOVA showed a significant main effect of group (F(3,552) = 23.19, p<0.0001). The Tukey 
post-hoc showed that both RIG-I and MDA5 were significantly different from each LGP2 set 
(*p<0.0001). The histogram (D) shows the number of ROIs expressing each E
app
 value (bin 
width = 0.1). The scatter plots (E-G) show the distribution of average concentrations at each 
NS3:NS4A region of interest. 
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7.3 Q-MSI analysis of the interaction of NS3 with LGP2 in the presence and absence 
of the PAMP poly I:C 
LGP2 is known to bind and respond to the pathogen associated molecule pattern 
(PAMP), poly I:C in cells (Childs et al., 2013). Given that NS3 and LGP2 continue to show an 
interaction even when only the NS3 helicase domain was present, it is possible that the 
Figure 7-10: Analysis of NS3:NS4A interaction 
with LGP2 in the presence and absence of 
poly I:C. HEK293T cells were co-transfected 
with CFP-NS3-4A and YFP-LGP2  plasmids. The 
cells were incubated for 20 hours and then 
transfected with either 0.36 µg/mL of poly I:C 
or vehicle. The cells were excited at 840 nm 
and 960 nm and the composite spectra un-
mixed and regions of interest were selected in 
each image. The average Eapp for the whole 
cells with and without poly I:C treatment was 
calculated along with the donor and acceptor 
concentrations. The histogram (A) shows the 
spread of Eapp values with and without poly I:C. 
A Brown-Forsythe test was performed and 
yielded a p value of <0.01. Concentrations of 
CFP-NS3-4A (donor) and YFP-LGP2 (acceptor) in 
cells not treated with poly I:C (B) and 
concentrations of CFP-NS3-4A and YFP-LGP2 in 
cells treated with poly I:C (C). To determine if 
the NS3:NS4A and LGP2 interaction was 
localized to the mitochondria, cells co-
expressing CFP-NS3-4A or YFP-LGP2 were 
either treated with 0.36 µg/ml of poly I:C or 
vehicle. The mitochondria were stained with 
Mito-Tracker Red and circled. A histogram 
showing the number of mitochondrial ROIs 
expressing each Eapp value (bin width = 0.05) 
(D). A Brown-Forsythe test was performed and 
yielded a p value of 0.344.  
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interaction is, in part, mediated through a shared binding to RNA. To test this hypothesis, the 
CFP-NS3:NS4A plasmid was co-transfected with YFP-LGP2 in HEK 293T cells. After 24 hours of 
expression, the cells were treated with either poly I:C (0.36 µg/mL) or vehicle for four hours. 
The treated cells were imaged using successive 840 nm and 960 nm excitations and analyzed 
with Q-MSI. Whole cell regions of interest were circled and Eapps calculated. The apparent Eapp 
values increased slightly with the addition of poly I:C from an average of 5% Eapp to an average 
of 7% Eapp (Figure 7-10 A). In addition, a shift in CFP and YFP protein concentration was 
observed with the addition of poly I:C. When poly I:C was added, a noticeable population of 
cells expressed lower overall CFP and YFP proteins, possibly indicating that the poly I:C 
treatment caused an interferon-induced repression of protein translation (Figure 7-10 B and C).  
To isolate the interaction to the mitochondrial regions of the cells, the cells co-
transfected with CFP-NS3:NS4A and YFP-LGP2 were stained with Mito-Tracker Red and then 
imaged.  The Mito-Tracker Red dye stained the mitochondria of the cells and the Mito-Tracker 
signal was unmixed from the composite spectra. This yielded a map of Mito-Tracker intensity 
across the cells. Sub-cellular Mito-Tracker ROIs were selected using this Mito-Tracker Red 
intensity map in cells co-expressing CFP and YFP signal. The ROIs selected in the Mito-Tracker 
image were then applied as a “mask” to the CFP and YFP intensity images to specifically target 
the mitochondrial regions of the cells. The histogram of Eapp values at the mitochondria show an 
increase from 7.7% to 8.2% with poly I:C treatment (Figure 7-10 D). Although there is a small 
increase in Eapp at the mitochondria with the addition of poly I:C, that increase is not statistically 
significant.   
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7.4 Significance of LGP2 and NS3 interaction 
In this study, the potential interaction of HCV NS3 helicase with the RIG-I like receptors 
was probed using ectopically expressed fluorescent fusion proteins and fully quantitative FRET 
imaging. The Q-MSI technique allows for the study of protein:protein interactions within sub-
cellular regions in living cells. LGP2 was the only RLR which showed any significant interaction 
with NS3 and experiments with deleted NS3 domains showed that this interaction appears to 
be due, in part, to an interaction with the NS3 helicase domain. It’s possible that the interaction 
is a direct protein:protein interaction or it may also be partially mediated through a joint 
interaction with RNA. However, given that the interaction of NS3 and LGP2 increased only 
slightly with the addition of poly I:C (Figure 7-10), it is unlikely that the interaction is solely 
mediated through a joint association with RNA.  
The interaction of NS3 and LGP2 may be biologically relevant if it aids NS3 in inhibiting 
the innate immune response by helping NS3 locate cleavage targets, such as MAVS. Previous 
work has looked at the role of the helicase in NS3-mediated cleavage of MAVs. A mutant of NS3 
(W501A) lacks helicase function but still retains the ability to block IRF-3 activation down 
stream of MAVs in response to Sendai virus infection, meaning that it is still likely able to cleave 
MAVs. However, NS3 expressing a non-functional protease was able to somewhat inhibit IRF-3 
induction as compared to vector alone, implying that other pathways of inhibition may be 
present (Foy et al., 2003). Another study showed that NS3 lacking the helicase domain is 
sufficient for MAVs cleavage (Horner et al., 2012). Although some studies show that the 
helicase domain is not necessary for cleavage of MAVs, it’s possible that the helicase domain 
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aids in the innate immune inhibition and MAVs cleavage. Perhaps the NS3 helicase domain 
increases the efficiency at which NS3 protease is able to localize to MAVs through interaction 
with an RLR.  
The LGP2:NS3 contact is a curious interaction because LGP2 is not known to make direct 
contact with MAVs, due to lacking the CARDs. However, it is possible that LGP2 may help 
shuttle NS3 to areas with MAVs through the known LGP2 interaction with MDA5. LGP2 is 
known to make an oligomer with MDA5 to aid in its recognition and binding of viral substrates. 
MDA5 then, in turn, releases its CARDs to interact with the CARDs on MAVs. It’s possible that 
NS3 binds to the LGP2:MDA5 complex and localizes to MAVs through the LGP2:MDA5 
interaction with MAVs. One experiment which could test this idea would be to create mutants 
which prevent the LGP2:MDA5 interaction. Then these mutants could be co-expressed along 
with fluorescently tagged NS3. Q-MSI could be used to see if the loss of LGP2:MDA5 interaction 
affects the interaction of NS3 with LGP2 at the mitochondria in response to a PAMP.  Since the 
LGP2:MDA5 interaction is thought to happen in the cytoplasm prior to the LGP2:MDA5 
localization to MAVs, the results that poly I:C does not increase the interaction of NS3 with 
LGP2 at the mitochondria  (Figure 7-10 D) but does increase the interaction in the cell as a 
whole (Figure 7-10 A) supports the idea that the LGP2:MDA5 interaction may be necessary for 
NS3 re-localization to MAVs. 
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Chapter 8 DDX3 causes LGP2 to re-localize into foci 
The intracellular innate immune system is the cell’s first line of defense against invading 
pathogens. It contains a group of proteins known as pattern recognition receptors (PRRs) which 
recognize conserved features of pathogens. These conserved features include nucleic acids, 
bacterial or viral proteins or carbohydrates and are jointly called pathogen associated molecular 
patterns (PAMPS). Once these PRRS have recognized their cognate ligand, they initiate a 
signaling cascade which results in the production of interferon and other cytokines (Errett and 
Gale, 2015b; Horner et al., 2011). 
One group of PRRs includes the RIG-I like receptors (RLRs). The RIG-I like receptors are 
made up of RIG-I, MDA5, and LGP2. The RIG-I like receptors are DExD/H box RNA helicases 
which specifically recognize the RNA of viral invaders. Once they have bound to their RNA 
ligand, they signal through the adaptor protein mitochondrial anti-viral signaling protein 
(MAVs) to initiate the production of interferon. One location of the cell where the RLRs might 
detect viral RNA PAMPS is in the non-ribosomal cytoplasmic ribonuclear protein (RNP) granules 
(Protter and Parker, 2016). RNP molecules were first described by developmental biologists 
studying dark staining “germ” granules that form at one pole of animal embryos which hold 
maternal mRNA necessary for germ line differentiation (Schisa et al., 2001). Heat shock 
granules (HSGs), which are similar in composition, were later discovered when cultures of 
tomato cells were incubated at 40°C.  HSGs contain heat shock proteins and “house-keeping 
mRNAs sequestered in insoluble aggregates which dissolve once homeostasis has been restored 
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(Nover et al., 1983). Similar granules appear in mammalian cells in response to oxidative stress, 
heat shock, UV-radiation, and viral and bacterial infections.  
It appears the role RNPs is to function as RNA repositories which sequester RNA when 
the cell is under stress and then disintegrate, releasing the translation machinery and RNA, 
once conditions have improved (Buchan et al., 2008; Kwon et al., 2007). These RNPs have been 
termed “stress granules” and the stress granules formed in response to viral exposure have 
been specifically called “anti-viral stress granules (Craig Mccormick and Denys A Khaperskyy, 
2017; Onomoto et al., 2012; Onomoto et al., 2014). Onomoto et al showed that the RIG-I like 
receptors localized to stress granules in response to influenza-1 infection (Onomoto et al., 
2012) and it’s possible that the RIG-I like receptors are using the RNA harboring stress granules 
as sites of RNA recognition and anti-viral coordination.  
8.1 Evidence that DDX3 recruits the RIG-I-like receptor LGP2 to Foci 
This project was initiated to examine the interaction of the RIG-I like receptors with 
hepatitis C NS3 helicase. To probe these interactions, we constructed a fluorescently tagged 
LGP2 and several other “control” helicases that are not RLRs (DDX1, DDX3, and DDX5). The 
fluorescent recombinant LGP2 was tagged with cyan fluorescent protein (CFP) and the DDX1, 
DDX3, and DDX5 helicases were tagged with yellow fluorescent protein (YFP) (Figure 8-1 B) and 
co-expressed in HEK293T cells for 24 hours. Cells expressing CFP-LGP2 alone were also imaged 
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and the image corresponding to the CFP peak emission of (475 nm) is shown (Figure 8-1A). 
Samples were excited at 800 nm and emission spectra were collected over 200 wavelengths. 
Figure 8-1 Co-overexpression of DDX3 and LGP2 causes DDX3 and LGP2 to accumulate in 
cytoplasmic foci. A) HEK293T cells transfected with the plasmid pCMV-mCFP-LGP2 which 
overexpresses the mCFP-LGP2 fluorescent fusion protein. The CFP signal appears to be localized 
to the cytoplasm of the cells. B) Diagram showing theoretical FRET between a CFP donor 
excited at 800 nm (two photon excitation) and a YFP acceptor emitting at 530 nm. C) Co-
expression of CFP-LGP2 and YFP DDX1 in HEK293T cells. The unmixed CFP intensity map and 
YFP intensity map taken from the mixed image of the cells co-expressing CFP-LGP2 and YFP-
DDX1 were overlaid. Both CFP-LGP2 and YFP-DDX1 are cytoplasmic proteins and pixel level 
FRET is shown. D) Co-expression of CFP-LGP2 and YFP-DDX3 in HEK293T cells. The unmixed CFP 
intensity map and YFP intensity map taken from the mixed image of the cells co-expressing 
CFP-LGP2 and YFP-DDX3 was overlaid. Cytoplasmic foci are seen and FRET is shown. E) Co-
expression of CFP-LGP2 and YFP-DDX5 in HEK293T cells. The unmixed CFP intensity map and 
YFP intensity map taken from the mixed image of the cells co-expressing CFP-LGP2 and YFP-
DDX5 was overlaid. DDX5 is a nuclear protein and LGP2 is a cytoplasmic protein. FRET between 
the two proteins is shown. 
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The donor and acceptor signal were un-mixed to generate maps of donor and acceptor signal 
using the FRET spectrometry technique discussed in Methods 3.5. The un-mixed donor (kDA) 
intensity map and the un-mixed acceptor (kAD) intensity map were used to calculate FRET (See 
Methods 3.5 for more details) and to generate maps of FRET intensity. The FRET generated 
here does not include a correction for direct excitation and therefore the intensity of FRET 
measured is not considered. Rather, the presence or absence of FRET in the each combination 
is considered only in relation to each other.  
The kDA and kAD intensity maps for CFP-LGP2 and each of the YFP tagged DDX proteins 
were overlaid (Figure 8-1 C-E). While examining the images of these proteins in cells, we made 
the serendipitous observation that co-expression of DDX3 (but not the homologs DDX1 and 
DDX5) led to a clear re-localization of LGP2 from the cytoplasm (Figure 8-1A) to distinct 
cytoplasmic foci (Figure 8-1 D). Stress granules are identified by the consistent presence of 
molecules such as poly-A binding protein (PABP) and translation initiation factors (eIF3, eIF4E, 
and eIF4G) along with mRNA and small ribosomal sub-units (Kedersha and Anderson, 2007) and 
DDX3 has been identified as a key nucleating component of stress granules (Valiente-Echeverría 
et al., 2015). In addition, the over-expression of DDX3 alone can initiate the formation of stress 
granules (Shih et al., 2012). Therefore, it’s possible that the foci observed in the images 
containing over-expressed DDX3 are stress granules and that LGP2 is re-localizing to the stress 
granules. In addition, FRET was observed between CFP-LGP2 and YFP-DDX3 within the 
cytoplasmic foci whereas no FRET was observed for the combinations of CFP-LGP2 and YFP 
DDX1 or CFP-LGP2 and YFP-DDX5 (Figure 8-1). 
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The re-localization of LGP2 to the DDX3 formed foci is reminiscent of what was seen by 
Onomoto et al who observed using immunofluorescence that the RLRs re-localized to anti-viral 
stress granules in response to influenza-1 infection. The stress granules were identified using 
fluorescent antibodies targeted to stress granule markers (such as eIF3) (Onomoto et al., 2012). 
Given that DDX3 over-expression is able to nucleate the formation of stress granules, it is likely 
that the foci seen in the images with over-expressed DDX3 are stress granules. It is possible that 
DDX3 is helping to shuttle LGP2 to stress granules and this could be shown through using 
immunofluorescence to stain endogenous DDX3, LGP2, and stress granule markers in cells 
infected with a virus that induces stress granules. 
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Chapter 9  Homo and hetero interactions of RIG-I like receptors in response to 
poly I:C 
The RIG-I like receptors (RLRs) are a set of sub-cellular DExD/H helicases which recognize 
the pathogen associated molecular patterns (PAMPs) of RNA viruses in almost every cell in the 
human body. The RLRs are made up of three different pattern recognition receptors (PRRs); 
retinoic acid inducible gene –I (RIG-I), melanoma differentiation associated protein-5 (MDA5), 
and laboratory of genetics and physiology protein-2 (LGP2). RIG-I and MDA5 both contain 
tandem CARDs, a helicase domain, and a C-terminal regulatory domain. RIG-I and MDA5 exist in 
an auto inhibited state in the cytoplasm of cells with their CARD domains swung in towards 
their helicase domain, preventing un-wanted CARD interaction and signaling. The C-terminal 
regulatory domain is exposed to the cytosol and is the first domain to recognize the RNA PAMP 
ligands. Once the C-terminal domain has bound to a prospective RNA PAMP ligand, it swings in 
to allow the helicase domain to interact with the ligand. Then the CARDs are released to 
oligomerize and interact with their downstream target, mitochondrial associated anti-viral 
signaling protein (MAVs).  
LGP2 is different from both RIG-I and MDA5 in that it lacks the CARDs necessary for 
downstream signaling. Instead, LGP2 exerts its effects through interaction with the other RLRs. 
The effect of LGP2 in innate immune signaling is antithetical with some studies indicating a 
positive regulatory effect while others indicate a negative regulatory role. Evidence that LGP2 
exerts a positive effect on interferon signaling include experiments showing that mice who 
express mutations in LGP2 are more susceptible to certain virus infections than littermates who 
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have a functional LGP2. In addition, experiments in cells lacking both LGP2 and MDA5, show a 
synergistic signal increase of an IRF3 reporter from exogenous co-expression of both MDA5 and 
LGP2, but not either one expressed independently. This suggests that the interaction of LGP2 
with MDA5 induces interferon signaling. Examples of LGP2 negative regulation can be seen 
from interferon reporter assays that show overexpression of LGP2 from an exogenous vector 
can downregulate interferon signaling induced via a viral infection(Childs et al., 2013; Pippig et 
al., 2009; Rodriguez et al., 2014). Alternatively, LGP2 does not enhance RIG-I interaction with 
MAVs and interferon signaling at low concentrations, but instead seems to only inhibit RIG-I at 
high concentrations (Bruns and Horvath, 2012). A unifying model has emerged where LGP2 
interaction with MDA5 exerts a concentration dependent enhancement of interferon signaling 
until it reaches a very high concentration. Then LGP2 takes on an inhibitory role for both MDA5 
and RIG-I, where its high-affinity binding to RNA PAMPS sequesters the RNA from recognition 
by RIG-I or MDA5, effectively slowing down signaling (Rodriguez et al., 2014). 
This study uses recombinant fluorescent fusion proteins to look at the homo and hetero 
interactions of the RLRs with other RLRs and with the downstream signaling protein, MAVs. Q-
MSI, which employs quantitative Förster Resonance Energy Transfer (FRET) with two-excitation 
wavelengths and fully quantitative analysis was applied to show that the RLRs form ordered 
complexes in living cells and that these interactions may be modulated through the presence or 
absence of a PAMP ligand. Prior studies have shown that RIG-I, MDA5, and LGP2 all form 
oligomers (Bruns et al., 2013; Wu et al., 2013; Wu et al., 2014) and that the hetero-interaction 
between MDA5 and LGP2 is important for MDA5 signaling (Bruns and Horvath, 2015; Bruns et 
al., 2013). But, the interactions have never before been seen in living cells. This study is able to 
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show the interactions of the RLRs at the mitochondria in living cells and to demonstrate that 
this interaction shifts with the addition of a PAMP RNA ligand. 
9.1 Sub-cellular analysis of the homo-interactions of the CFP and YFP tagged RIG-I 
like receptors in response to poly I:C 
Q-MSI was used to examine the current models which show the RIG-I like receptors 
responding to viral RNA PAMPs by forming larger oligomeric complexes and interacting with 
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Figure 9-1 Dual excitation fluorescence micro-spectroscopy analysis of cells co-expressing 
donor, acceptor, and the sub-cellular mitochondrial tag, MitoTracker. A) Cells expressing only 
CFP-MDA5 and excited at 840 nm (two-photon excitation). The peak 485 nm emission is shown as 
a CFP intensity map of the cells. The orthogonal view of the circled region in the cell intensity 
map is shown along with the calculated fluorescent spectrum. B) Cells expressing only YFP-LGP2 
and excited at 960 nm (two-photon excitation). The peak 525 nm emission is shown as a YFP 
intensity map of the cells. The orthogonal view of the circled region in the cell intensity map is 
shown along with the calculated fluorescent spectrum. C) Cells stained only with MitoTracker and 
excited at 840 nm (two-photon excitation). The peak 599 nm emission is shown as a MitoTracker 
intensity map of the cells. The orthogonal view of the circled region in the cell intensity map is 
shown along with the calculated fluorescent spectrum. D) Cells co-expressing CFP-MDA5 and YFP-
LGP2 and stained with MitoTracker were excited at 840 nm. The fluorescence intensity map 
showing the 525 nm emission is shown. The orthogonal view and spectrum of the circled region 
is also shown. E) The 2D spatial distribution map of the donor fluorescence in the presence of 
acceptors k
DA
(λex1). F) 2D map of acceptor fluorescence in the presence of donor k
AD
(λex1). G) 2D 
map of MitoTracker k
M
(λex1) intensity.  
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MAVS at the mitochondrial membrane. If the models are correct, then it should be expected 
that the fluorescently tagged RLRs accumulate at the mitochondria. Since the ISRE promoter is 
stimulated by the over-expression of the RLRs (Figure 7-3F), it would be expected that this 
accumulation should occur even in the absence of PAMP but should be enhanced in the 
presence of PAMP. However, upon visual inspection of the images, there was no sub-cellular 
localization evident when the RLRs were expressed in HEK293T cells (Figure 7-3 C-E). Instead 
the proteins looked diffuse throughout the cytoplasm of the cells. Therefore, to localize the 
analysis to the mitochondria, the Mito-Tracker Red dye was used to label the mitochondria of 
live cells co-expressing the CFP and YFP tagged RLRs. The Mito-Tracker Red dye was selected 
because it fluoresces in a region of the spectrum distinct from CFP and YFP. The dye was used 
to select mitochondrial regions of the cell for analysis with Q-MSI. To identify and separate the 
mitochondrial localized YFP and CFP tagged proteins, the spectra from cells singly expressing 
either CFP (Figure 9-1A) or YFP (Figure 9-1B) or cells only stained with the Mito-Tracker Red 
(Figure 9-1C) were used to unmix the composite spectra from the cells co-expressing CFP and 
YFP and also stained with Mito-Tracker (Figure 9-1D). The regions of interest (ROIs) were 
identified on the CFP (kDA) map (Figure 9-1E) and the YFP (kAD) (Figure 9-1F) map by applying the 
mask created on the Mito-tracker (kM) map (Figure 9-1G). This allowed for the calculation of 
FRET (Eapp) and concentrations of CFP and YFP proteins specifically in the mitochondrial regions 
of interest. No FRET would be visible if there is no interaction of CFP and YFP at the 
mitochondria. If there is a small amount of CFP and YFP interacting pairs at the mitochondria or 
if there is a complex with a lot of donors and only a few acceptors, then a low level of FRET 
would be detected in the mitochondrial regions. If there are many CFP and YFP interacting pairs 
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Figure 9-2 Response of mitochondrial 
localized RIG-I, MDA5, and LGP2 to poly 
I:C exposure.  A) Expected FRET from 
mitochondrial localized CFP and YFP 
proteins under different proposed 
interaction conditions. For each 
experiment, cells co-expressing a donor 
and acceptor tagged protein were exposed 
to poly I:C (0.36µg/mL media) for four 
hours prior to imaging. The cells were 
stained with MitoTracker and then 
analyzed with Q-MSI where the 
mitochondrial regions were selected using 
the MitoTracker 2D intensity map and the 
selections applied as a mask to the donor 
and acceptor images. The average Eapp for 
each ROI was calculated. B) Histogram  
(0.05 bin size) showing the calculated 
average Eapp for each ROI in cells co-
expressing CFP-RIG-I and YFP-RIG-I.  A 
Brown-Forsythe test was performed and 
yielded a p value <0.01. Plots of the 
average concentrations of CFP and YFP 
within each ROI region measured (with and 
without poly I:C treatment  is also shown.  
C) A histogram showing the calculated 
average Eapps for each ROI in cells co-
expressing CFP-MDA5 and YFP-MDA5. A 
Brown-Forsythe test was performed and 
yielded a p-value of <0.001. Plots of the 
average concentrations of CFP and YFP 
within each ROI region measured (with and 
without poly I:C treatment  is also shown. 
D) A histogram showing the calculated 
average Eapps for each ROI in cells co-
expressing CFP-LGP2 and YFP-LGP2. A 
Brown-Forsythe test was performed and 
yielded a p-value of <0.001. Plots of the 
average concentrations of CFP and YFP 
within each ROI region measured (with and 
without poly I:C treatment  is also shown.  
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or if there is a complex with many more acceptors than donors, then there would be very high 
FRET at the mitochondria (Figure 9-2A). 
In the first set of experiments, cells were co-transfected with plasmids expressing 
recombinant fluorescent YFP-RIG-I and CFP-RIG-I or YFP-MDA5 and CFP-MDA5. Some of the 
cells were treated with poly I:C at a concentration of 0.36 µg/mL in cell growth media and the 
rest of the cells were exposed to vehicle (TurboFect) only.  Poly I:C is a synthetic double 
stranded RNA PAMP which both RIG-I and MDA5 recognize. Previous work has shown that RIG-I 
and MDA5 accumulate at the mitochondria in response to poly I:C (Hou et al., 2011). When Q-
MSI was used to calculate the Eapp at the mitochondria of the cells co-expressing either YFP-RIG-
I:CFP-RIG-I or YFP:MDA5:CFP-MDA5, clear differences were apparent between the set treated 
with poly I:C and the set not treated with poly I:C. Although the average Eapp for RIG-I only 
changed slightly from 3% to 4% with the addition of poly I:C,  there was a very noticeable shift 
in overall population distribution. The addition of poly I:C caused the accumulation of a 
population of YFP-RIG-I and CFP-RIG-I molecules interacting at the mitochondria with high Eapp 
values ranging from 50% to 90%. These high FRET values indicate the development of a few 
large oligomeric complexes at the mitochondria in the presence of poly I:C which were not 
present in the absence of poly I:C (Figure 9-2B). 
When CFP-MDA5 was co-expressed with YFP-MDA5 and the Eapp at the mitochondria 
was analyzed via Q-MSI, a shift in the population of mitochondrial ROIs expressing higher Eapps 
in response to poly I:C is visible. Almost identical populations of Eapps are visible around 0 to 10 
% Eapp in those cells treated and un-treated with poly I:C. This is expected, because not every 
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cell expressing the CFP and YFP tagged MDA5 proteins would have necessarily been exposed to 
the poly I:C application. However, a segment of ROIs with higher Eapps develops in response to 
poly I:C. This indicates the formation of a set of higher order oligomeric complexes at the 
mitochondria in response to poly I:C (Figure 9-2C). It is important to note that the spread of the 
data is not error, but instead shows a variety of different combinations of donor and acceptor 
molecules within a population of oligomeric complexes. 
Lastly, the same sub-cellular analysis was performed on cells co-transfected with 
plasmids expressing CFP-LGP2 and YFP-LGP2. LGP2 lacks the CARD regions necessary for direct 
interaction with MAVs. Therefore, we did not expect to see much accumulation of LGP2 at the 
mitochondria in response to poly I:C because any mitochondrial accumulation of LGP2 would 
most likely occur through interaction with the low levels of endogenous MDA5. Not surprisingly 
then, the results show that there is not a large difference in the FRET between YFP-LGP2 and 
CFP-LGP2 at the mitochondria in response to poly I:C and a sub-population of higher FRET 
efficiencies does not develop, like what was seen with RIG-I and MDA5. In fact, less FRET is seen 
when poly I:C is added, suggesting that the addition of an RNA PAMP is causing the breakup of 
some of the LGP2:LGP2 complexes (Figure 36D). One explanation for this decrease in Eapps in 
response to poly I:C, is that LGP2 homo-oligomers may be dissociating to interact with MDA5 
on the RNA and to aid in MDA5 RNA recognition. It’s possible that the addition of poly I:C 
stimulated the endogenous expression of more MDA5, and that LGP2 is now interacting with 
more MDA5:RNA complexes, thus diluting the direct LGP2:LGP2 interaction and reducing FRET 
efficiency at the mitochondria. 
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9.2 Sub-cellular analysis of the hetero-interactions of the CFP and YFP tagged RIG-I  Figure 9-3: Response of mitochondrial 
localized LGP2 and MDA5 to poly I:C. In 
both experiments, cells were transfected 
with plasmids co-expressing a fluorescent 
recombinant protein construct tagged with 
either CFP or YFP. The cells allowed to 
incubate for 20 hours prior to poly I:C 
(0.36 µg/mL of media) transfection. After 
4 hours of poly I:C exposure, the cells were 
stained with MitoTracker-Red to identify 
the mitochondria. Mitochondrial regions 
were selected using the MitoTracker 
staining and those regions of interest were 
then applied to the CFP and YFP 
expressing images to calculate an average 
Eapp and an average concentration of CFP 
and YFP for each mitochondrial ROI. A) 
Histogram FRET analysis of cells co-
expressing CFP-LGP2 and YFP-MDA5 with 
and without poly I:C transfection. A 
Brown-Forsyteh test was performed and 
yielded a p value of 0.03. B) Eapp values vs. 
the molar fraction of acceptor molecules 
with and without poly I:C. C) and D) 
Average concentrations of CFP and YFP 
proteins within selected ROIs with and 
without poly I:C transfection. E) Histogram 
of the FRET analysis of cells co-expressing 
CFP-MDA5 and YFP-LGP2 with and without 
poly I:C transfection. A Brown-Forsythe 
test was performed and yielded a p value 
of <0.001. F) A Eapp values vs. the molar 
fraction of acceptor molecules with and 
without poly I:C exposure. G) and H) 
Average concentrations of CFP and YFP for 
each ROI with and without poly I:C 
transfection. 
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Previous research has shown that there is a special interaction between LGP2 and MDA5 
which is not present between RIG-I and LGP2 (Bruns et al., 2014; Bruns and Horvath, 2015; 
Bruns et al., 2013; Rodriguez et al., 2014). To examine this interaction, cells were co-expressed 
with plasmids expressing recombinant fluorescent CFP-LGP2 and YFP-MDA5. The cells were 
then treated with either poly I:C (0.36µg/mL) for four hours or vehicle. After exposure to poly 
I:C or vehicle the cells were stained with Mito-Tracker and the mitochondrial regions identified 
and selected. The resulting ROIs were analyzed by Q-MSI. In the absence of poly I:C, these cells 
showed some LGP2:MDA5 interaction with Eapps between 0-20% confirming that simple over-
expression of LGP2 and MDA5 can result in the formation of oligomeric interactions at the 
mitochondria (Figure 9-3A). A small population of higher FRET efficiencies developed in 
response to the addition of poly I:C. (Figure 9-3A). It was also noted that in all the ROIs 
measured, the molar fraction of acceptor ([A]/([D]+[A])) was shifted towards complexes 
containing many more donors than acceptors (Figure 9-3B). The overall range of molar fraction 
of acceptor was 0 to 0.6 with the majority of the ROIs expressing molar fractions around 0.2. 
This would imply that the mitochondrial ROIs contain many more LGP2 molecules than MDA5 
molecules.  
To test this notion, a second transfection was performed where the fluorescent tags on 
the MDA5 and LGP2 molecules were switched. This time, CFP-MDA5 and YFP-LGP2 were co-
transfected in HEK293T cells and again some of the cells were treated with poly I:C (0.36µg/mL) 
and some were treated with vehicle (TurboFect) for four hours. After poly I:C treatment, the 
cells were stained with Mito-Tracker Red so the mitochondria could be located and selected. 
The mitochondrial ROIs were analyzed with Q-MSI. The combination of CFP-MDA5 and YFP-
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LGP2 yielded similar FRET efficiencies to the previous combination when the tags were 
switched in the absence of poly I:C. In the absence of poly I:C, the FRET efficiencies ranged from 
0-20%. However, when poly I:C was added, there was a dramatic shift to higher FRET 
efficiencies with a large population of ROIs exhibiting FRET efficiencies between 20%-60% and a 
few ROIs with even higher FRET efficiencies (Figure 9-3E). In addition, the molar fraction of 
acceptors shifted to being between 0.4 to 1.0 for both the set with and without poly I:C 
treatment (Figure 9-3F). However, the highest FRET efficiencies were seen only in the set 
treated with poly I:C. This confirms the hypothesis that the mitochondrial ROIs contain more 
LGP2 than MDA5 molecules. It also shows that the interaction of LGP2 and MDA5 is increased 
at the mitochondria in response to poly I:C stimulation evidence by the dramatic increase in 
Eapp with the addition of poly I:C treatment. 
9.3 Analysis of the hetero-interactions of RIG-I receptors like receptors in response 
to poly I:C at the pixel level  
Previous experiments were performed by applying Q-MSI to proteins tagged with either 
CFP or YFP.  Although the CFP:YFP FRET pair works well for Q-MSI, it requires a correction for 
direct excitation of the acceptor at the donor excitation wavelength. This is because the peak 
excitation for CFP occurs around 840 nm (two photon excitation) and YFP is still easily excited at 
840 nm (Figure 3-1 A). To correct for direct excitation of the acceptor, the quantity of acceptor 
fluorescence in the absence of donor must be calculated. To accomplish this, a second 
excitation at a longer wavelength targeting the acceptor alone is used (See Methods 3.5 for 
more details). The time it takes to move between the first (FRET) excitation and the second 
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excitation is about 40 seconds which is sufficient time to allow for molecular diffusion. Since the 
proteins have time to diffuse away from their original position between the first and second 
excitations, only average FRET efficiencies were calculated over selected regions of interest. 
The correction for direct excitation and the required second excitation prevents the calculation 
of FRET at pixel level.  
To calculate FRET at pixel level, the fluorescent protein pairs used to visualize the RIG-I 
like receptors were switched to GFP2 as the donor and either YFP or Venus as the acceptor. The 
GFP2 protein excitation spectrum is spectrally very similar to wild-type GFP. Unlike CFP, which 
excites optimally at 840 nm (two photon excitation), GFP2 (and wild-type GFP) excite optimally 
at 800 nm. At 800 nm, both YFP and Venus are not excited at all (Figure 3-1 B and C). This 
allows the FRET equation to be simplified because the fluorescence of the acceptor at 
wavelength 1 is now equal to zero (See Methods 3.5 for details).  When using either GFP2 and 
YFP or GFP2 and Venus the calculation of Eapp can be accomplished using only one excitation 
wavelength. This eliminates the issue of molecular diffusion and allows for a calculation of Eapp 
at the pixel level. 
Pixel level Eapp values can then be organized into histograms of Eapp values contained 
within selected regions of interest. The pixel level histograms generated for each region of 
interest contain many characteristic peaks and features which may be attributed to unique 
combinations of donors and acceptors within the large oligomeric complexes. To gain an 
understanding of the overall predominant Eapp combinations within the regions of interest, 
predominant peaks from each histogram are collected and binned in an overall meta-
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histogram. This meta-histogram represents the overall predominant donor and acceptor 
configurations within the region of interest (Stoneman et al., 2017). 
9.3.1 Pixel level FRET analysis of the interaction of GFP2-LGP2 and Venus-MDA5  
Pixel level, fully quantitative FRET analysis was used to examine the interaction between 
GFP2-LGP2 and Venus MDA5 at the mitochondrial membrane. Previous experiments showed a 
small increase in average FRET efficiency when the mitochondrial regions of the cell were 
analyzed with Q-MSI and LGP2 was tagged with the donor (CFP) and MDA5 was tagged with the 
acceptor (YFP) (Figure 9-3A). A similar increase in FRET efficiency would be expected when the 
tags were changed to a FRET pair which does not require a correction for direct excitation. In 
this case the donor is GFP2 and is tagged to LGP2 and the acceptor is Venus and is tagged to 
MDA5.  
Plasmids expressing recombinant fluorescent GFP2-LGP2 and Venus-MDA5 were 
transfected into HEK 293T cells. The cells were allowed to incubate and express the 
fluorescently tagged proteins for 20 hours. After 20 hours of protein expression, the cells co-
transfected with both GFP2-LGP2 and Venus-MDA5 were transfected with either poly I:C 
(0.36µg/mL) or vehicle. The cells were incubated for additional 4 hours. Then, the mitochondria 
of the cells were stained with Mito-Tracker Red. The cells were excited at 800 nm which excited 
the donor and did not directly excite the acceptor. The 800 nm excitation also excited the Mito-
Tracker Red. Elementary spectra were collected using cells solely expressing GFP2-LGP2, Venus-
MDA5, and only stained with Mito-Tracker Red. The elementary spectra were used to de-
convolute the composite image and to calculate Eapp at every pixel in the image. A map 
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depicting the 2D spatial distribution of pixel-level Eapps was also generated. For more detail on 
microscopy, un-mixing, or Eapp calculation, please see Methods 3.5. 
Un-mixing of the composite spectra in cells co-expressing GFP2-LGP2 and Venus-MDA5 
yielded the 2D spatial fluorescence intensity maps of kDA (Figure 9-4A),  kAD (Figure 9-4B) and of 
Mito-Tracker, kM, (Figure 9-4C).  
The kDA  and kAD  values calculated at each pixel were used to calculate the 2D spatial 
distribution of Eapp (Figure 9-4D). The Mito-Tracker map was used to select the mitochondrial 
regions of the cell (Figure 9-5A) and then this mitochondrial region mask was applied to the Eapp 
map to select only the mitochondrial regions (Figure 9-5B). For each mitochondrial region of 
interest, a histogram of Eapp peaks was created (Figure 9-5C). The collection of Eapp histograms 
was then analyzed to select the predominant peak in each histogram. The predominant peak 
Figure 9-4: Unmixed k
DA
 , k
AD 
, MitoTracker and Eapp (FRET) 2D intensity maps. Cells were co-
transfected with plasmids expressing GFP2-LGP2 and Venus-MDA5.  The mitochondria were 
stained with MitoTracker-Red and the FRET was calculated at a pixel level. A)The 2D fluorescence 
intensity map for GFP2-LGP2 (k
DA
). B)The 2D fluorescence intensity map for Venus-MDA5 (k
AD
). 
C)The 2D fluorescence intensity map for MitoTracker. D) The FRET intensity distribution for cells 
co-expressing GFP2-LGP2 and Venus-MDA5.  
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was selected from each histogram and compiled into a meta-histogram with a bin width of 2 
(Figure 9-5D). 
Figure 9-5: Pixel level FRET analysis of sub-cellular regions of cells co-expressing 
GFP2-LGP2 and Venus-MDA5. A) Cells co-expressing GFP2-LGP2 and Venus-MDA5 
were stained with MitoTracker to locate the mitochondria. The unmixed 
MitoTracker image was used to select sub-cellular mitochondrial regions. The 
selected mitochondrial ROIs were then used as a mask and applied to the Eapp 
intensity map to select the Eapp intensity within each mitochondrial region. The Eapp 
values in each mitochondrial region can be graphed as a histogram showing the 
frequency of each Eapp value within that ROI. The peaks from these individual ROI 
histograms were selected to generate a Meta-histogram compiling all the peak Eapp 
values across all mitochondrial ROIs selected. B) The same set of cells used for 
analysis in (A) were re-analyzed by selecting general cytoplasmic regions using a 
consistent circle comprising 146 pixels. The circle was placed throughout the k
DA
 
intensity map such that most of the cell’s cytoplasm was selected but none of the 
circles were over-lapping. The mask created on the k
DA 
intensity map was then 
applied to the Eapp intensity map to select random cytoplasmic regions of a 
consistent size. The Eapp values from the selected cytoplasmic ROIs can each 
generate a histogram of Eapp values within that ROI. The peak Eapp value from each 
cytoplasmic ROI histogram was selected to generate a Meta-histogram comprising 
all peak Eapp values selected 
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Most of the predominant pixel-level Eapp values within the mitochondrial regions were 
zero (Figure 9-5A). This is not surprising considering that the interacting proteins should exist 
on the mitochondrial membrane, yet it’s impossible to just select the mitochondrial membrane. 
Therefore, many of the mitochondrial ROIs contain many pixels which would constitute the 
inside of the mitochondria and not just the mitochondrial membrane. Since the RLRs are not 
expected to accumulate inside the mitochondria, it would make sense that this region would be 
largely devoid of FRET. When the mitochondrial regions were analyzed in previous experiments 
and an average taken over the whole area, this detail was lost in the average. But at pixel level, 
it is apparent that much of the mitochondrial ROIs do not contain interacting GFP2 and Venus 
proteins. However, in some of the histograms, the predominant peak was non-zero and for the 
set of cells not treated with poly I:C, the Eapp range was between 0-20%. This is very similar to 
what was seen with CFP-LGP2 and YFP-MDA5 (Figure 9-3A) which also showed an Eapp range 
between 0-20%. When poly I:C was added to the cells, a sub-set of cells exhibited Eapp values 
larger than 20% and up to a maximum of 40% (Figure 9-5A). Previous experiments also showed 
a small increase in Eapps within the population of cells transfected with poly I:C, however it 
never reached 40%.  This could be due to the averaging of Eapp values with regions of zero 
interaction which is necessary when the tags CFP and YFP are used but irrelevant with GFP2 and 
Venus when a pixel level analysis is possible. Pixel level analysis allows these zero pixels to be 
separated out of the overall analysis instead of averaged. 
Another set of ROIs were selected on the same set of cells co-expressing GFP2-LGP2 and 
Venus-MDA5. These ROIs were selected using the kDA image (Figure 9-5B). A circle containing 
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146 pixels was used as the ROI template and was placed throughout the cell selecting circular, 
non-overlapping cytoplasmic regions. The regions were only selected in cells expressing both 
GFP2 and Venus signal. This created a mask of cytoplasmic regions containing the same number 
of pixels and this mask was applied to the Eapp map to create Eapp histograms for each ROI 
selected The predominant peak was selected from each of the Eapp histograms and compiled 
into a meta-histogram (Figure 9-5 A and B).  
The ROIs selected were randomly generated throughout the cell and there are 
significant regions which do not contain interacting GFP2-LGP2 and Venus-MDA5. Therefore, 
the most common Eapp value in the meta-histogram was zero.  The non-zero Eapp values for the 
cells not treated with poly I:C were between 0-20%. This is the same range seen when the 
mitochondrial ROIs were circled (Figure 9-5A) and when the fluorescent tags used were CFP and 
YFP (Figure 9-3A). However, a small population of higher FRET efficiencies were present in the 
cells not transfected with poly I:C. In those cells, Eapps as high as 50-60% were calculated. The 
cells transfected with poly I:C also showed a population of ROIs with predominant peak Eapps 
above 20%, but there were not as many of them and they only reached a maximum of 45%. The 
cytoplasmic ROIs include not only the mitochondria, but also the surrounding cytoplasmic 
regions. The current model of RLR function predicts that MDA5 and LGP2 interact in the 
cytoplasm and jointly recognize PAMP RNAs, forming oligomeric complexes before interacting 
with MAVs at the mitochondria (Bruns et al., 2014; Bruns and Horvath, 2015; Bruns and 
Horvath, 2014; Rodriguez et al., 2014). Since the oligomeric complexes formed in the cytoplasm 
between MDA5 and LGP2 is predicted to be solely between those two proteins and the RNA 
PAMP, it’s possible that the Eapp in the cytoplasm would be overall higher than the when the 
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complex forms at the mitochondria, where it is also interacting with the CARDs on MAVs. The 
interaction of the MAVs CARDs may shift the overall Eapp value for the complex at the 
mitochondria to be slightly lower and therefore, the overall population displays a slightly lower 
predominant Eapp peak. 
9.3.2 Pixel level FRET analysis of the interaction of MAVs with RIG -I like receptors 
 The RIG-I like receptors exert their down-stream signaling effect through the adaptor 
protein MAVs. MAVs was first identified as a protein essential for NF-ƙB and IRF3 activation by 
RNA viruses (Seth et al., 2005). It contains an N-terminal CARD-like domain and a C-terminal 
transmembrane domain which localizes MAVs to the mitochondrial membrane. Suppression of 
MAVs was shown to block interferon production and to increase viral replication. Over-
expression of MAVS augmented interferon production and decreased viral replication. Deletion 
of the CARD domain completely inhibited the MAVs anti-viral effect implying that interaction 
through the CARD domain was essential for MAVs function (Seth et al., 2005).  
 The RIG-I like receptors, RIG-I and MDA5, exert their downstream effect directly through 
MAVs by seeding the formation of a MAVs filament through the interaction of RIG-I or MDA5 
CARDs with the MAVs CARD. The formation of a MAVs filament initiates the down-stream 
signaling cascade which results in the production of interferon and other cytokines (Wu and 
Hur, 2015). Previous research using acceptor photo bleaching has shown that tagging RIG-I with 
the donor (GFP2) and MAVs with the acceptor (YFP) yields FRET in the MAVs regions of the cell 
(Baril et al., 2009). In addition, molecular modeling using a GFP2 tagged MAVs and YFP tagged 
RIG-I (Badhu, Raicu and Frick, unpublished) indicated that the MAVS:RIG-I CARD interaction 
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should be stable and should yield at least one possible GFP2 and YFP interaction with a distance 
close enough to achieve productive FRET (Table 9-1 ).  
To study the interaction of RIG-I with MAVs, cells were transfected with plasmids 
expressing recombinant fluorescent GFP2-MAVs and 
YFP-RIG-I. The cells were incubated for 20 hours to 
allow protein expression and then the cells co-
transfected with GFP2-MAVS and YFP-RIG-I were 
transfected with either poly I:C (0.36µg/ml) or 
vehicle. The cells were allowed to incubate for an 
additional 4 hours and then imaged using two 
wavelengths, 800 nm and 960nm. Although only the 
800 nm wavelength was used for the calculation of 
Eapp. The imaging procedure has been described 
previously in Methods 3.5. Elementary spectra were 
obtained from cells expressing either solely GFP2-
MAVS (Figure 9-6A) or YFP-RIG-I (Figure 9-6B). The 
elementary spectra were used to un-mix the 
composite spectra from cells co-expressing GFP2-MAVS and YFP-RIG-I (Figure 9-6C). The Eapp 
was calculated by using the kDA (Figure 9-7A) and kAD (Figure 9-7B) 2D spatial distribution maps 
generated from un-mixing the composite spectra of cells co-expressing GFP2-MAVS and YFP-
RIG-I and excited at 800 nm. The Eapp values were calculated for each pixel and used to create 
the 2D spatial distribution of Eapp values (Figure 9-7C).  
Table 9-1: Distances calculated using 
molecular dynamic simulations 
between fluorescent proteins in the 
RIG-I:MAVS complex. A theoretical 
GFP2-MAVS and YFP-RIG-I oligomer was 
constructed using known crystal 
structures of RIG-I and MAVS. The 
distances between the GFP2 and YFP 
protomers were calculated at time zero 
and after 21 nanoseconds of simulation.  
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 Sub-cellular MAVS regions were selected on the kDA map in only those cells co-
expressing GFP2 and YFP signal. The selected MAVS regions were then used to create a mask to 
apply to the Eapp map. Each MAVS ROI generated a histogram of Eapp values within that ROI 
(Figure 9-7D and E). The peak Eapp value for each histogram was selected and compiled into a 
meta-histogram containing all the peak Eapp values from every MAVS region selected. The meta-
Figure 9-6: Dual excitation fluorescence micro-spectroscopy analysis of 
cells co-expressing GFP2-MAVS and YFP-RIG-I. A) Cells expressing only 
GFP2-MAVS and excited at 800 nm (two photon excitation). The peak 
510 nm emission is shown as a GFP2 2D intensity map of the cells. The 
orthogonal view of the circled region within the GFP2 intensity map and 
the calculated fluorescent spectrum is also shown. B) Cells expressing 
only YFP-RIG-I and excited at 960 nm (two photon excitation). The peak 
525 nm emission is shown as a YFP 2D intensity map of the cells. The 
orthogonal view of the circled region within the YFP-RIG-I intensity map 
and the calculated fluorescent spectrum is also shown. C) Cells co-
expressing GFP2-MAVS and YFP-RIG-I and excited at 800 nm (two photon 
excitation). The orthogonal view of the circled region within the GFP2-
MAVS + YFP-RIG-I intensity map is shown, along with the fluorescent 
spectrum. 
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histogram shows the frequency at which any given peak Eapp value appears within the circled 
MAVS ROI (Figure 9-7F).  
The peak Eapp values calculated were primarily less than 20% with the majority falling 
around 5% Eapp. This is not unexpected given the molecular modeling which predicts a distance 
of about 80 Angstroms between GFP2 and YFP in the MAVS:RIG-I complex. Interestingly, there 
was no shift in Eapp with the addition of poly I:C., implying that the MAVS:RIG-I complex is 
unchanged with the addition of a PAMP. This is surprising given previous results between RIG-
I:RIG-I which suggested that there may be the formation of a few large oligomeric complexes at 
the mitochondria in response to poly I:C addition (Figure 9-2A). However, since it’s known that 
RIG-I signaling occurs even in the absence of PAMP (Figure 7-3F), it’s possible that the RIG-
Figure 9-7: Pixel level FRET (Eapp) 
calculation and meta-histogram analysis 
for cells co-expressing GFP2-MAVS and 
YFP-RIG-I. A) The 2D spatial fluorescence 
intensity map of donor in the presence of 
acceptor showing the distribution of GFP2-
MAVS in cells co-expressing YFP-RIG-I. B) 
The 2D spatial fluorescence intensity map 
of acceptor in the presence of donor 
showing the distribution of YFP-RIG-I in 
cells co-expressing GFP2-MAVS. C) The 
calculate pixel level Eapp map showing the 
distribution of FRET efficiencies in cells co-
expressing GFP2-MAVS and YFP-RIG-I. D) 
and E) Histograms of Eapp values for the 
MAVS regions of interest indicated in the 
k
DA
 intensity map. F) Meta-histogram of 
selected peak FRET efficiencies for every 
MAVS region of interest selected from the 
k
DA 
 intensity map. 
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I:MAVS signaling complex is already formed with over-expression and does not shift with the 
addition of PAMP. Another possibility is that the shift in complex occurs between sub-units too 
far away to produce productive FRET. Since the molecular modeling between RIG-I and MAVS 
indicated that most of the interacting sub-units were too far away from each other to FRET, it’s 
possible that any shift in the complex with addition of PAMP occurs between those sub-units 
and is not visible in this FRET assay with the fluorescent tags in their current positions on the 
proteins. 
 In addition to RIG-I, MDA5 is known to interact with MAVS via tandem CARDs. To study 
the interaction of MDA5 with MAVS, plasmids encoding fluorescent recombinant GFP2-MAVS 
Figure 9-8: Dual excitation fluorescence 
micro-spectroscopy analysis of cells co-
expressing GFP2-MAVS and YFP-MDA5. A) 
Cells expressing only GFP2-MAVS and excited 
at 800 nm (two photon excitation). The peak 
510 nm emission is shown as a GFP2 2D 
intensity map of the cells. The orthogonal 
view of the circled region within the GFP2 
intensity map and the calculated fluorescent 
spectrum is also shown. B) Cells expressing 
only YFP-MDA5 and excited at 960 nm (two 
photon excitation). The peak 525 nm 
emission is shown as a YFP 2D intensity map 
of the cells. The orthogonal view of the 
circled region within the YFP-MDA5 intensity 
map and the calculated fluorescent 
spectrum is also shown. C) Cells co-
expressing GFP2-MAVS and YFP-MDA5 and 
excited at 800 nm (two photon excitation). 
The orthogonal view of the circled region 
within the GFP2-MAVS + YFP-MDA5 intensity 
map is shown, along with the fluorescent 
spectrum. 
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and YFP-MDA5 were co-transfected into HEK293T cells. The cells were allowed to incubate for 
20 hours after which they were transfected with either poly I:C or vehicle and allowed to 
incubate for an additional 4 hours. After incubation, the cells were imaged at 800 nm and 960 
nm excitations. The method was the same as described above for RIG-I.  Elementary spectra 
were obtained for cells solely expressing either GFP2-MAVS (Figure 9-8A) or YFP-MDA5 (Figure 
9-8B). These elementary spectra were used to un-mix the composite spectra for the cells co-
expressing GFP2-MAVS and YFP-MDA5 (Figure 9-8C). The Eapp was calculated by using the kDA 
(Figure 9-9A) and kAD (Figure 9-9B) 2D spatial distribution maps generated from un-mixing the 
composite spectra of cells co-expressing GFP2-MAVS and YFP-RIG-I and excited at 800 nm. The 
Eapp values were calculated for each pixel and used to create the 2D spatial distribution of Eapp 
values (Figure 9-9C).  
Figure 9-9: Pixel level FRET (Eapp) calculation and 
meta-histogram analysis for cells co-expressing 
GFP2-MAVs and YFP-MDA5. A) The 2D spatial 
fluorescence intensity map of donor in the 
presence of acceptor showing the distribution of 
GFP2-MAVS in cells co-expressing YFP-MDA5. B) 
The 2D spatial fluorescence intensity map of 
acceptor in the presence of donor showing the 
distribution of YFP-MDA5 in cells co-expressing 
GFP2-MAVS. C) The calculated pixel level Eapp map 
showing the distribution of FRET efficiencies in 
cells co-expressing GFP2-MAVS and YFP-MDA5. D) 
and E) Histograms of Eapp values for the MAVs 
regions of interest indicated in the k
DA
 intensity 
map. F) Meta-histogram of selected peak FRET 
efficiencies for every MAVS region of interest 
selected from the k
DA 
 intensity map. 
167 
 
 MAVS regions were selected on the kDA map in only those cells co-expressing GFP2 and 
YFP signal. The selected MAVS regions were then used to create a mask to apply to the Eapp 
map. Each MAVs ROI generated a histogram of Eapp values within that ROI (Figure 9-9D and E). 
The peak Eapp value for each histogram was selected and compiled into a meta-histogram 
containing all the peak Eapp values from every MAVS region selected. The meta-histogram 
shows the frequency at which any given peak Eapp value appears within the circled MAVS ROI 
(Figure 9-9F). 
 The maximum peak Eapp calculated for the interaction of GFP2-MAVS and YFP-MDA5 was 
slightly over 20%. But the majority of the Eapps fell below 10%. It is thought that the MDA5 
Figure 9-10: Dual excitation fluorescence 
micro-spectroscopy analysis of cells co-
expressing GFP2-MAVS and Venus-MDA5. 
A) Cells expressing only GFP2-MAVS and 
excited at 800 nm (two photon excitation). 
The peak 510 nm emission is shown as a 
GFP2 2D intensity map of the cells. The 
orthogonal view of the circled region within 
the GFP2 intensity map and the calculated 
fluorescent spectrum is also shown. B) Cells 
expressing only Venus-MDA5 and excited at 
960 nm (two photon excitation). The peak 
525 nm emission is shown as a Venus 2D 
intensity map of the cells. The orthogonal 
view of the circled region within the Venus-
MDA5 intensity map and the calculated 
fluorescent spectrum is also shown. C) Cells 
co-expressing GFP2-MAVS and Venus-MDA5 
and excited at 800 nm (two photon 
excitation). The orthogonal view of the 
circled region within the GFP2-MAVS + 
Venus-MDA5 intensity map is shown, along 
with the fluorescent spectrum. 
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oligomer is larger than the RIG-I oligomer (Lässig and Hopfner, 2017) and the overall reduced 
Eapps for the MDA5:MAVS interaction compared to the RIG-I:MAVS interaction could be due to 
shielding from a larger MDA5:MDA5 complex which prevents closer association of the 
fluorescent tags on MDA5 and MAVS. Similar to the results for the interaction of RIG-I and 
MAVS, there did not appear to be a shift in interaction upon addition of poly I:C. It was shown 
that MDA5 over-expression (similar to RIG-I) causes interferon signaling (Figure 7-3F) 
presumably through MAVS. Therefore, it’s possible that the MAVS:MDA5 oligomer may already 
be in its optimal signaling configuration before PAMP RNA is added. However, it is also possible 
that the tags are located in regions where the shift in the MDA5:MAVS complex is not readily 
visible. FRET is never able to prove there is no interaction (or no change in interaction), it can 
only prove that there is an interaction because multiple other factors affect the success of FRET 
(discussed in Literature Review and Methods) besides just the interaction of the proteins to 
which fluorescent tags are attached. 
 An additional experiment looking at the interaction of MAVs and MDA5 was also 
performed in the same manner as the previous experiment, except for two changes. The tag on 
MDA5 was changed from YFP to Venus. Venus is a YFP variant which is more stable and matures 
faster than YFP but otherwise has the same emission and excitation spectrum as YFP. The 
additional change was the length of the linker connecting MDA5 to the fluorescent protein. In 
the previous experiment, the link was only two amino acids long, so MDA5 and the fluorescent 
protein were very close to each other. The connection between the Venus fluorescent protein 
and MDA5 is 15 amino acids long. Therefore, there is much more space between the 
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fluorescent tag and the protein of interest.  In contrast, the linker between the GFP2 and MAVS 
is only 2 amino acids long.  
 To collect the elementary spectra from GFP2 and Venus, HEK293T cells expressing solely 
GFP2-MAVS or Venus-MDA5 were imaged at 800 nm excitation and 960 nm excitation. This 
created the GFP2 800 nm elementary spectrum (Figure 9-10A) and the Venus 960 nm 
elementary spectrum (Figure 9-10B). These elementary spectrum were used to unmix the 
composite spectra containing both the GFP2-MAVS and the Venus-MDA5 excited at 800 nm 
(Figure 9-10 C). This generated the kDA (Figure 9-11A) and kAD (Figure 9-11B) maps. GFP2-MAVS 
regions were selected and used to create a mask which was applied to the Eapp map (Figure 9-
11C). Each selected MAVS region in the Eapp map generated a unique histogram of Eapp values 
Figure 9-11: Pixel level FRET (Eapp) calculation 
and meta-histogram analysis for cells co-
expressing GFP2-MAVS and Venus-MDA5. A) 
The 2D spatial fluorescence intensity map of 
donor in the presence of acceptor showing 
the distribution of GFP2-MAVS in cells co-
expressing Venus-MDA5. B) The 2D spatial 
fluorescence intensity map of acceptor in the 
presence of donor showing the distribution of 
Venus-MDA5 in cells co-expressing GFP2-
MAVS. C) The calculated pixel level Eapp map 
showing the distribution of FRET efficiencies 
in cells co-expressing GFP2-MAVS and Venus-
MDA5. D) and E) Histograms of Eapp values for 
the MAVS regions of interest indicated in the 
k
DA
 intensity map. F) Meta-histogram of 
selected peak FRET efficiencies for every 
MAVS region of interest selected from the k
DA 
intensity map. 
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(Figure 9-11D and E). The Peaks from these histograms were collected in a meta-histogram 
(Figure 9-11F). 
 The meta-histogram of GFP2-MAVS and Venus-MDA5 shows overall higher Eapp values 
than the previous experiment performed with GFP2-MAVS and YFP-MDA5. This could be due to 
the stability of the acceptor (Venus). It could also be due to the difference in linker length 
connecting Venus to MDA5. It’s possible that the longer linker length allows for better 
interaction of the tags connecting MDA5 and MAVS. It is also possible that the increased 
Figure 9-12: Dual excitation 
fluorescence micro-spectroscopy 
analysis of cells co-expressing GFP2-
MAVS and YFP-LGP2. A) Cells 
expressing only GFP2-MAVS and 
excited at 800 nm (two photon 
excitation). The peak 510 nm 
emission is shown as a GFP2 2D 
intensity map of the cells. The 
orthogonal view of the circled region 
within the GFP2 intensity map and 
the calculated fluorescent spectrum 
is also shown. B) Cells expressing 
only YFP-LGP2 and excited at 960 nm 
(two photon excitation). The peak 
525 nm emission is shown as a YFP 
2D intensity map of the cells. The 
orthogonal view of the circled region 
within the YFP-LGP2 intensity map 
and the calculated fluorescent 
spectrum is also shown. C) Cells co-
expressing GFP2-MAVS and YFP-LGP2 
and excited at 800 nm (two photon 
excitation). The orthogonal view of 
the circled region within the GFP2-
MAVS + YFP-LGP2 intensity map is 
shown, along with the fluorescent 
spectrum. 
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stability of Venus allowed for more stably expressed acceptors. Since FRET is dependent on the 
number of acceptors present, if the YFP acceptor is not stable, then less acceptors would be 
present to receive energy from the donors. It is possible that the GFP2 and Venus is a better 
FRET pair. In addition, a small population of ROIs expressing higher FRET efficiencies are visible 
in the cells treated with poly I:C. These ROIs showed Eapps as high as 40%. It’s possible that the 
longer linker length is increasing the sensitivity of the assay by changing how the tags interact 
and making a shift in complex due to poly I:C which was previously not detected, visible in this 
FRET assay set up (Figure 9-11). 
 LGP2 is the third RLR which is not known to directly interact with MAVS due to its lack of 
CARDs. However, it does interact with MDA5 which in turn interacts with MAVS, and it is known 
that simply over-expressing LGP2 somewhat increases interferon signaling (Figure 7-3F). Since 
LGP2 cannot signal directly, this increase in interferon signaling must be through the interaction 
with endogenous MDA5. To test the interaction of LGP2 and MAVS, cells were transfected with 
plasmids co-expressing GFP2-MAVS and YFP-LGP2 and they were treated in the same manner as 
was described for RIG-I:MAVS and MDA5:MAVS experiments above. The elementary spectra for 
cells solely expressing GFP2-MAVS (Figure 9-12A) or YFP-LGP2 (Figure 9-12B). The elementary 
spectra were used to unmix the composite spectra for those cells co-expressing GFP2-MAVS and 
YFP-LGP2 (Figure 9-12C). This unmixing generated kDA  (Figure 9-13A) and kAD  (Figure 9-13B) 2D 
spatial intensity maps which were used to calculate pixel level Eapps and to generate an Eapp  
map (Figure 9-13C) for each field of view. MAVS region ROIs were selected on the kDA map for 
only those cells co-expressing GFP2 and YFP signal. This MAVS ROI mask was then applied to the 
Eapp map and Eapp histograms generated for each sub-cellular region (Figure 9-13D and E). The 
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peak values from each ROI within the Eapp regions selected were compiled into a meta-
histogram (Figure 9-13F). 
 
Surprisingly, the combination of GFP2-MAVS and YFP-LGP2 yielded high FRET efficiencies 
of up to 20% for both cells treated and not treated with poly I:C. Given that LGP2 should not 
interact with MAVS directly, it is unexpected that there be such high FRET efficiencies. It’s 
possible that the interaction of endogenous MDA5 with YFP-LGP2 is positioning LGP2 such that 
the YFP interacts with the GFP2 on MAVS. In addition, there is the development of a small 
population of ROIs with higher FRET efficiencies with the addition of poly I:C. If LGP2 is indeed 
being recruited by endogenous MDA5 to the MAVS complex, then it makes sense that the 
addition of poly I:C would increase/change this interaction.  
Figure 9-13: Pixel level FRET (Eapp) calculation 
and meta-histogram analysis for cells co-
expressing GFP2-MAVS and YFP-LGP2. A) The 
2D spatial fluorescence intensity map of donor 
in the presence of acceptor showing the 
distribution of GFP2-MAVS in cells co-
expressing YFP-LGP2. B) The 2D spatial 
fluorescence intensity map of acceptor in the 
presence of donor showing the distribution of 
YFP-LGP2 in cells co-expressing GFP2-MAVS. C) 
The calculated pixel level Eapp map showing 
the distribution of FRET efficiencies in cells co-
expressing GFP2-MAVS and YFP-LGP2. D) and 
E) Histograms of Eapp values for the MAVS 
regions of interest indicated in the k
DA
 
intensity map. F) Meta-histogram of selected 
peak FRET efficiencies for every MAVS region 
of interest selected from the k
DA 
 intensity 
map. 
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9.4 Significance of the interactions of the RIG-I like receptors in response to poly 
I:C 
The RIG-I like receptors have previously been shown to form oligomers with the use of 
electron microscopy (Bruns et al., 2014; Bruns and Horvath, 2015; Bruns and Horvath, 2012; 
Bruns et al., 2013; Bruns and Horvath, 2014). To look at the interactions of RLRs in living cells, 
ectopically expressed fluorescent fusion proteins were used in conjunction with fully 
quantitative FRET imaging and analysis (Corby et al., 2017; Stoneman et al., 2017). When whole 
cells were selected as ROIs, the self-interaction of both RIG-I and MDA5 was very low, whereas 
the FRET between LGP2:LGP2 self-interactions was noticeable, even in the absence of RNA 
PAMP (Figure 7-4K). This suggests that only LGP2 forms self-oligomers in the cytoplasm in the 
absence of PAMPs. 
Noteworthy self-interactions between RIG-I:RIG-I and MDA5:MDA5 in the absence of 
RNA PAMP were visible when the region of interest was switched from the whole-cell to the 
mitochondria. But the FRET between RIG-I:RIG-I was smaller than the self-interaction between 
MDA5 (Figure 9-2 B and C). This is consistent with other research which states that RIG-I forms 
smaller, shorter oligomers and is responsible for detecting shorter RNA PAMPs with different 
end modifications versus MDA5 which is implicated in sensing longer chain RNA PAMPs (del 
Toro Duany et al., 2015; Peisley et al., 2014; Peisley et al., 2012). However when poly I:C was 
added, the RIG-I:RIG-I interaction included the development of a few very large Eapps as large as 
80-90% whereas the MDA5:MDA5 interaction included a much larger population shift to larger 
Eapps but they only reached a max of 50%. The differences in Eapps at the mitochondria could be 
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indicative of the formation of different oligomers between RIG-I:RIG-I and MDA5:MDA5 at the 
mitochondria. The differences in MDA5 and RIG-I oligomers could mean that the signal they 
transmit through MAVS is specific to the type of PAMP which they recognize. 
Despite the differences between the RIG-I:RIG-I and MDA5:MDA5 FRET at the 
mitochondria in response to poly I:C (Figure 9-2 B and C) there do not appear to be large 
differences caused by the addition of PAMP between RIG-I:MAVS or MDA5:MAVS. Although the 
overall populations of FRET efficiencies was lower between MDA5: MAVS as compared with 
RIG-I:MAVS (Figure 9-7F and 9-9F), there was no visible shift with the addition of poly I:C. This 
may mean that the complex formed between MAVS and either RIG-I or MDA5 is similar with 
and without the addition of PAMP. Meaning that over-expression alone induces the formation 
of an oligomer which is the same as the oligomer induced in the presence of RNA PAMP. 
However, it could also mean that the shift in oligomer is not visible with this FRET assay in the 
current conditions. An additional experiment performed with MAVS and MDA5 where the 
fluorescent tag on MDA5, as well as the linker between the fluorescent tag and MDA5 were 
switched gives credence to the latter explanation. In this experiment, the FRET between MAVS 
and MDA5 was higher overall and a shift in population to a set of ROIs expressing higher Eapps 
(as high as 40%) was apparent in response to poly I:C transfection (Figure 9-11F). Therefore, it’s 
possible that there is a shift in oligomer occurring with addition of PAMP and that the linker 
length or fluorescent tags need to be switched to allow that shift to become visible in this FRET 
assay. 
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The self-interaction of LGP2:LGP2 at the mitochondria in response to poly I:C contained 
overall larger Eapps than the self-interaction of either MDA5 or RIG-I with Eapps both with and 
without poly I:C reaching as high as 30% (Figure 9-2D). Interestingly, the FRET for the LGP2 self-
interaction was highest in the absence of poly I:C and then decreased when poly I:C was added. 
This possibly indicates that the presence of a PAMP encourages LGP2 interaction with MDA5 to 
aid in the PAMP recognition, thus decreasing the self LGP2:LGP2 interaction.  
The largest FRET efficiencies seen in this Q-MSI study were seen between LGP2 and 
MDA5. This interaction has been studied previously and it is known that LGP2 and MDA5 
interact on RNA PAMPs (Bruns et al., 2014; Bruns and Horvath, 2012; Uchikawa et al., 2016; Wu 
et al., 2014). When YFP-LGP2 was co-expressed with CFP-MDA5 an effect was seen. In the 
absence of poly I:C, there was a small population of Eapps as high as 10%, but with the addition 
of poly I:C, the Eapp values shifted above 20%, with some reaching as high as 80-90% FRET 
efficiency (Figure 9-3D). When the tags were switched, the overall FRET efficiency decreased 
(Figure 9-3A and B) but there was still an overall shift to higher Eapp values with the addition of 
poly I:C. In addition to the shift in Eapp values, the molar fraction of acceptor shifted when the 
tags were switched between LGP2 and MDA5. When the acceptor was tagged to LGP2 and the 
donor attached to MDA5, a shift towards higher molar fractions of acceptor was visible. In 
contract, when the donor was LGP2 and the acceptor was MDA5, the molar fraction of acceptor 
shifted lower. All this data combined suggests that LGP2 does not just prime RNA filaments for 
MDA5 interaction, but rather is the dominant protomer in a larger MDA5: LGP2 oligomer. 
Taken together, this data reinforces the idea that addition of an RNA PAMP leads to 
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accumulation of LGP2 at the mitochondria through interaction with either endogenous or 
exogenous MDA5. 
Chapter 10 The two excitation peaks of the wild-type GFP protein and the 
development of a novel GFP variant.  
The development of the green fluorescent 
protein, from its isolation in jellyfish to its wide-
spread use today as a fluorescent tag and 
indicator, involved many groups and over 40 
years of work. The work was monumental and 
culminated in the 2008 Nobel Prize in Chemistry. 
The green fluorescent protein (GFP) was first 
discovered by Shimomura et al as a chemiluminescent protein found in Aequorea jellyfish 
(Shimomura et al., 1962). Soon after, the GFP protein was purified and crystalized and its 
absorption spectrum and quantum yield measured (Morise et al., 1974). Next it was proposed 
and later confirmed that the chromophore is 4-(p-hydroxybenzylidene)imidazolidin and that the 
chromophore is attached to the backbone of the protein through the 1 and 2 positions of the 
ring (Figure 10-1) (Shimomura, 1979). Over the next 20 years, several GFP variants possessing 
mutations which shifted the excitation and/or emission spectra, increased photo-stability, 
increased efficient folding at 37°C and increased brightness were developed by Tsien and other 
groups (Heim et al., 1995; Shaner et al., 2005; Tsien, 1998).  
Figure 10-1: The GFP chromophore is 4-
(p-hydroxybenzylidene)imidazolidin. 
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The green fluorescent protein has a spectrum with two excitation peaks (Figure 3-1 B 
and C). One excitation peak is at about 400 nm (or 800 nm two-photon excitation) and the 
second excitation peak is at 480 nm (or 960 nm two photon excitation). Shifting the excitation 
spectra of GFP to favor one excitation over another may be desirable in some cases and is 
achieved through altering the local environment of the GFP chromophore. If the protonated 
form is stabilized then the 400 nm excitation is dominant. If the deprotonated anion is 
stabilized, then the 480 nm excitation is preferred. There are several classes of GFP proteins 
which can be separated based on their excitation and emission properties. GFP class 1 variants 
includes wild-type GFP. Class 1 GFP proteins have retained the two excitation maxima 
(Battistutta et al., 2000). Class 2 GFP variants have a S65T mutation in the chromophore which 
stabilizes the phenolate anion of the chromophore. This mutation causes the excitation spectra 
of class 2 variants to shift towards a predominantly 480 nm excitation peak. Class 3 GFP 
molecules have mutations near the chromophore (such as S202F or T203I) which preference 
the neutral phenol form of the chromophore. The neutral form shifts toward the 400 nm 
excitation peak (Zacharias and Tsien, 2006). 
Selection of the appropriate fluorescent proteins with the best characteristics for the 
particular FRET experiment is of the utmost importance. When using pixel level FRET 
spectrometry to analyze protein:protein interactions there needs to be a sufficient difference 
between donor and acceptor excitation spectra such that the acceptor is not excited at the 
donor excitation wavelength. If the acceptor is excited at the donor excitation wavelength, then 
an additional correction for direct excitation is necessary. This correction employs the use of a 
second excitation wavelength and the time necessary to switch between two excitation 
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wavelengths is enough to allow molecular diffusion such that the results can no longer be 
analyzed at the pixel level. Instead, averages over larger regions of interest must be used. 
Although averages can still be informative (King et al., 2016), pixel level allows for the 
acquisition of a much greater amount of information over smaller areas and has been used to 
determine more information about the specific quaternary arrangement of the protein sub-
units (see Methods 3.5 for more detail) (Corby et al., 2017; Stoneman et al., 2017).  
The fluorescent proteins GFP2 and YFP or GFP2 and Venus make ideal FRET pairs for pixel 
level FRET spectrometry analysis because the GFP2 has an excitation peak at 800 nm (two 
photon excitation) and both the YFP and Venus fluorescent proteins do not excite at 800 nm 
(Figure 3-1 B and C). GFP2 is very similar in sequence to Clonetech’s eGFP protein except that 
GFP2 converts the S65T mutation, present in the eGFP protein, back to the wild type S65. This 
has the effect of reverting the GFP2 back to the wild-type GFP excitation spectra. In addition, 
GFP2 incorporates the non-dimerizing mutation, A206K, which decreases the tendency of 
fluorescent proteins to dimerize. See Figure 3-2 for an alignment of the sequences of wild-type 
Figure 10-2: Emission of GFP2 overlaps YFP and Venus absorption spectra. A) Overlay of 
GFP2 emission spectra and YFP absorption spectra. B) Overlay of GFP2 emission spectra and 
Venus absorption spectra. 
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GFP, Clonetech eGFP, and GFP2. Both YFP and Venus excite optimally at 960 nm (two photon 
excitation) and are excited by GFP2 emission (Figure 10-1) allowing for efficient energy transfer 
between the fluorescent molecules.  
10.1 Protein concentration calculations and the gamma ratio  
An additional desirable component of FRET spectrometry is the ability to measure 
protein concentrations in cells. Although this is not necessary for a pixel level FRET analysis, the 
calculation of concentration can allow for an analysis of how FRET changes with protein 
expression (Mishra et al., 2016). In addition, it can provide information on shifts in protein 
expression or localization (Figure 7-10B and C). To calculate protein concentration in a solution 
for which the protein concentration cannot be directly measured (i.e. fluorescent proteins 
expressed in cells) the total fluorescence of the donor (FD) and the total fluorescence of the 
acceptor (FA) must be calculated. To calculate FA and FD in cells co-expressing both donor and 
acceptor molecules, two excitation wavelengths must be used. The calculation for FA and FD was 
previously discussed in detail in Methods 3.5. The FA and FD values can then be compared 
against a standard curves generated for the acceptor and donor respectively and discussed in 
Methods 3.5.6.  
In order to calculate the FA and FD values from samples co-expressing donor and 
acceptor, the gamma ratios of donor and acceptor at each excitation wavelength must be 
determined. The gamma for the donor is calculated by taking the ratio of the donor emission at 
each wavelength (Figure 3-4A). The gamma ratio for the acceptor is calculated by taking the 
ratio of the acceptor emission at each wavelength (Figure 3-4B). The gamma ratio is necessary 
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when converting between the emission of the donor (or acceptor) at one wavelength to the 
emission of the donor (or acceptor) at the second wavelength. See Methods 3.5.5 for a more 
detailed description of the calculation and use of the gamma ratios in the calculation of FD and 
FA. To obtain a gamma ratio for GFP2 for use in calculation of GFP2 concentrations, HEK 293T 
cells were transfected solely with plasmids expressing GFP2. The cells were allowed to express 
the GFP2 protein for 24 hours and then imaged at 100X using 800 nm and 960 nm two-photon 
excitations. The resulting images were un-mixed (Methods 3.5) to remove any background 
noise. Then the intensity of the GFP2 expression at one wavelength was divided by the intensity  
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at a second wavelength to obtain the 
gamma ratio using equations 3.9 and 3.10 
shown again below.: 
𝐹𝐴(𝜆𝑒𝑥,1) =
г𝜆𝑒𝑥,1,𝐴
г𝜆𝑒𝑥2,𝐴
∙  𝐹𝐴(𝜆𝑒𝑥,2)  
 𝐹𝐷(𝜆𝑒𝑥,2) =
г𝜆𝑒𝑥,2,𝐷
г𝜆𝑒𝑥1,𝐷
 ∙  𝐹𝐷(𝜆𝑒𝑥,1) 
Where 𝐹𝐴(𝜆𝑒𝑥,1) is the fluorescence 
intensity of the acceptor at wavelength 1 
and 𝐹𝐴(𝜆𝑒𝑥,2) is the fluorescence intensity 
of the acceptor at wavelength 2. Similarly, 
𝐹𝐷(𝜆𝑒𝑥,1) is the fluorescence intensity of 
the donor at wavelength 1 and 𝐹𝐷(𝜆𝑒𝑥,2) 
is the fluorescence intensity of the donor 
at wavelength 2. 
Thus the intensity of the acceptor at wavelength 1 and wavelength 2 is related via the acceptor 
gamma ratio  
г𝜆𝑒𝑥,1,𝐴
г𝜆𝑒𝑥2,𝐴
 .  The intensity of the donor at wavelength 1 and wavelength 2 is related 
via the donor gamma ratio  
г𝜆𝑒𝑥,2,𝐷
г𝜆𝑒𝑥1,𝐷
 . 
The gamma ratio calculated for cells expressing GFP2 was indeterminate with an average 
of 1.5 and a standard deviation of almost 1 (Figure 10-2). The variation of gamma ratio seen in 
cells solely expressing GFP2 is evidence that the GFP2 molecule is existing in two ionization 
Figure 10-3: GFP2 expressed in HEK293T cells 
generates a wide range of gamma ratio values. A 
plasmid encoding GFP2 was expressed in 
HEK293T cells for 24 hours. Images were taken at 
either the 800 nm or 960 nm excitation 
wavelengths and unmixed to remove background 
signal. The ratio was taken of the mean intensity 
emission at 960nm/800nm for several fields of 
view. The ratio of 960nm/800nm is termed the 
gamma ratio and was plotted. The average 
gamma ratio was 1.553 with a standard deviation 
of 0.97. 
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states. One where the chromophore contains a neutral phenol and prefers the 800 nm 
excitation and one where the chromophore contains a phenolate anion and prefers the 960 nm 
excitation. The variation in gamma ratio shows that the GFP2 molecules preferring the 800 nm 
excitation versus those preferring the 960 nm excitation is not stable in cells.  
To test the factors which contribute to variation in excitation maxima in GFP2, a series of 
experiments were conducted with purified eGFP and GFP2. There are only two mutations that 
are different between eGFP and GFP2. One of those mutations is the A206K mutation which 
affects dimerization and does not affect the GFP chromophore. The other mutation is the S65T 
mutation. The S65T mutation is present in eGFP and stabilizes the phenolate anion of the 
chromophore. This causes eGFP to have a much higher 960 nm (two photon) excitation as 
compared to GFP2. The GFP2 variant returns to the wild-type S65 and therefore retains the wild-
type GFP’s ability to be excited at both 800 nm and 960 nm (two photon excitation).  
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The first experiment looked at the variation of the excitation spectrum of eGFP in 
different pHs. The pH variation should affect the protonation state of the chromophore and it 
would be expected that the excitation spectrum would shift when the proteins were exposed to 
different pH buffers. Purified eGFP was diluted to a final concentration of 10 µM in a sodium 
phosphate buffer with a pH of either 4, 6, 7, or 9. Next, 200 µL of each solution was imaged in a 
well plate. An excitation scan was performed on wells containing eGFP at each pH whereby the 
protein is excited at each excitation wavelength between 720 nm to 1000 nm and the intensity 
of emission at each wavelength is graphed as a function of the excitation wavelength (Figure 
10-4 A-D). The only change in excitation spectra due to pH was a change in intensity. The 
overall emission intensity increased with pH and pH 4 was significantly less intense than pH 6, 7, 
or 9 (Figure 10-4E). There was no change in relative excitation peak intensities with pH (Figure 
Figure 10-4: eGFP does not change much with pH but GFP2 shows a dramatic change in 
excitation spectrum with pH change. A) eGFP excitation spectrum at pH 4 scanned twice 
succesively . B) eGFP excitation spectrum at pH 6.  C) eGFP excitation spectrum at pH 7 scanned 
twice successively.  D) eGFP excitation spectrum at pH 9 scanned twice successively. E) Overlay 
of the GFP2 excitation spectra in varying pH. F) Normalized excitation spectra for GFP2 at varying 
pH. 
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10-4E). This is most likely due to the S65T mutation which stabilizes the phenolate anion on the 
chromophore and maintains the protein in a consistent ionization state. In addition, successive 
excitation scans were taken of eGFP suspended in either pH 4, 7, or 9 buffer and no shift in 
excitation spectrum was observed after a repeat scan was taken in the same region of the 
plate. If the same proteins were being successively imaged, it would be expected that either a 
bleaching effect or an excitation spectrum shift due to photo-ionization of the chromophore 
would be apparent on the second excitation scan. There was no difference between the first 
and second scans at any pH measured and this is most likely due to the 200 µL well volume 
which allows for continual renewal of the eGFP proteins measured via molecular diffusion.  
To test the effect of pH on GFP2, the same sodium phosphate buffers were used to 
dilute purified GFP2 to a final concentration of 10 µM. The solutions were added to a well plate 
and the excitation spectra were measured for each pH in a method identical to that described 
above for eGFP. The intensity for GFP2 at pH 4 did not go above noise and therefore was not 
included in the final analysis. The effect of pH on the excitation spectra for GFP2 was 
remarkable. The peak emission excitation intensity for GFP2 in pH 6 was 800 nm whereas the 
960 nm excitation was significantly lower. Increasing the pH to 7 shifted the spectrum so that 
the 800 nm excitation was lower and the 960 nm excitation was higher. When the GFP2 protein 
was suspended in pH 9 buffer, the 800 nm excitation was practically non-existent and the 960 
nm excitation was dominant (Figure 10-3F). This shift in excitation spectra with pH shows how 
the protonation state of the chromophore of GFP2 affects the emission spectra. When the 
phenol is protonated and in a neutral state, the 800 nm excitation is dominant. But as the pH is 
increased and more and more of the GFP2 molecules are de-protonated, the 960 nm excitation 
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increases and the 800 nm excitation decreases. Then at pH 9, most of the molecules are 
deprotonated and the 960 nm excitation dominates, as is seen in the eGFP variant containing 
the S65T mutation.  
 
Figure 10-5: Effect of multiple laser excitations on eGFP and GFP
2
 at varying pH. A) Effect 
of successive 960 nm excitations on the intensity of the 800 nm excitation peak of eGFP at 
pH 6,7, and 9. B) Effect of successive 800 nm excitations on the intensity of the 960 nm 
excitation peak of eGFP at pH 6,7, and 9. C) Effect of successive 960 nm excitations on the 
intensity of the 800 nm excitation peak of GFP
2
 at pH 6,7, and 9. D) Effect of successive 
800 nm excitations on the intensity of the 960 nm excitation peak of GFP
2
 at pH 6,7, and 
9. 
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Another way that the GFP chromophore may shift its protonation state is through 
photo-ionization. To test the photo-ionizability of eGFP and GFP2 and to see if pH affects the 
ionization of the chromophore, 10 µL of 10 µM solutions of eGFP and GFP2 at either pH 6,7, or 9 
were dotted on glass slides. They were covered with a coverslip and allowed to dry for 15 
minutes prior to imaging. By imaging the proteins on a slide as opposed to in solution, it is more 
likely that the same molecules are being successively imaged since most of the fluorescent 
molecules should be attracted to the glass slide surface and only a thin layer of molecules is 
spread across the slide under the coverslip. The slides were imaged first at 800 nm to establish 
a baseline intensity, then successively excited at 960 nm in the same region of the slide. Then 
imaged again at 800 nm to determine if the intensity of the emission of the 800 nm excitation 
had changed. This procedure was then altered so that the first excitation was 960 nm and then 
several successive 800 nm excitations were performed on the same region of the slide. Then 
the region was again measured at 960 nm to determine if the intensity of emission at the 960 
nm excitation had changed by successively exciting at 800 nm. 
For eGFP, it is apparent that the molecule excites much better at 960 nm than at 800 nm 
at all pHs measured, which reinforces the measurements already taken in free moving solution. 
Successive laser excitations appeared to only exert a small bleaching effect. There was no 
photo-bleaching effect apparent at pH6, but pH 7 and pH 9 both exhibited successive decreases 
in emission intensity when successive 960 nm excitations were used in the same region of the 
slide. When successive 800 nm excitations were used and then the 960 nm excitation was once 
again tested, the 960 nm emission intensity at 960 nm excitation was lowered, again indicating 
a photo-bleaching effect (Figure 10-5).  
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When GFP2 was excited at 960 nm and then successively excited at 800 nm, the 
intensity of the 800 nm emissions remained relatively constant, and the re-measurement at 960 
nm excitation yielded an emission intensity which was roughly the same as the original 
measurement for pH 6 and 7. But when GFP2 was subjected to repeated 800 nm excitations at 
pH 9, the emission intensity when the same region was re-measured at 960 nm excitation was 
increased. This implies that only once the pH was high enough to favor the de-protonation of 
the chromophore, was the 800 nm excitation able to deprotonate it and thus increase the 
emission at the 960 nm excitation. Interestingly, when the GFP2 protein was successively 
excited at 960 nm, the emission intensity of the 800 nm excitation increased at every pH. 
However, this increase was small for both pH 6 and pH 9 possibly indicating that the 960 nm 
excitation is not strong enough to change the protonation state and instead the time between 
the first and last 800 nm excitations was sufficient to allow recovery of the some of the GFP2 
molecules to a protonated state (Figure 10-5). The measurements at pH 7 show a molecule 
which is increasing in emission intensity after each successive excitation. It is possible that the 
slide was not fully dried and new molecules were diffusing into the region being measured over 
the course of the measurements. However, an alternative explanation would be that somehow 
the 960 nm excitation is encouraging the protonation of the GFP2 chromophore and therefore 
shifting towards a preference for the 800 nm excitation. Whatever the molecular explanation 
may be, it is apparent that the intensity of the GFP2 emissions for either the 800 nm excitation 
or the 960 nm excitation is not consistent between different pHs and that laser light may be 
able to ionize the chromophore and further shift the equilibrium between emission intensities. 
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10.2 Development of a novel GFP variant  
Over time, many GFP mutations have been made which expand the GFP color tool box 
to almost every color imaginable. In addition, more subtle mutations have been made which 
shift the excitation or emission spectra of GFP slightly. One example of an excitation spectrum 
shifting mutation is the S65T mutation which shifts the excitation peak maxima for the eGFP 
protein towards the 960 nm peak by stabilizing the phenolate anion form of the GFP 
chromophore (Heim et al., 1995). Another example of an excitation spectrum shifting mutation 
is used in the GFP variant H9 and H9-40. H9 and H9-40 incorporate the mutation T203I near the 
chromophore. The T203I mutation is reported to preference the 800 nm excitation peak and 
decrease the 960 nm excitation peak by encouraging protonation of the chromophore to a 
neutral phenol (Tsien, 1998). The H9 GFP variant was further improved upon to incorporate a 
few additional mutations which improved folding stability at 37°C and named “Turbo-Sapphire” 
(Zapata-Hommer and Griesbeck, 2003). A GFP protein which preferences and stabilizes the 800 
nm excitation and eliminates or greatly reduces the 960 nm excitation would be ideal for pixel 
level FRET spectrometry while still allowing for the calculation of consistent gamma ratios and 
the calculation of reliable protein concentrations in cells.  
Figure 10-6: Alignment of the protein sequences of wild type GFP, eGFP, GFP2, GFP2(T203I), 
and Sapphire 
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The T203I mutation was made in the pCMV-GFP2-MAVS vector and the new GFP variant 
was termed GFP2(T203I). An alignment of the protein sequences of the newly created 
GFP2(T203I) variant along with GFP wild type, eGFP, GFP2, and Sapphire is shown in Figure 10-6.  
Mutation WT GFP eGFP GFP2 GFP2 (T203I) mT-Sapphire 
26 Q H H H H 
65 F L L L F 
66 S T S S S 
71 C C C C V 
73 S S S S A 
101 Y F F F F 
142 M L L L L 
146 Y Y Y Y F 
164 V V V V A 
173 K E E E E 
176 S S S S G 
203 T T T I I 
220 I V V V V 
232 H L L L L 
Table 10-1: Summary of different amino acid substitutions in wild-type GFP (WT GFP), eGFP, 
GFP
2
, GFP
2
(T203I), and mT-Sapphire.  
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If the T203I mutation functions to favor the 400 nm (800 nm two photon excitation) 
excitation, then when GFP2(T203I)-MAVS was expressed in cells, the 400 nm excitation should 
always be the higher of the two possible GFP excitation maxima. To test the new GFP2(T203I) 
variant, a plasmid expressing GFP2(T203I)-MAVS was solely expressed in HEK 293T cells. After 
24 hours, the cells were imaged with fluorescent excitation scans beginning at 720 nm and 
ending at 1000 nm. A total of three successive scans looking at the same region of interest were 
collected. The first excitation scan of GFP2(T203I)-MAVS in cells showed that the 800 nm 
excitation was stabilized and had a higher emission intensity than the 960 nm excitation scan. 
However, each successive excitation scan decreased the 800 nm excitation and increased the 
960 nm excitation (Figure 10-7). 
Figure 10-7: Excitation scans of GFP2(T203I)-MAVs, Sapphire, and GFP2 expressed in cells. A) 
Successive excitation scans of GFP2(T203I)-MAVS expressed in HEK 293T cells. B) Successive 
excitation scans of Sapphire expressed in HEK293T cells. C) Overlay of the normalized excitation 
scans of GFP2(T203I), Sapphire and GFP2 expressed in cells. 
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To compare GFP2(T203I)-MAVS to Sapphire, an additional set of HEK 293T cells were 
transfected solely with a plasmid expressing Sapphire. After being given 24 hours to express, 
successive excitation scans were taken of the same region in the cells expressing sapphire. The 
first excitation scan of sapphire was similar to the first excitation scan of GFP2(T203I)-MAVS 
with the 800 nm excitation producing a higher intensity than any other excitation wavelength 
observed. However, successive excitation scans in the same region exhibit a shift where the 
emission when the cells were excited at 960 nm is now comparable to the emission when the 
cells were excited at 800 nm. In contrast to the GFP2(T203I)-MAVS protein, the emission 
intensity at 800 nm did not decrease upon successive excitations (Figure 10-6). To compare the 
initial excitation spectra of GFP2(T203I)-MAVS, to Sapphire and GFP2, all three proteins were 
expressed alone in cells and then the excitation spectra collected from 720 nm to 1000 nm for 
each one (Figure 10-6). The excitation spectrum for all three proteins contain a peak at 800 nm 
and one at 960 nm. It was expected that the relative size of the peaks of the 800 nm excitation 
versus the 960 nm excitation would preference the 800 nm peak in both the sapphire and 
GFP2(T203I) variants given that the T203I mutation was present in both and no additional 
reported chromophore altering mutations were included in sapphire. However, in terms of the 
relative size of 800 nm excitation peak to 960 nm excitation peak, GFP2(T203I) was much more 
similar to GFP2 than to Sapphire. The excitation peak of sapphire at 960 nm was much lower 
relative to the 800 nm peak than it was for both GFP2 and GFP2(T203I). The major difference 
between the spectra of GFP2 and GFP2(T203I) appears to be in the wavelengths between 800 
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nm and 960 nm. GFP2 exhibits a much noisier spectrum between 800nm and 960 nm, whereas 
GFP2(T203I) lacks the additional peaks and is smoother, similar to Sapphire. 
Chapter 11 Conclusions and Future Directions  
This thesis focuses on the interactions of HCV NS3 helicase with itself and with several 
other cellular helicases. The homo and hetero interactions of multiple cellular helicases such as 
the RIG-I like receptors was also explored.  A new technique, Quantitative Microspectroscopic 
Imaging (Q-MSI), was developed that allows for the determination of FRET and fluorescent 
protein concentrations within specific sub-cellular regions in live cells under different 
conditions (i.e. in the presence or absence of ligand). Lastly, a novel fluorescent GFP molecule 
(termed GFP2(T203I) was developed and some of its properties were explored. 
Chapter 4 concentrated on the characterization of a new inhibitor, HPI, which has the 
ability to inhibit both the protease and helicase domains of NS3. HPI was shown, using HCV sub-
genomic replicons expressing a renilla luciferase reporter and using rt-PCR, to be a potent 
inhibitor of HCV genotypes 1b, 3a, and 4a whereas HCV genotype 2a was insensitive to HPI 
(Figure 4-1). Therefore it was concluded that HPI is specific to the helicase and not binding non-
specifically. Currently approved macrocyclic protease inhibitors were designed to make 
contacts in both the helicase and the protease domains and yet the macrocyclic protease 
inhibitors are unable to inhibit both functions. HPI appears to behave differently from 
macrocyclic protease inhibitors because it is able to inhibit not only the helicase but also the 
protease activity. HPI is proposed to bind to the allosteric site between the helicase and 
protease domains (Figure 4-2). 
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 If HPI binds to the allosteric site between the protease and the helicase domain, it may 
be affecting the conformation of the NS3 protein. NS3 can exist in an open conformation with 
the protease domain swung out from the helicase domain or it can exist in a closed 
conformation with the protease domain tucked in close to the protease domain. These two 
conformations have biological significance related to the cleaving of the HCV poly-peptide. 
Specifically, the NS3 protease must cleave itself in cis and in trans. In order to cleave itself in cis, 
NS3 must adopt a closed conformation and to cleave itself in trans it must adopt an open 
conformation (Figure 4-4). 
Modeling and protease activity assays suggest that HPI may be able to lock NS3 in a 
closed conformation and limit the ability of NS3 to cleave the HCV poly-peptide in trans. 
Peptide cleavage assays performed on NS3 proteins containing mutations in the helicase active 
site and the allosteric site between the helicase and protease domains showed that residue 
M485 when mutated to an alanine, resulted in a protein which was more sensitive to HPI 
(Figure 4-2). Modeling showed that M485 is located in the allosteric site and that the 
methionine residue may be blocking HPI access to the allosteric site. This suggests that HPI is 
binding in the allosteric site between the helicase and protease domains. In addition, the NS3 
variant containing a covalently linked NS4A molecule (scNS3) was more sensitive to HPI than a 
full length NS3 with NS4A added exogenously (NS3:NS4A). The scNS3 molecule has only been 
crystallized in the compact (closed) conformation and in our lab it migrates faster than full 
length NS3 on a size exclusion column (despite its larger size). This may mean that scNS3 favors 
the closed conformation and it’s possible that scNS3 is more sensitive to HPI because HPI binds 
better to the closed conformation than to the open conformation. 
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Lastly, HPI was tested in combination with linear and macrocyclic protease inhibitors 
using HCV sub-genomic replicons expressing a renilla luciferase reporter. The combination of 
HPI with macro-cyclic protease inhibitors danoprevir, and particularly grazoprevir, showed a 
synergistic interaction. Since the macro-cyclic protease inhibitors have been shown to make 
contacts in both the protease domain and the allosteric domain, it’s possible that this 
synergistic interaction is due to HPI locking NS3 into a closed conformation and allowing the 
protease inhibitors better access to both the protease and helicase domains in which to make 
contacts (Figure 4-4). (Ndjomou et al., 2015).  
The study looking at the interaction of HPI with HCV NS3 is the first time that the 
protease and helicase activities of NS3 have been targeted simultaneously. Future work with 
HPI could involve crystallizing HPI with the NS3 protein to visualize its mode of binding. This 
could lead to a greater understanding of the interaction of the NS3 helicase and protease 
domain during replication and could confirm our proposed model of HPI inhibition (Figure 4-5).  
Chapter 5 sought to analyze the binding of a fluorescently tagged HCV NS3 protein with 
a fluorescently tagged DNA ligand using multiple FRET calculation techniques. The techniques 
chosen focused on the decrease in the donor emission upon binding to an acceptor (equation 
2-2). The first technique used the peak emission intensity of the donor at the first point in the 
titration as intensity of the donor emission in the absence of acceptor and it was assumed that 
any change in the donor emission upon acceptor addition would be due to FRET. The peak 
donor intensity was then recorded at each point in the titration and FFRET was calculated using 
equation 2-4. The second technique utilized spectral unmixing and determined the peak 
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emission co-efficient for the contribution of each component spectrum to the overall 
composite spectrum. The donor emission in the absence of acceptor was again calculated using 
the first point in the titration when there was no titrant added. Equation 2-2 was used to 
calculate Eapp. The last FRET calculation technique mimicked what would be necessary in a 
microscopy experiment where the emission of the donor in the absence of acceptor cannot be 
measured directly. Instead, the emission of the donor in the absence of acceptor was back-
calculated using equation 3-8 for each point in the titration and FRET was then calculated in the 
same way as the two previous methods using equation 2-2.  
The resulting FRET efficiency values were graphed as a function of concentration of 
acceptor (Figure 5-2D) and fit to equation 3-8. The kd, DT, (total donor concentration) and EAD 
(pairwise FRET efficiency for a dimer containing both one donor and one acceptor) values 
yielding the best fits were determined (Table 5-1). The overall titration curves for the FRET 
calculated using each technique are very similar (Figure 5-2). The results determined using each 
technique demonstrated that the back-calculation of the donor emission in the absence of 
acceptor produces results which are all within two fold or less of the values calculated through 
measurement of the donor emission directly.  
Chapter 6 sought to look at the role of the NS4A anchor domain in anchoring a 
fluorescently labeled NS3 molecule in live cells. Images acquired when fluorescently labeled 
NS3 variants NS3h, NS3, scNS3,and NS3:NS4A were transfected into HEK293T cells show that 
only the NS3:NS4A molecule which contains the NS4A membrane anchors was able to localize 
into foci within the cells. The other proteins were diffuse throughout the cell. This confirms 
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previous work (Andrew Kohlway et al., 2014) which showed that the membrane anchors are 
necessary for sub-cellular localization of NS3 to replicase complexes.  
In addition, the fluorescently labeled NS3 variants were co-transfected with a 
fluorescently tagged NS3 substrate containing a nuclear localization signal. When the substrate 
is cleaved, the nuclear localization signal is exposed and the fluorescent marker moves to the 
nucleus. As expected, the NS3h (lacking the protease domain) was unable to cleave the 
substrate. The NS3 molecule (lacking NS4A) was also unable to cleave the substrate. However, 
both the scNS3 and the NS3:NS4A were able to cleave the substrate, demonstrating that sub-
cellular localization is not necessary to cleave protease substrates. Given that the NS3 protease 
has multiple targets in addition to the HCV poly-peptide, it makes sense that the localization to 
replicase complexes is not necessary for proteolytic cleavage.  
Lastly, the full length NS3 (lacking NS4A) was unable to cleave the fluorescent substrate 
in cells but experiments in vitro using the full length NS3 (lacking NS4A) show that NS3 is able to 
cleave a protease substrate. Future work could explore why NS4A is necessary for proteolytic 
cleavage in cells but not in vitro. It could be that the pH in cells is different from the pH in vitro 
and it’s possible that the pH is affecting the ability of the protease to cleave its substrate. It is 
also possible that the cell has lower concentrations of both NS3 and substrate than would be 
present in an in vitro experiment and therefore the less active NS3 (lacking NS4A) is ineffective 
in cells.  
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 Chapter 7 looked at the interaction of HCV NS3 helicase with the RIG-I like receptors 
using ectopically expressed fluorescent fusion proteins and fully quantitative FRET analysis. Q-
MSI was used to localize the interaction to sub-cellular regions within living cells. LGP2 was the 
only RLR which showed any significant interaction with HCV NS3 and domain deletion mutants 
of NS3 showed that the interaction of NS3 and LGP2 is due, in part, to the helicase domain. It’s 
possible that this interaction is a direct protein:protein interaction or it’s also possible that the 
interaction is mediated through shared binding to a ligand. However, when NS3 and LGP2 were 
co-expressed and exposed to the RNA ligand, poly I:C, (Figure 7-10), the FRET between NS3 and 
LGP2 increased only slightly.  
The interaction between NS3 and LGP2 may be biologically relevant if it aids NS3 in 
localizing to MAVS so that the NS3 protease may cleave MAVS and disrupt RLR signaling.  
Normal RLR function involves the formation of an oligomer which localizes to the mitochondria 
to seed the formation of a MAVS filament. The formation of a MAVS filament initiates a 
signaling cascade which results in the production of interferon and other cytokines (Figure 11-
1A). The NS3 protease disrupts RLR signaling through cleaving MAVS and preventing the 
formation of a MAVS filament. This is one way that HCV is able to establish an undetected 
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persistent infection. It is possible that NS3 is interacting with LGP2 in order to efficiently localize 
to MAVS so that the NS3 protease can cleave MAVS and abrogate signaling (Figure 11-1B). 
 
Previous work has looked at the role of NS3 helicase in the cleavage of MAVS. A study using a 
mutant NS3 (W501A) that lacks helicase function showed that NS3 was still able to block IRF-3 
activation in response to Sendai Virus infection, meaning that NS3 was still able to cleave 
MAVS. However, when a mutant NS3 lacking protease function was used in the same assay, 
there was still some inhibition of IRF-3 signaling, implying that there may be other pathways of 
inhibition (Foy et al., 2003). Another study showed that an NS3 lacking the helicase domain was 
Figure 11-1: Model of HCV NS3 interacting with the RLR oligomer to aid in 
the cleavage of MAVS. A) In the absence of HCV, the RLR oligomer localizes to 
MAVS where the RLR CARDs interact with the MAVs CARDs to initiate a 
downstream signaling cascade. B) Proposed model for HCV NS3 interaction 
with the RLR filament to aid NS3 in localizing to and cleaving MAVS so as to 
disrupt the propagation of a downstream signal. 
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sufficient for MAVS cleavage (Horner et al., 2012). Despite these findings, it is still possible that 
an LGP2:NS3helicase interaction is still aiding NS3 in localizing to MAVS. It is possible that 
although NS3 is still able to cleave MAVs in the absence of the helicase domain, it may be able 
to find MAVs more efficiently through an interaction with LGP2. Future work could include 
confirmation of the LGP2:NS3 interaction through alternative techniques such as co-purification 
using an epitope tag or yeast two-hybrid assays. In addition, confirmation of the interacting 
using immunofluorescence on endogenous LGP2 and HCV infection would be informative.  
Chapter 8 looked at the curious re-localization of LGP2 to sub-cellular foci when it was 
co-expressed with DDX3. This re-localization is reminiscent of what was seen by Onomoto et al  
who used immunofluorescence to visualize RLR re-localization to stress granules in response to 
influenza-1 infection (Onomoto et al., 2012). Since the over-expression of DDX3 is known to 
induce the formation of stress granules, it is possible that the foci seen (Figure 8-1) are stress 
granules. DDX3 may help to shuttle LGP2 to stress granules. Future work could involve the use 
of immunofluorescence to look at the behavior of endogenous LGP2 and DDX3 in response to 
viral infection.  
Chapter 9 looked at the homo and hetero interactions of the RIG-I like receptors. The 
RIG-I like receptors have previously been shown to form oligomers using electron microscopy 
(Bruns and Horvath, 2015; Bruns and Horvath, 2014). Q-MSI was used to look at the 
interactions of RLRs in living cells. When whole cell regions of interest were selected, the self-
interaction of RIG-I and MDA5 was very low. But the interaction of LGP2:LGP2 was noticeable, 
200 
 
even in the absence of RNA (Figure 7-4). This may suggest that LGP2 forms homo-oligomers in 
the cytoplasm in the absence of PAMPs.  
The incorporation of a third fluorescent marker to identify the mitochondria showed 
significant interaction of RIG-I:RIG-I and MDA5:MDA5 at the mitochondria (Figure 9-2). This 
interaction increased with the addition of a PAMP. However, the increase in interaction 
(identified by increased FRET efficiency) was much greater overall for MDA5 than for RIG-I. The 
differences in the range of FRET efficiency values found between RIG-I:RIG-I and MDA5:MDA5 
may be indicative of the different oligomers formed at the mitochondria between those 
proteins. In the electron microscopy experiments, the MDA5 molecules formed much larger 
oligomers than the RIG-I molecules. It is possible that the overall larger shift in MDA5 FRET 
efficiency values in the presence of RNA PAMP is indicative of the greater number of larger 
MDA5 oligomers, as opposed to a smaller number of RIG-I:RIG-I oligomers.  
This chapter also sought to look at the interaction of RIG-I and MDA5 with MAVS at the 
mitochondria. There were no major shift in FRET efficiency between RIG-I:MAVS or 
MDA5:MAVs in response to the synthetic RNA ligand. This may mean that the complex formed 
between RIG-I and MAVS and MDA5 and MAVS due to over-expression of MDA5 and RIG-I is 
the same complex formed when a PAMP is present. However, it could also mean that the shift 
in oligomer structure is not currently visible in this assay. An additional experiment performed 
between MAVS and MDA5 where the fluorescent protein on MDA5 and the linker between 
MDA5 and the fluorescent protein was changed showed overall higher FRET between MAVS 
and MDA5 and a larger increase in FRET in response to RNA ligand transfection (Figure 9-11). 
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This implies that the conditions in the previous MAVS:RIG-I and MAVS:MDA5 assays may not be 
optimal to see that shift in oligomer structure in response to PAMP addition. Future work could 
include changing the fluorescent proteins, changing the location of the fluorescent protein, or 
changing the linker between the fluorescent protein and the MAVS, MDA5, and/or RIG-I 
molecules. 
The largest FRET efficiency increase in response to RNA PAMP was seen between LGP2 
and MDA5. This interaction was previously studied and it is known that LGP2 and MDA5 
interact on RNA PAMPS (Bruns and Horvath, 2015). When fluorescently tagged LGP2 and MDA5 
were co-expressed there was a small population of FRET efficiencies greater than 10%, but 
upon addition of the RNA ligand, the FRET efficiencies increased dramatically, with some 
reaching as high as 80-90% (Figure 9-3). This suggests that LGP2 may not just “prime” RNA 
filaments for MDA5 interactions as has been previously proposed. But instead, LGP2 may be the 
dominant protomer in the LGP2:MDA5 oligomer (Figure 11-2). 
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Future work should include Q-MSI analysis of endogenous RLRs using 
immunofluorescence. In addition, the behavior of the RLRs in response to live virus infection 
could be explored. Lastly, the collection of more fluorescent images using RLRs tagged with 
carefully chosed fluorescent tags (i.e. GFP2 and Venus) and the collection of the images using a 
single wavelength excitation and analysis using FRET spectrometry could lead to more 
information as to the specific architecture of the RLR complexes. 
Chapter 10 sought to improve future FRET spectrometry experiments through the 
development of a GFP variant which would be optimally excited at 800 nm (two-photon 
excitation) and not excited at 960 nm (two-photon excitation). Optical microspectroscopy and 
FRET spectrometry rely on the very careful selection of fluorophores such that the acceptor 
Figure 11-2: Model for LGP2:MDA5 oligomer. A) Proposed model for LGP2: MDA5 oligomer where 
LGP2 functions as an endcap or primer for the MDA5 filament. B) Proposed model for the 
LGP2:MDA5 oligomer where LGP2 is the predominant protomer in the overall MDA5:LGP2 
oligomer. 
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molecule is not excited at the donor excitation wavelength. This allows for the use of only a 
single excitation wavelength and eliminates the need for a second excitation scan to correct for 
direct excitation of the acceptor at the donor excitation wavelength. Using a single wavelength 
excitation, FRET spectrometry can generate spectrums of FRET efficiency as a function of 
number of pixels. These FRET spectrums can be fit to models to determine the overall 
architecture of the fluorescent protein complex. However, FRET spectrometry may be further 
refined through the generation of FRET efficiency spectrums as a function of protein 
concentrations or the molar fraction of protein concentrations. To calculate protein 
concentrations, a second excitation wavelength must be used and a value called the “gamma 
ratio” must be employed in the calculation (equations 3-9 and 3-10). A fluorescent protein 
combination which is optimal for single wavelength FRET spectrometry is GFP2 and YFP. 
However, when the gamma ratio for GFP2 is calculated in cells, there is a wide range of values 
(Figure 10-3).  
A GFP2 variant which incorporates the T203I mutation present in Sapphire was 
developed with the hope that it would produce an excitation spectrum with a 800 nm two-
photon excitation maxima which was stable despite pH fluctuations and repeated fluorescent 
excitations. However, when the variant GFP2(T203I) was tested in cells, the excitation spectra 
displayed properties similar to GFP2 (Figure 10-4F) in that it fluctuated with pH and with 
repeated excitation scans (Figure 10-7A). Future work could involve making more mutations 
near the GFP2 chromophore and then characterize the properties of those mutations to see if 
there are any mutations which stabilize the 800 nm excitation and minimize the 960 nm 
excitation over varying pHs or after repeated fluorescent excitations. The creation of a GFP 
204 
 
fluorescent protein with a stable 800 nm excitation and a minimal 960 nm excitation would aid 
in the calculation of Eapp at pixel level. 
Q-MSI is a powerful technique which allows for the calculation of protein:protein 
interactions in live cells and the determination of fluorescent protein concentrations in small 
sub-cellular regions of interest. Q-MSI was used to show that the interaction and 
oligomerization of the RIG-I like receptors could be monitored in live cells and it was used to 
discover a new and potentially biologically relevant interaction between LGP2 and HCV NS3. 
Continuation of the experiments to include pixel level FRET spectrometry analysis will allow for 
the elucidation of the specific oligomeric structure of the RIG-I like receptors and the LGP2:NS3 
complex in live cells. It is possible that the oligomeric structure of the RIG-I like receptors may 
be different in response to different RNA PAMPS and an understanding of the structure could 
lead to a greater understanding as to how the RIG-I like receptors discriminate self from non-
self and how the RLRs transmit their signal downstream. In addition, determination of specific 
oligomeric structure of the LGP2:NS3 complex could elucidate its function and provide 
information as to the biological relevance of the interaction. 
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Frankowski, K.J., Schoenen, F.J., Frick, D.N. (2015) Simultaneously targeting the NS3 
protease and helicase activities for more effective hepatitis C therapy. ACS Chem Biol. 
10(8), 1887-96. 
 
 
TEACHING AND MENTORING EXPERIENCE 
 
Mentor to high school SMART teams            Milwaukee, WI 
Milwaukee School of Engineering Center for Bio-molecular Modeling                       2014 – 2017 
 Advisor for SMART (Students Modeling A Research Topic) teams 
 Assist high school SMART teams in identifying and carrying out research on the structure 
and function of a protein of interest to aid in the preparation of physical bio-molecular 
models and a poster and presentation at a national conference. 
 
Teaching assistant, Chemistry 603 – Introduction to Biochemistry Lab               Milwaukee, WI 
Department of Chemistry – UW-Milwaukee                                                                     2014 - 2015 
 Prepared laboratory experiments for a class of ten undergraduate and graduate students 
including PCR, restriction enzyme digests and ligation, E.coli transformation, protein 
expression and purification, and in-vitro fluorescent enzyme assays 
 Received exemplary student and faculty reviews 
 
Teaching assistant, Chemistry 100 – Chemical Science                                            Milwaukee, WI 
Department of Chemistry – UW-Milwaukee   2012 - 2014 
 Prepared discussion lectures for over 100 students each semester  
 Covered basic chemical concepts including electronic structure of an atom, chemical 
bonding, reaction rates and equilibrium, REDOX reaction, and chemical naming 
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Teaching assistant, Chemistry 103 – Survey of Biochemistry for Nurse               Milwaukee, WI 
Department of Chemistry – UW-Milwaukee   2014  
 Prepared discussion lectures for 50 students  
 Covered identifying, naming, and drawing basic organic functional groups, chemical 
reactions and equilibria, basic organic chemistry as it applies to the healthcare field, 
metric conversions, chemical bonding 
 Ran a laboratory where classroom principals were tested in a way applicable to healthcare 
 
Research Assistant, Classroom Salon – Online social learning forum            Milwaukee, WI 
Department of Chemistry – UW- Milwaukee                                                                              2012 
Carnegie Mellon University 
The International Society for Technology in Education 
 Project entitled “A Socially-Centric Blended Learning Model for At Risk Youth in an Urban 
Institution.”  
 Tested Classroom Salon and communicated with principal investigator to improve student 
outcomes 
 Integrated insights gained from online classroom learning into classroom discussions 
 
Mentor to incoming chemistry department teaching assistants                           Milwaukee, WI 
University of Wisconsin – Milwaukee                                                                              2012 – 2013 
 Provided mentor support to new teaching assistants 
 Observed classroom management, communication skills, and level of preparedness 
 Offered feedback throughout the new teaching assistant’s first semester 
 Formally reviewed each teaching assistant at the close of the semester 
 
Teaching assistant, Chemistry 104 – General Chemistry II                                    Milwaukee, WI 
Department of Chemistry – UW-Milwaukee                                                                               2012  
 Prepared discussion lectures for over 50 students 
 Taught chemistry concepts such as: chemical kinetics, equillibria, acid-base chemistry, and 
chemical thermodynamics 
 Ran laboratory  
 Created and administered quizzes to gauge student learning  
 
HONORS AND AWARDS 
 
Advanced Opportunity Fellowship                                                    
Graduate School, University of Wisconsin - Milwaukee                                       2015 – 2018 
 Twenty-five awards given to the top students pursuing graduate degrees 
 
Alice C. Helland Fellowship                          
Greater Milwaukee Foundation                                                                                                       2015 
 Honors top-performing, non-traditional female students pursuing an undergraduate or 
graduate degree at a University of Wisconsin school. 
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McFarland Graduate Research Award 
Department of Chemistry – UW-Milwaukee   2014 
 Exceptional poster and presentation 
 
First Place in Liberal Arts Essay Contest                              
University of Wisconsin System                                                                                               2012 
 Top essay regarding the benefits of a liberal arts education. 
 
 
NATIONAL CONFERENCE PRESENTATIONS 
                                                                                           
 Corby, M.J., Stoneman, M., Biener, G., Raicu, V., Frick, D.N. Ligand induced changes in the 
quarternary structure of the LGP2/MDA5 signaling complex. In: Midwest Enzyme 
Chemistry Conference.; 2016; University of Illinois-Chicago, Chicago, IL. 
 
 Corby, M.J., Biener, G., Raicu, V., Frick, D.N.  FRET studies examining the interaction of 
hepatitis C NS3 helicase and human DExD/H box helicases .  American society for 
biochemistry and molecular biology national meeting; 2016; San Diego, CA. 
 
 Corby, M.J., Biener, G., Raicu, V., Frick, D.N. The hepatitis C virus helicase interacts with 
human pattern recognition receptor LGP2. In: 3
rd
 Biennial symposium:  Optical micro-
spectroscopy and molecular imaging.; 2015; University of Wisconsin Milwaukee, 
Milwaukee, WI. 
 
 Mahim, A., Corby, M.J., Rajesh, K., Biener, G., Raicu, V., Frick, D.N. Probing the possible 
interaction between hepatitis C virus NS3 helicase and host DExD/H box helicases using 
flourescent fusion proteins. In: Midwest Enzyme Chemistry Conference.; 2014; 
Northwestern University, Evanston, IL. 
 
 Corby, M.J., Ndjomou, J., Hanson, A., Frick, D.N. Effect of combining helicase and protease 
inhibitors on hepatitis C NS3-4A. In: American Chemical Society 247
th
 National Meeting; 
2014; Dallas, TX. 
 
 Corby, M.J., Ndjomou, J., Hanson, A., Frick, D.N. Targeting a multifinctional protein: Effects 
of protease and helicase inhibitors on hepatitis C NS3 protease/helicase. In: Midwest 
Enzyme Chemistry Conference; 2013; Loyola University, Chicago,  IL. 
 
UNIVERSITY ORGANIZATIONS 
 
Bio-physics Graduate Student Council 
Co-chair                                                                                                                                        2016 - 2018 
 Coordinate UWM -Biophysics 2017 Conference in conjunction with local and national 
faculty.  
227 
 
 
University of Wisconsin-Milwaukee – Media Services                                                                  2017 
Intern              
 Interviewing and writing scientific stories to promote the university and its faculty and 
students 
 
Chemistry and Biochemistry Graduate Student Council 
Co-chair                                                                                                               2014 - 2015 
 Designed and coordinated annual Chemistry Awards Day 
 Grant writer to fund awards day, travel awards, and student council operation costs 
 
 
 UNIVERSITY SERVICE 
 
Co-chair: 4th Biennial Symposium: Optical Microspectroscopy and Molecular Imaging     2017 
 Coordinate and organize conference 
 Invite and host speakers from around the world 
 
UW-Milwaukee Graduate School Ambassador                                                               2015 - 2017 
 Present research to potential donors 
 
 
 
